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Abstract 
Urinary tract infections (UTIs) cause high morbidity, mortality and economic burden. 
Pseudomonas aeruginosa can cause persistent UTIs and it has many virulence factors 
including quorum sensing systems and iron acquisition mechanisms. Furthermore, 
this pathogen is highly resistant to antibiotics and has been highlighted by the        
World Health Organisation as a pathogen for which there is critical need for new 
antimicrobials.  
I have characterised P. aeruginosa UTI isolates from both the UK and Kuwait. The UTI 
isolates were variable in terms of their phenotypic characteristics and genomic 
composition. Multiple resistance genes linked to resistance to different classes                      
of antibiotics including aminoglycosides, fluoroquinolones and β-lactams were 
identified from the sequence data using the CARD database, particularly in the 
isolates from Kuwait. These isolates were pan-resistance and multidrug resistance, 
with the ability to spread resistance via horizontal gene transfer.  
Laboratory media are commonly used to study bacteria in vitro. Nutrient rich            
media does not accurately reflect the physiological environment, prompting the 
development of multiple media mimicking human body fluids such as Artificial Urine 
Medium (AUM). My results show that bacterial responses in LB and AUM were highly 
different. AUM and urine showed similar responses with regards to the increase in 
proteins associated with iron acquisition mechanisms and of the decrease in proteins 
associated with the Type III secretion system. However, differences were observed in 
other important pathways such as those involved in phenazines production. This 
suggests that AUM is a more reflective media than LB to study P. aeruginosa UTI 
isolates, particularly when the environment needs to be highly controlled/consistent, 
such conditions cannot be controlled in urine. The difference in the protein 
abundance profile in AUM suggest that further optimisation of the medium could be 
performed for better resemblance of urine.  
Hormones are regulatory substances that are produced by the host and transported 
around the body. Sex-related hormones, oestrogen (oestradiol), progesterone and 
testosterone are examples of these. Previous studies have indicated that sex 
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hormones such as oestradiol may modulate P. aeruginosa mucoidy and alter innate 
immune responses in females. In this study, treatment with all three hormones 
decreased the abundance of P. aeruginosa proteins associated with iron acquisition 
mechanisms. Furthermore, individual hormones also showed specific bacterial 
changes such as increased protein abundance in pqs quorum sensing mechanism by 
oestradiol compared to testosterone and progesterone. This study suggests that           
P. aeruginosa pathogenesis may be variable in UTI infections based on the host 
hormonal profile. Understanding the individual role of host factors could allow us to 
fully understand the contribution of host components and the impact these may have 
on infection susceptibility and outcome. Therefore, further research is required into 
the role of host components, in particular sex hormones, in host-pathogen 
interactions.    
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Chapter 1 
1 General introduction  
1.1 Urinary tract: Anatomy and Function    
 The urinary tract is comprised of the urethra, bladder, two ureters and two kidneys. 
Urine is formed by the process of tubular filtration and secretion in the nephrons of 
the kidneys and then the diluted urine is transported to the bladder via two ureters 
[1]. In the bladder, urine is stored, and its composition maintained until expulsion 
from the body through the urethra. The bladder wall consists of three layers of 
smooth (involuntary) muscle tissue which promotes voluntary voiding of urine. Both 
inner and outer muscles are arranged longitudinally, however, the middle layer has a 
circular arrangement [2]. This muscular structure is covered by the peritoneum, a 
serosal membrane which covers the outermost surface [3]. Additionally, the bladder 
is a hollow structure lined with the uroepithelium which is considered the main 
protective barrier between the musculature, urine and causative agents of urinary 
tract infections (UTIs) [4]. The lamina propria divides the urothelium from the 
musculature and is comprised of an extracellular matrix containing multiple 
structures/cell types such as blood vessels, fibroblasts, adipocytes, and nerve endings 
[5]. The urothelium is known to play secretory roles by secreting compounds such as 
prostaglandins, nitric oxide, and acetylcholine [6]. The urothelium expresses 
purinergic receptors and discharges active chemicals such as ATP in response to 
chemical, mechanical and thermal stimuli [7].  
1.2 Urinary tract infections    
1.2.1 Prevalence, classification and diagnosis 
UTIs are some of the most widespread infections in healthcare and community 
settings worldwide, with around 150 million people infected per annum [8], [9]. In 
the United States, UTI infections resulted in 10.5 million outpatient visits and an 
additional 2-3 million emergency department (ED) visits in 2007 [10]–[12]. In the 
period between 2006-2009, over 10.8 million ED visits were recorded with 16.7% 
amongst those admitted acute care hospitals in United States [13]. The economic 
burden is devastating, as 3.5 billion USD is spent on treating UTIs and related 
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complications. UTIs are the most common reason for prescribing antibiotics in 
Western Europe and the United States of America [14]. Children, older men and 
women of varying age groups are at higher risk of contracting UTIs [8]. The majority 
of UTIs are relatively easily treated. However, some infections can lead to 
complications such as bacteraemia, sepsis and death [8], [12]. 
UTIs are clinically classified into two groups: uncomplicated or complicated. The 
latter is used to describe UTI patients with structural or neurological abnormality 
[12]. This is caused by several factors that compromise the function of the urinary 
tract and the immune system [15]. These factors include the presence of indwelling 
catheters and renal calculi [8]. In addition, urinary obstruction, urinary retention, 
pregnancy and renal transplantation exacerbate complicated UTIs [12], [15]. In the 
absence of these complications the infection would be classified as uncomplicated 
[16], [17]. Infections may occur in the bladder, in the lower part of the urinary tract 
(cystitis) or in the upper part of the tract in one or both kidneys (pyelonephritis) [15], 
[16]. Cystitis symptoms may include some or all of the following symptoms; dysuria, 
haematuria and suprapubic tenderness, while flank pain and fever can be signs of 
acute pyelonephritis [18]. Risk factors include genetic susceptibility, female gender, 
obesity, previous UTI, vaginal infection, sexual engagement and diabetes [12], [15]. 
UTI infection may be resolved or can become recurrent due to either the persistent 
presence of the same uropathogen or re-infection with a different one [19].  
Presence of bacteria in the bladder is known as bacteriuria, which is divided into 
asymptomatic (ABU) and symptomatic/significant [18], [20]. Historically, colony 
forming units above 105 per ml in two clean-catch samples of urine in women is 
considered clinically significant, with only one sample needed from men [18]. In 
catheter-associated urinary tract infection (CAUTI),a CFU ≥ 103 derived from the 
catheter is considered positive [18]. Immune responses to UTI can be measured by 
the presence of an elevated count of polymorphonuclear leukocytes (PMNs) in urine 
(e.g. ≥10 PMNs per mm3 of urine), clinically defined as pyuria [21]. Presence of 
symptomatic bacteriuria and pyuria is indicative of a UTI, without significant 
bacteriuria count, pyuria could be associated with kidney stones or malignancy (Table 
1.1) [18].  
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Table 1.1 Common terminology used in clinical settings for UTI related diagnosis 
 
1.2.2 Studying uropathogenic bacteria   
To study the events that lead to infection and progression in UTIs, cell culture-based 
assays have been used extensively [22]. These assays are comprised of immortalised, 
primary and cancer cell lines derived from the urothelium of the bladders or the 
proximal tubule epithelial cells of the kidneys [22]. The UTI mouse model has been 
involved heavily in the last two decades in understanding events leading up to 
invasion and colonisation of the bladder and kidneys during UTIs [23]. These models 
are considered as a good animal model to study host-pathogen interactions in 
humans.  This is due, partly, to similar bladder structure and cellular composition 
between humans and mice [23]. Additionally, Type I pilus, a uropathogenic 
Clinical classification Description 
Cystitis Inflammation of the bladder 
Urethritis Inflammation of the urethra 
Acute urethral syndrome Symptoms of cystitis with significant Bacteriuria 
Acute pyelonephritis Kidney inflammation 
Asymptomatic bacteriuria Isolation of bacteria at significant counts without 
symptoms 
Recurrent urinary tract infection Persistence of infection or reinfection at least 
three times within 12 months 
Pyuria Presence of white blood cells in urine 
Dysuria Discomfort in urination, stinging and burning 
pain 
Haematuria Presence of excessive number red blood cells in 
urine 
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Escherichia coli (UPEC) virulence factor can mediate attachment to the uroepithelium 
in both of humans and mice [23], [24]. A variety of Inbred mice can be utilised to 
reflect the genetic heterogeneity in humans that may result in individuals susceptible 
to the development of chronic infections [25]. Briefly, the process of developing a UTI 
in mice consists of multiple steps; female mice with different susceptibility to UTIs 
are anaesthetised followed by delivering the uropathogen of interest via a catheter 
into the mouse bladder. Collection of urine and blood samples from mice are utilised 
as a means of monitoring the infection. The mice are sacrificed at different time 
points depending on the experimental design. Bladders, kidneys, blood and urine are 
harvested or homogenised in preparation for analyses such as bacterial counts, 
measurement of leukocyte population, serum cytokines and  microscopy [23]. One of 
the main microorganisms used in these studies is UPEC. 
 Several infectious agents are implicated in UTIs including fungi, viruses, Gram-
positive and Gram-negative bacteria (Table 1.2). An overview of the key causative 
agents is given in the next page. 
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Table 1.2  Common aetiology of uncomplicated and complicated UTI infection, in descending 
order of prevalence in the United States [8] 
Uncomplicated 
infection 
Prevalence Complicated 
infections 
Prevalence 
Escherichia coli 75% Escherichia coli 65% 
Klebsiella 
pneumoniae 
6% Enterococcus spp 11% 
Staphylococcus 
saprophyticus 
6% Klebsiella 
pneumoniae 
8% 
Enterococcus spp 5% Candida species 7% 
Group B 
Streptococcus 
5% Staphylococcus 
aureus 
3% 
Proteus mirabilis 2% Proteus mirabilis 2% 
Pseudomonas 
aeruginosa 
1% Pseudomonas 
aeruginosa 
2% 
Staphylococcus 
aureus 
1% Group B 
Streptococcus 
2% 
 
1.2.3 UTI causing bacteria  
1.2.3.1 Escherichia coli 
Escherichia coli (E.coli) is a Gram-negative bacteria and the most common causative 
agent amongst uncomplicated and complicated UTIs, causing around 65 to 90% of 
infections (Table 1.2) [8], [12].  The bacterium resides as part of the gastrointestinal 
flora as a facultative anaerobe. The pathogen colonises the periurethral and vaginal 
areas prior to bladder invasion by using adhesive appendages or adhesins. By utilising 
an arsenal of virulence factors such as adhesins, toxins, flagella, polysaccharides and 
iron-acquisition mechanisms, it can also ascend to the kidneys, which can result in 
more complications [26]. Four phylogroups (A, B1, B2 and D) have been identified 
based on the their pathogenicity islands and virulence factors, most UPEC isolates 
belong to phylogenetic group B followed by group D [26], [27]. Multiple reference 
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UPEC strains are utilised to study a host-pathogen interactions such as UTI89 and 
CFT073 [28], [29].    
Despite the increasing rates of resistance to antibiotics by UPEC [30], treatment is 
generally easier compared to other uropathogens such as Pseudomonas aeruginosa, 
since most UPEC are sensitive to a large number of classes of antibiotics which can 
clear the infection. These  include the carbapenem, imipenem ( up to 100% clearance 
success rate), ertapenem (99.98%), the aminoglycoside amikacin (99.94%), and the 
nitrofuran nitrofurantoin (99.91%) [26].  
1.2.3.2 Klebsiella pneumoniae  
Klebsiella pneumoniae is a Gram-negative encapsulated bacterium that is generally 
found in the flora of the skin, mouth and intestines [31]. It is involved in a range of 
infections such as UTIs, soft tissue infections, pneumonia and bacteraemia in 
susceptible individuals [32]. In UTIs, K. pneumoniae is the second most common 
causative pathogen of invasive bloodstream infections due, in part, to the action of 
several key virulence factors [33]. K. Pneumoniae produces a polysaccharide capsule 
that surrounds the outer membrane with 70 known different antigenic types which 
facilitate immune evasion. The key function of the capsule is to neutralise 
phagocytosis in the host [34]. The importance  of other virulence factors such as 
fimbriae, liposaccharides, urease, siderophores and efflux pumps has been 
demonstrated in a variety of infections [35]. Carbapenem-resistant K. pneumoniae 
have been listed as a pathogen with critical priority in the development of new 
antimicrobials  by the World Health organisation (WHO) [36].   
1.2.3.3 Proteus mirabilis  
Proteus Mirabilis is a member of Enterobacteriaceae family and is a Gram-negative, 
facultative anaerobe [37]. The bacterium contributes to 1%-2% of uncomplicated 
UTIs and 5% of complicated infections following catheterisation [38][39]. This 
uropathogen is known for its ability to utilise swarming motility and hyper-flagellar 
movement as a prominent virulence factor [40]. CAUTI biofilm formation is enhanced 
by potent urease activity, which leads to crystalline biofilm formation and could act 
as a protective armour [41], [42]. Upon bladder invasion, the pathogen can form 
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stones and consequently ascend to the kidneys and develop kidney stones followed 
by bloodstream invasion [43]. 
1.2.3.4 Enterococci Spp  
Enterococci are Gram-positive, catalase negative, facultative anaerobes [44]. 
Enterococci are members of the gut flora, they can cause nosocomial infections in 
the urinary tract, wounds and the bloodstream [45]. About 5% of uncomplicated UTIs 
and 11% in complicated infections are caused by enterococci, ranked second only to 
E. coli [8], [18]. Enterococcus faecalis and Enterococcus faecium are the two common 
causative agents in UTI and amongst all enterococcal associated infections [46]. The 
latter is intrinsically resistant to penicillins and can be vancomycin-resistant, 
prompting the WHO to classify it as a ‘’High priority’’ bacteria in need of urgent 
development of new treatment options [36]. 
1.2.3.5 Pseudomonas aeruginosa in UTIs   
P. aeruginosa are Gram-negative motile rods that have one polar flagellum [47]. This 
bacterium is an opportunistic pathogen that infects immunocompromised people or 
those with a breach in normal bodily defences. P. aeruginosa is a versatile pathogen 
that can infect all tissues and systems of humans such as the urinary tract, respiratory 
tract, bone, joint, soft tissue (burns) and dermatitis [48]. The bacteria also infect 
susceptible patients suffering from conditions such as cystic fibrosis (CF), cancer       
and acquired immunodeficiency patients (AIDS) [49]–[51]. The ability to exist in 
nosocomial settings poses a major challenge to healthcare systems around the world. 
The WHO has declared P. aeruginosa as one of the most critical pathogens in need of 
urgent new treatments such as antibiotics [36]. P. aeruginosa is ubiquitous in soil and 
water and can be found in biofilms on surfaces and substrates or as a swimming 
planktonic cell [48]. At 37C, the bacteria can grow optimally but can also grow at a 
variety of temperatures including up to 42C [52]. The bacterium is intrinsically 
resistant to many antibiotics, can resist weak antiseptics and high concentrations of 
salts and dyes. P. aeruginosa has been found growing in distilled water demonstrating 
its ability to grow with minimal growth requirements [52].  
P. aeruginosa is not found in significant numbers in the gut or vaginal microbiomes 
in healthy individuals [18]. Thus, the primary route to the urinary tract occurs in 
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nosocomial settings, UTIs account for 40% of hospital acquired infections [47]. The 
percentage of UTIs attributed to P. aeruginosa is estimated at 12.0%, indicating that 
the pathogen is proficient at causing these infections [47]. The presence of patients 
in hospitals for more than 30 days increases the risk of acquiring UTIs by almost 100% 
[53]. Infections caused by CAUTI P. aeruginosa are usually known to be severe, 
persistent and antibiotic resistant [54]. P. aeruginosa isolates are more likely to be 
carbapenem resistant than any other uropathogens according to recent studies in 
England [55]. Insertion of catheters pave the way for progression of uropathogens by 
comprising defences of the bladder due to fibrinogen accumulation on the catheter 
[8], [56]. Consequently, P. aeruginosa invades the periurethral space in order to 
initiate infection. They then ascend to the urethra and subsequently to the bladder 
where they can further ascend to the kidneys via the ureter to colonize it [57], [58]. 
Without medical intervention, the uropathogen can cross the tubular epithelial cell 
barrier and cause bacteraemia and potentially sepsis [8] 
1.3 Initiation of P. aeruginosa UTI  
1.3.1 Adhesion 
 Adherence is a major pathological step in invasion and colonisation of the host. The 
epithelial layers of the human host are protected by fibronectin (Fn), a large 
extracellular matrix, dimeric adhesive glycoprotein [59]. Fn is present during 
pathological changes and wound healing of the epithelium [60]. The protective 
coating can induce phagocytosis, though it can be lost during stress and illness [61]. 
P. aeruginosa is also capable of adhering to mucin, which is a glycoprotein that 
provides protection on mucous membranes [62]. The mucin layer acts as a primary 
defensive barrier. Its role is to resist adherence of uropathogens and harmful 
elements in urine [63]. The bladder contains a mucopolysaccharide (MPS) layer with 
anti-adherence bacterial properties [64]. Epithelial damage is thought to occur after 
extracellular bacterial multiplication and biofilm formation [8]. The main adhesins in 
P. aeruginosa are the flagella and type IV pili, the pili are considered the most 
important adhesin [48], both structures will be discussed in detail in section 1.3.3 and 
1.3.4, respectively.  
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1.3.2 Motility 
P. aeruginosa possess at least three types of motility mechanisms, reflecting its ability 
to survive in different niches.  It utilises a single polar flagellum to swim in aqueous 
environments and in low-agar (<0.4%) medium, cellular movements respond to 
repellents and attracts via chemotaxis [65]. Movement by extension and retraction is 
known as twitching motility, in which type IV pili are required [66]. Both types of 
movements can be used to move across abiotic surfaces [67]. Swarming motility is 
the third distinctive type, P. aeruginosa propagates across semisolid surfaces in a 
multi-factorial process depending on flagella, pili, rhamnolipids and amino acids [68]. 
In 2008, a fourth type of motility was discovered in PAO1 flagella- type IV pili double 
mutants and was given the name sliding motility. The movement is similar to 
swarming since it responds to the same environmental conditions and regulatory 
proteins [69].  Further discussion of the role of motility will take place in chapter 3.        
1.3.3 Flagella 
P. aeruginosa tend to have one polar flagellum that aids in motility and chemotaxis 
functions; mainly enabling swimming in liquids and some surfaces [70]. The flagella 
consist of three components; the basal body embedded into the cell surface, a curved 
short hook and a long external filament [71]. This organelle is anchored in the cell by 
several other proteins that help stabilize it and consequently, improve its chances of 
nutrient acquisition [71]. 50 genes are involved in synthesis, preserving and executing 
these functions, highlighting its significance to the bacterium for adaptation and 
survival. These genes are often highly conserved across bacterial species [72]. Genes 
such as fleQ, fleS, fleR, flgM, fliA and fleN are clustered in three separate regions on 
the chromosome. These encode multiple proteins that are involved in control and 
regulation of flagella [65] . Changes in flagellar motility are essential for the lifestyle 
shift from planktonic cells to sessile forms that could ultimately lead to biofilm 
formation [73]. Multiple flagellar genes (excluding fliC) were shown to facilitate 
binding to respiratory mucin [74]. Cyclic-di-GMP (C-di-GMP) is a secondary 
messenger that attaches to FleQ, a master regulator, resulting in suppression of 
flagella genes and promoting the expression of exopolysaccharides Psl and Pel [75], 
[76]. Thus, C-di-GMP is inversely correlated with flagellar motility. The switch from 
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flagellar movement to biofilm formation is also observed in CAUTI as reported by         
Cole et al (2016)  upon investigating the role of  C-di-GMP in biofilm formation [77]. 
Briefly, the study utilised a murine CAUTI model, which was infected by strains 
overexpressing either diguanylate cyclases (DGCs) (generators of cellular C-di-GMP), 
or by phosphodiesterases (PDEs) that remove C-di-GMP from the cell. The strains 
which overexpressed the DGCs were more capable of infecting the bladder and 
disseminating to the kidneys compared to wild-type strains. In contrast, strains 
overexpressing PDEs exhibited attuned ability to infect the bladder and progress to 
the kidneys compared to P. aeruginosa wildtype. These results indicate that C-di-
GMP is key in the switch to a sessile life-style typical in CAUTIs [77]. 
Flagella have been demonstrated as a key virulence factor.  Experiments in a burned 
mouse model demonstrated that strains lacking flagella were less virulent than their 
flagellated counterparts [78]. Global deficiency in flagella and pili was attributed to 
loss of rpoN gene which led to attenuated mutants unable to colonise and persist in 
a rat mucosal model [79].  P. aeruginosa flagella are a virulence factor and also highly 
immunogenic. It has therefore been investigated as a vaccine target [80]. Flagellin 
subunits within the flagellar complex are classified as pathogen associated molecular 
pattern (PAMP) which activate innate immunity via toll-like receptor 5 (TLR5) in the 
lung [81], [82]. The resulting inflammatory response contributes to P. aeruginosa 
eradication and may lead to induction of extracellular net traps (NETs) [83]. Isolates 
from CF patients are often flagella- deficient suggesting that loss may aid evasion of 
the immune system to gain a survival advantage in chronic respiratory infections [84]. 
1.3.4 Pili 
Pili are filamentous appendages that allow bacterial cells to adhere to cell surfaces 
[85].The appendages are comprised of pilin, a 15 kDa protein encoded by the pilA 
gene [86]. Five distinct groups of pilA have been identified so far in P. aeruginosa 
strains [85]. Pilins are regulated by PilS and PilR proteins, a two component regulatory 
system [86]. The number of mapped genes involved in regulating pilin activity is 40. 
Similar to flagella, PilA has been investigated as a vaccine target. Hertle et al (2001) 
showed that an immune response was mounted against the variable C-termini of the 
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protein via asialo-GM1 receptor on epithelial cells [87]. P. aeruginosa isolates with 
mutated pilA may have a selective advantage based on a reduced immune response.  
Type IV pili are the most significant and extensively studied type in P. aeruginosa and 
can promote biofilm formation and twitching motility [88]. The latter is a distinctive 
type of motility in which extension, tethering and retraction of the pilus occurs [89]. 
Type IV pili associated motility enhanced the virulence of P. aeruginosa in keratitis 
isolates in a mouse model. In UTI isolates, a study by Tielen et al (2011) showed that 
70% of isolates can perform twitching motility, suggesting a potential role in infection 
and biofilm formation [90].   
1.3.5 Outer membrane proteins 
The outer membrane plays a crucial role in survival and pathogenicity of                                        
P. aeruginosa. It acts as a selective permeability barrier [91]. The outer membrane 
proteins contribute to many facets of growth and development of the cell, such as 
maintaining the integrity of the cell and affecting the passage of nutrients across it 
[92]. P. aeruginosa produces as many as 100 outer membrane proteins with variable 
structures and functions such as OprF, OprD and TonB-dependent receptor [93]. This 
is exemplified by porins which were defined by Henderson et al (2016) as ‘the outer 
membrane β-barrel proteins which allows the passage of solutes or contribute to the 
envelope stability’ [94].  
Porins also contribute to antimicrobial resistance, loss of oprD was found to be the 
main mechanism of resistance to imipenem in P. aeruginosa isolates obtained from 
sputum, urine, blood and tissue [95].  OprF porin has been studied extensively. It is 
involved in biofilm formation, maintenance of the integrity of the cell membrane, 
adhesion to mammalian proteins, and outer membrane vesicle biogenesis [92]. To 
assess the impact of oprF deletion on full virulence, Fito-Boncompte et al, (2011) 
conducted a comparative phenotypic analysis between PAO1, an isogenic oprF 
mutant, and an oprF-complemented strain. These strains were used to infect four 
infection models: the plant Cichorium intybus, the worm Caenorhabditis elegans, glial 
cells of rats and human Caco-2/TC7. The absence of oprF impacted the function of 
several virulence factors. Namely, impaired adhesion to animal cells, attenuated 
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production of ExoS and ExoT, and impaired quorum sensing dependent virulence 
factors such as exotoxin A, pyocyanin, lectin PA-1L and elastase [96]. 
1.3.6 Lipopolysaccharides 
The cell wall of Gram-negative bacteria contains an endotoxin known as 
lipopolysaccharide (LPS) which is a major cell wall component [97]. LPS is present in 
the outer membrane of the cell wall, which is part of the cell wall along with inner 
membrane (IN) and peptidoglycan [98]. The structure of LPS is comprised of three 
distinct regions; a hydrophobic lipid region, a core oligosaccharide, and a repeating 
O-linked oligosaccharide. The molecular weight of LPS is over 10,000 D [98].                     
P. aeruginosa LPS contains a basic lipid A structure which is comprised of an N- and 
O-acylated diglucosamine bisphosphate backbone [4-P-β-D-GlcpNII-(1→6)-α-D-
GlcpNI-(1→P], the primary acyl groups can be variable chemically [99]. Most strains 
of P. aeruginosa utilised in laboratory settings produce a penta-acylated LPS (75%) 
and smaller subset of strains (25%) produce hexa-acylated LPS [99]. The difference in 
both isoforms is that penta-acylated LPS does not possess an O-linked 3-hydroxy 
decanoic acid (10:0(3-OH)) group at position 3 of the first glucosamine [99].  
The second LPS domain is called the core oligosaccharide, which is classified into the 
inner and outer core[100]. The inner core is comprised of sugar components, which 
in turn, is comprised of two residues of 3-deoxy-D-manno-octulosonic acid (KdoI and 
KdoII) and two residues of L-glycero-D-manno-heptose (HepI and HepII) [101]. The 
outer core, on the other hand, is comprised of one D-galactosamine (GalN), one L-
Rha, and three or four D-glucose (GlcI–GlcIV) residues [102]. 
The third major component of LPS is the O-antigen, on which the serotype of                  
P. aeruginosa is based upon [102]. Structurally, the O-antigen consists of N-acyl 
derivatives of rhamnose and different amino sugars to make up a compound known 
as monosaccharides [103].  
The interaction between the P. aeruginosa LPS and the CF lung has been an area of 
interest. CF isolates express either smooth O-side chains (long) or rough side chains 
(few or none). Alteration from smooth to rough variants occurs in the CF lung and is 
linked to switching from serum sensitivity to serum resistance [104]. Ernst et al, 
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(2003) reported that during CF infection, P. aeruginosa modify its lipid A structure in 
response to different environmental conditions. As an example, a novel hepta-
acylated variant was found in a subset of P. aeruginosa clinical isolates obtained from 
CF patients with severe pulmonary disease [105].     
As in other gram-negative bacteria, the lipid A region of the LPS is targeted by TLR4 
upon recognition by PAMPs, these are part of the innate immune defences of the 
host [106]. P. aeruginosa alteration of its lipid A structure modulates a strain 
dependent host inflammatory response [105].  
1.4 Virulence Factors  
1.4.1 Quorum sensing associated virulence factors 
1.4.1.1 Quorum sensing  
Many bacterial species can form interactive communities capable of communicating 
via chemical signals. This process is known as quorum sensing (QS) [107]. This is 
achieved by gene regulatory mechanisms that are highly dependent on the density 
of bacterial cell populations [108]. The regulatory mechanism is controlled by 
secreted signalling molecules which are low molecular weight compounds. These 
compounds are referred to as auto-inducers and act as activators depending on the 
concentrations of the signal [109]. Crucially, the QS system contains 3 major elements 
known as QS synthase, the signal molecule and the signal receptor [110]. When cell 
density is low, the signalling molecules are at a low level and generally diffuse away 
without reaching a critical threshold level. At higher cell densities, the signalling 
molecules reach the threshold level thus activating downstream gene expression 
[109]. This process of QS allows the co-ordination of bacterial communities which can 
adapt/respond to environmental changes. It has been shown that in P. aeruginosa, 
QS can control expression of about 10% of the entire genome [111]. QS systems are 
extremely important for bacteria since they control aspects such as virulence factors, 
swarming motility as well as efflux pump activity that can promote antibiotic 
resistance [112].   
P. aeruginosa contains a sophisticated QS system where four interconnecting 
signalling systems (las, rhl, pqs and iqs) are involved in orchestrating bacterial 
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responses to environmental changes (Figure 1.1) [109]. In the las system, lasI encodes 
the synthase enzyme which produces an auto inducer signal, 3-oxo-dodecanoyl 
homoserine lactone (3-oxo-C12HSL). The 3-oxo-C12HSL binds and activates LasR. The 
discovery of the las system was unravelled by the identification of LasR as a key 
regulator of lasB gene, which encodes the metalloprotease elastase [113]. Further 
discoveries revealed that LasR is essential in the transcription of other virulence 
factor genes such as lasA and toxA expression [113]–[115]. In the rhl system, the 
signal molecule is butyryl homoserine lactone (C4-HSL) [116]. C4-HSL is produced by 
the rhlI synthase which acts on the rhIR transcriptional activator [109], [117]. QS 
signal molecules are thought to directly impact on host cells where they were shown 
to provoke inflammatory response in renal tissues [118]. Furthermore, 3-oxo-C12HSL 
can disrupt adherent junctions in epithelial tissues [119]. 
 
Figure 1.1 An outline of P. aeruginosa QS hierarchy and the regulons involved in conducting 
and release of associated virulence factors. Stimulatory effect represented by arrows, while 
inhibitory are indicated by perpendicular line [109] 
A third QS system signalling molecule was discovered in 1999 known as PQS [120]. 
The structure of the molecule is 2-heptyl-3-hydroxy-4-quinolone and the regulator, 
is PqsR [121]. The regulator binds to the promoter region of pqsABCD and regulates 
the expression of the operon. This QS system is linked to P. aeruginosa virulence 
[122]–[124]. Reduced biofilm formation was observed and down-regulation of 
virulence factors pyocyanin, rhamnolipids, and elastase occurred due to a mutation 
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in the PQS system [125], [126]. In multiple model organisms; plants and nematode, 
PQS is necessary for complete virulence [125], [127], [128]. Bala et al, (2014) 
investigated the impact of the PQS system to assess its impact in mouse model of 
acute UTI pathogenesis. Upon deletion of pqsA and pqsH, attenuated virulence was 
observed, and lower pro-inflammatory cytokines produced against the mutants 
compared to PAO1 wild type [129]. 
The most recently identified QS system is IQS. The IQS signal molecule is 2-(2-
hydroxyphenyl)-thiazole-4-carbaldehyde and produced by the autoinducer synthase 
AmbBCDE [130]. Disruption of the auto-inducer affects the Rhl and PQS systems 
negatively and consequently, reduces the expression of pyocyanin, elastase, and 
rhamnolipids. These phenotypes, however, can be re-established with the addition 
of 10 nmol/L IQS [131]. When P. aeruginosa encounters environments in which 
phosphate is scarce, the IQS system is thought to partially assume the role of the las  
system [131].                   
1.4.1.2 Biofilm formation 
Biofilms contain a group of organized microorganisms sharing polymeric substances 
within a protective matrix [132]. Biofilms are ubiquitous in almost every environment 
and can be formed on biotic and abiotic surfaces [133]. They may be single species or 
polymicrobial and occur in different chronic infections. In short term CAUTI, 
infections are caused by a single species, whereas, long-term CAUTI tend to be 
polymicrobial with Gram-negative microorganism such as E. coli, P. aeruginosa and 
K. pneumoniae [134]–[136]. These communities are attached to a matrix made 
primarily of polysaccharides along with lipids, proteins and nucleic acids to form 
extracellular polymeric substances (EPS) [137]. Other macromolecules such as 
glycopeptides, lipids and lipopolysaccharides are involved in constructing a scaffold 
which protects the structure of biofilms [138].    
The significance of the role of biofilms in infection is highlighted by their prevalence 
in almost 80% of infections [139]. Evidence of their role in pathogenicity and 
persistence can be witnessed in a range of infections such as P. aeruginosa ventilator 
associated pneumonia and diabetic foot infections by Staphylococcus aureus [140], 
[141]. Biofilms can form on medical devices such as catheters or implants [142]. 
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Microbial communities within biofilms utilise gene transfer to exchange DNA 
including resistance genes and virulence factors [143]. Furthermore, the EPS in the 
matrix acts as shield to prevent diffusion of antibiotics across the biofilm [144]. 
Biofilm formation in vitro leads to the formation of mushroom-like structures [145]. 
Five stages of biofilm formation take place; 1) P. aeruginosa cells attach to the surface 
2) EPS are produced to solidify the attachment. 3) The architecture of the biofilm 
starts developing followed by 4) Maturation of the architecture of the biofilms, and 
eventually 5) Dispersal of planktonic cells occurs [146].   
Several virulence factors and cell components contribute to biofilm formation 
including rhamnolipids, exopolysaccharides, extracellular DNA and, type IV pili [130]. 
P. aeruginosa utilises exopolysaccharides such as alginate, pel and psl during biofilm 
formation [137]. Alginate is the first and the best characterised owing to its presence 
in the lungs of CF patients where it gains mucoidy phenotype in over-producing 
clinical isolates [147]. In other non-mucoid clinical and environmental strains, either 
pel or psl is expressed [147]. In UTI isolates, expression of alginate was observed in 
lesser amounts than isolates derived from other types of infection [90], [148]. In vivo 
murine model of CAUTI revealed that alginate is not needed to form biofilm [56].  
Several complex processes involving numerous genes and environmental factors 
contribute to biofilm formation such as C-di-GMP, small RNAs, and QS systems [149] 
however the roles are not fully understood [150]. The role of the QS systems in              
P. aeruginosa in biofilm formation is complex. There is little evidence that QS 
contributes to biofilm attachment and the early stages of biofilm growth, however 
there may be a role in biofilm maturation [151]. QS controls the production of 
rhamnolipids which contribute to the channels involved in the distribution of 
nutrients and  waste removal in biofilms [152], [153]. 
1.4.1.3 Pyocyanin  
Pyocyanin is a phenazine pigment and a secondary metabolite produced by                     
P. aeruginosa as a secreted, potent virulence factor [154]. Pyocyanin is a product of 
several phenazine encoding genes, some of which are located on two operons known 
as phzABCDEFG and other genes such as phzM, phzH and phzS (Figure 1.2) [155]. 
Structurally, pyocyanin contains a nitrogen ring which belongs to aromatic tricyclic 
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phenazines [156]. It is considered as a weak acid (pKa= 4.9) since it harbours a phenol 
group [156], [157]. At physiological pH level of 7.4,  pyocyanin appears as a blue 
colour that could turn to red if pH drops to acidic levels [156], [158], [159]. As a 
zwitterion with low molecular weight, pyocyanin can penetrate host cell membranes 
easily [154], [156], [158].  
 
Figure 1.2 The signalling system and biosynthesis of pyocyanin production. Chorismic acid is 
converted via the PhzA to -G protein pathway into phenazine-1-carboxylic acid, which, in 
turn, is converted into different phenazines by the action of enzymes PhzS, PhzM and PhzH. 
The product of phzM, 5-Methyl phenazine-1-carboxylic acid betaine is converted to 
pyocyanin by phzS. Adapted from [160] 
Pyocyanin is controlled by QS mechanisms [161]. Once the threshold of cell density 
is reached, LasR and RhlR activate genes contributing to pyocyanin biosynthesis 
[154]. The PQS quorum sensing via pqsR regulates pyocyanin positively by acting on 
rhlR and to a lesser extent lasR. GacS/GacA is a global signal transduction two-
component system in Gram-negative bacteria, which has been implicated in 
swarming motility, biofilm formation, antimicrobial resistance and virulence of type 
III and VI secretion systems [162]. Virulence factor regulator (vfr) is another 
transcriptional regulator which is controlled by cyclic AMP. This promotes the Type 
III secretion system, ToxA, type IV pili and las QS system both directly and indirectly  
[163]. Both systems (GacS/GacA and VfR) have a role in pyocyanin production as 
mutants in both systems produced less pyocyanin [161].  
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Pyocyanin can cause cell cytotoxicity by activating intracellular reactive oxygen 
species (ROS) such as superoxide and hydrogen peroxide [164]–[166] . This activation 
event can have deleterious impact on host cells by disrupting the cell cycle and 
damaging DNA [164], [167]. Strains that discharge higher amounts of pyocyanin  
cause greater levels of oxidative stress, leading to significant cell lysis and subsequent 
release of extracellular DNA (eDNA) [168].  Pyocyanin intercalates with eDNA to form 
biofilms in UTIs by promoting cell to cell interactions and exerting influence on 
cellular surface properties [168]. Recent experimental evidence suggests that this is 
the route by which biofilm formation occurs in UTIs.  
Pyocyanin has been detected in sputum samples of CF patients with concentrations 
reaching 130 µM [165]. Reports of existing  pyocyanin in the bladder or elsewhere in 
the urinary tract are currently lacking [134]. However, in vitro detection of UTI 
isolates demonstrated that the concentration of pyocyanin could reach up to 39 µM  
[169]. UTI isolates appear to produce more pyocyanin compared to other                           
P. aeruginosa isolates in other types of infection according to a report by Al-Ani et al, 
2016 [169]. Urothelial cells can be susceptible to damage by pyocyanin. Mcdermott 
et al (2012) showed that treating urothelial RT4 cells with 25 µM or greater reduced 
cell viability [170]. Pyocyanin induction of 25-50 µM accelerated RT4 cellular 
senescence as witnessed by the increased production of senescence-associated β-
galactosidase (SA-β-gal). This impact may inhibit cell repair processes by the host, 
resulting in recurrent UTI [171]. 
1.4.1.3 Elastase and LasA  
Elastin is a major component of the human extracellular matrix (ECM) that is vital in 
many mammalian tissues such as the bladder, lungs, arteries, ligaments, tendons 
[172], [173]. Elastolytic activity can be observed in nosocomial UTI pathogens such as 
S. aureus and P. aeruginosa [174], [175]. The vast majority of  P. aeruginosa isolates 
possess the ability to be proteolytic and elastolytic [176]. LasA is a serine protease 
that acts synergistically with elastase and alkaline proteinase to impose proteolytic 
activity on elastin and sensitise it to degradation to other proteolytic enzymes, 
including elastase [177]. Expression of both proteins are controlled by LasR [113], 
[178].                  
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LasA protease, which is also known as staphylolysin, has been implicated in several 
types of P. aeruginosa infections; including keratitis (where a functional LasA,LasB 
and LasR is required for full virulence) [179], tracheal, wound, UTI [180] and chronic 
infection in CF lungs [181]. In the latter, high levels of lasA mRNA transcripts were 
expressed in the CF isolate  LES431 [181]. However, it is unknown whether elastase 
has a prominent role in UTI [175]. In a mouse UTI model, an isogenic mutant to PAO1, 
failed to colonise the renal tissue due to attenuated virulence in proteases, 
rhamnolipids and elastases [118].  
1.4.1.4 Alkaline protease 
Alkaline protease (AprA) is one of the earliest discovered virulence factors with 
proteolytic activity in P. aeruginosa  [182]. This metalloprotease is secreted via a type 
I secretion system The pathway depends on three major components; AprD (ATP 
binding Cassette), AprE (membrane fusion) and (AprF) outer membrane [183]. The 
exact role of alkaline protease in invasion and colonisation of CF lungs has not been 
fully identified. However, production of antibodies directed at this protease in vivo 
suggests it is involved in CF lung pathogenesis [184]. Alkaline protease can inhibit 
cytokine TNF-α induced signalling in A549 epithelial cells and therefore this process 
may alter immune signalling in the lungs of infected CF patients by inhibiting pro-
inflammatory responses [185]. Although the exact role of alkaline protease in 
keratitis may not be clear, in isolates from keratitis infection there was a correlation 
between alkaline protease production and enhanced virulence [186]. A recent study 
examined 93 P. aeruginosa isolates from acute and chronic infections from blood, CF, 
urine, tracheal, rectum, sputum and venous catheters samples, by utilising in vitro 
zymography, elastase, and gelatinase assays. The authors found high levels and 
heterogenous production of alkaline protease, with the highest levels detected in the 
tracheal isolates [187]. 
 1.4.1.5 Phospholipase C 
Phospholipases are a group of diverse enzymes that are capable of hydrolysis of one 
or more ester linkages in glycerophospholipids [188]. Phospholipase C (PLC)  targets 
and hydrolyses the phosphodiester bond in the phospholipid backbone and is 
therefore a significant virulence factor which suppresses the neutrophil respiratory 
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burst [189][188]. PLC is found in multiple bacteria such as Clostridia, Bacillus, Listeria 
(Gram-positive) and P. aeruginosa [190]. PLC is classified into haemolytic (PLC-H), and 
non-haemolytic (PLC-N) [191]. PLC-H and PLC-N are encoded by a set of genes that 
share DNA homology. Though they possess different substrate specificities [192], 
both can hydrolyse phosphatidylcholine. PLC-H can also target sphingomyelin while 
PLC-N exerts hydrolytic activity on phosphatidylcholine [192]. 
Lema et al, (2000) provided evidence of PLC-H hydrolysis of cow lung surfactant 
extract (CLSE) which is similar in composition with human surfactant [193]. 
Comparative analysis between mucoid and non-mucoid CF isolates revealed, that 
non-mucoid strains produced greater amounts of PLC-H [193], [194]. Although PLC-H 
appears to contribute to bacterial virulence at all stages of CF lung infection, it is more 
apparent in the final stages where lung deterioration and collapse occurs [195]. The 
exact role of PLC has not been elucidated yet in UTI pathogenies.  
1.4.1.6 Rhamnolipids 
Rhamnolipids are amphipathic glycolipids that contain L-rhamnose and β-hydroxy 
fatty acids moieties, and as a surfactant, rhamnolipids perform multiple functions in 
pathogenicity and are under the regulation of the QS system [196]. The Rhl QS system 
regulates production of 3 enzymes; RhlA, RhlB and RhlC, which, in turn, synthesize 
rhamnolipid and its associated precursors 3-(3-hydroxyalkanoyloxy) alkanioc acid 
(HAA) [196], [197] [198]. Rhamnolipids were detected in the CF lung and their role is 
thought to be in dissolving surfactants in acute and chronic lung infection [118],[199]. 
Several studies have suggested a role for rhamnolipid in swarming motility through 
reducing surface tension, thereby promoting flagellum movement along semifluid 
surfaces [200], [201]. This may be of benefit in the urinary tract as rhamnolipids, 
could promotes swarming motility on urinary catheters. In vitro and in vivo UTI 
analysis showed that absence of rhl QS (and therefore absence of rhamnolipid) 
reduced bacterial virulence [118].   
1.4.1.7 Hydrogen Cyanide  
 P. aeruginosa is one of the few bacteria that produce and secrete hydrogen cyanide 
(HCN), a highly toxic virulence factor that inhibits multiple biochemical cellular 
processes in host cells (Table 1.3) [202]. The Rhl QS system controls HCN [203]. A HCN 
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concentration of 40 µM in host blood has been shown to be lethal [204].  Ryall et al, 
(2008) found a high level of HCN (mean average 72 µM) in the sputum of CF and 
bronchitis patients and absence of P. aeruginosa correlated with absence of HCN 
[205]. A clinical study on 167 CF patients observed that 74% of P. aeruginosa isolates 
produced HCN, and up to 83% of patients were infected with at least one strain that 
could produce HCN [206]. Reduction of lung function was observed in CF patients due 
to HCN production, which may have a role in P. aeruginosa persisting in the lung by 
affecting the host ability to resist and clear the infection [205]. The role of HCN in P. 
aeruginosa UTI has not been studied yet. 
 1.4.2 Virulence factors not controlled by QS 
1.4.2.1 Type III secretion system 
T3SS system has been implicated in P. aeruginosa infections such as CF and keratitis, 
however, the role in UTI pathogenesis remains unclear. In addition, the possible 
involvement of the T3SS systems in UTI pathogenesis of other Gram-negative 
bacteria is unclear. For example, a study on the contribution of T3SS to the 
pathogenesis of  P. mirabilis in an acute ascending UTI mouse model revealed no 
involvement, despite the presence of a fully functional T3SS system [207]. Miyazaki 
et al, 2002 identified 3 strains out of 100 UPEC isolates  which contain T3SS system 
[208]. A study on atypical enteropathogenic Escherichia coli (aEPEC) found an 
association between adherence to HeLa epithelial cells and T3SS [209]. Shulman et 
al, (2018) examined an E. coli strain (O2) known to cause UPEC and sepsis, the strain 
contains a pathogenicity island ETT2 that includes predicted genes of T3SS. However, 
no evidence was found of T3SS effectors in the secretome [210].                 
1.4.2.2 Structure of the Type III secretion system (T3SS) 
The T3SS is a macromolecular structure that is evolutionarily related to the flagellar 
complex in Gram-negative bacteria [211]. The structure spans multiple layers of the 
bacterial and host membranes including the inner membrane, the periplasmic space, 
the peptidoglycan, the outer membrane and then into the cytosol of the host cell 
[212]. The T3SS machinery can be categorised into; the secretion apparatus, the 
translocation or the targeting apparatus, the secreted toxin (effectors) and the 
cognate chaperones (Figure 4.1) [213]. 
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Figure 1.3 A schematic diagram showing the T3SS secretion apparatus. The system consists 
of the needle complex, the translocation apparatus, effector proteins and chaperones. 
Modified from [213] 
1.4.2.3 Regulation of the T3SS proteins   
Regulation of the T3SS injectosome and the effectors are strictly controlled. The 
system comprises of 36 genes on five clustered operons, with an additional six genes 
located around the chromosome, all contributing to the biogenesis of the T3SS [212].  
Expression of the T3SS is tightly controlled and is upregulated in response to 
environmental cues, such as low concentrations of extracellular Ca+2, casein and 
albumin and contact with the host cell [214]–[216].  The transcriptional activator ExsA 
binds to its own promoter and a consensus element on the promoter of T3SS genes 
[217]. The secretion activity of the T3SS apparatus is dependent on the coupling of 
EsxA with three proteins; ExsD, ExsC and ExsE [218]. ExaA, the transcriptional 
activator, is inhibited by ExsD when the needle is not in contact with the host plasma 
membrane [219]. Upon initiating injection, however, ExsE is released from its bound 
state with ExsC to inactivate ExsD. This, in turn, releases ExsA and allows it to bind 
the promoter region of T3SS (Figure 4.2) [220], [221]. For a detailed analysis of the 
transcriptional activity see Hauser et al, 2009 [212].   
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Figure 1.4 Proteins involved in the control of the T3SS. ExsA is the transcriptional regulator 
which activates the T3SS machinery depending the coupling of the protein with ExsD or ExsE. 
A): prior to cell interaction with the host cell, ExsA is coupled with ExdD. B): ExsD is replaced 
with ExsE which turns on the T3SS secretion system [213]     
1.4.2.4 The needle complex 
The needle complex consists of the basal body and a needle-like structure called the 
injectosome [212]. The basal body is an intracellular component which spans the 
inner membrane, the peptidoglycan, and the outer membrane [222]. This structure 
acts as the base for the injectosome which is anchored within [213]. Multiple proteins 
contribute to the functionality of the basal body, such as PscJ, PscC, PscN and PscW 
[212]. The protein PscJ is predicted to be a component of the inner membrane 
segment of the basal body, while PscC functions as an outer membrane component 
that belongs to the secretin family of outer membrane proteins [213]. Secretins 
produce large pores dependent on the formation of 12-14 subunits forming a 
homomultimeic ring that covers the length of the outer membrane and protrudes 
into the cytoplasm [223]. PscC forms a channel in the outer membrane by 
24 
 
oligomerisation with PscW and proteins PscJ (lipoprotein) and PscN (ATPase) to form 
part of the basal body [224]–[226]. The injectosome assembly is dependent on the 
helical polymerisation of PscF proteins [227]. The aim of the needle is to deliver the 
effectors from the bacterial cell, through the basal body to the targeting apparatus 
[228].      
1.4.2.5 The Translocation apparatus  
The function of the translocation apparatus (also known as the targeting apparatus), 
is to transport the effector toxins from the needle across the plasma membrane and 
eventually into the cytosol of the targeted host cell [212], [213]. Contact with the 
host cell initiates the formation of the injectosome, which in turn leads to the 
activation of the translocational apparatus with subsequent insertion into the plasma 
membrane of the host cell and formation of a fully functional translocation pore 
[212]. Three proteins are required to form the targeting apparatus: PopB, PopD and 
PcrV, known as the translocators. The interaction of those proteins as a collective unit 
forms the translocation pore [229]. PopB and PopD are comprised of hydrophobic 
domains which oligomerise in order to form the pore [230]. PcrV is hydrophilic and is 
required for a functional pore [231]. 
1.4.2.6 Effector proteins 
Four effector proteins are currently known to be injected into the cytosol of the host 
cell, ExoS, ExoT, ExoU and ExoY [212]. Experimental evidence based on bacterial 
persistence in the mouse lung model of acute pneumonia suggest that P. aeruginosa 
producing ExoU causes more severe infections followed by ExoS [232].  
ExoS and ExoT contain two domains with differing functions; N-terminal GTPase-
activating protein (GAP) and ADP-ribosyltransferase (ADPRT) [213]. The GAP domain 
is biochemically identical in both effector proteins. GAP target GTP proteins in the 
cell and causes alterations to the inactive GDP-bound state [233]. Targeting of 
GTPases such as Rho and Cdc42 leads to the actin cytoskeletal rearrangement and 
consequently cell rounding, detachment and inhibition of phagocytosis. The ExoS Gap 
domain causes internal apoptosis to host cells [234]. Evidence of T3SS ExoT-
dependent inhibition of cytokinesis in mammalians cells has emerged. Such inhibition 
leads to impaired host cell division which plays a partial role in wound healing [235].  
25 
 
ADPRT functions and targets differ between ExoS and ExoT. ADPRT in ExoS acts as a 
modulator of cytotoxicity in contrast to ExoT, in which it interferes with phagocytosis 
of the host cell [212]. The ADPRT domain of ExoT acts synergistically with the GAP 
domain to disrupt cytoskeletal formation and is involved in delayed wound healing, 
allowing P. aeruginosa to invade through the compromised mucosal barriers [236]. 
The ADPRT domain is also responsible for causing cell apoptosis by probable 
inhibition of Crk [237]. ExoS is known to cause apoptosis, albeit at a later stage of the 
infection. ExoS ADP ribosylates an extensive range of host proteins, including 
members of the Ras superfamily, the intermediate-filament protein vimentin, and 
the cellular mediator cyclophlin [213], [238]. ADP ribosylates radixin, ezrin and 
moesin, interfering with the cytoskeletal rearrangements [239], [240]. Thus, the 
impact of ADP ribosylation of host proteins leads to apoptotic-like cell death, 
cytoskeletal rearrangements, inhibition of DNA synthesis, endocytosis and 
movement of cellular vesicles[212], [213]. ExoS also can promote bacterial survival, 
escape and killing of macrophages once internalised within the phagosome by 
increasing the expression of bacterial mgtC and oprF [241]. Mgtc promotes growth 
within macrophages while OprF is an outer membrane protein which is implicated in 
survival inside macrophages [92], [96], [242].   
ExoU has a severe debilitating impact on host cells owing to its cytotoxicity and     
broad phospholipase A2 activity [243]. The toxin targets and kills innate immune 
components such as macrophages and neutrophils. Depletion of the latter leads to 
localised immunosuppression and increased susceptibility to secondary infections 
[244], [245]. ExoU inhibits pro-inflammatory cytokine production in macrophages 
and is correlated with acute cytotoxicity [246].  Modulatory effects on host immunity 
by ExoU and extensive epithelial tissue damage contribute to pathogenicity and 
extensive damage to the host [213].   
ExoY is the latest discovered effector and its exact function is yet to be fully elucidated 
[212]. ExoY is an adenylate cyclase that increases intracellular concentration of cyclic 
AMP resulting in alteration of the actin cytoskeleton of the host cell [247]. ExoY 
functions through the target human effector, the filamentous form actin [248].      
Kloth et al (2018) demonstrated that ExoY contributes to P. aeruginosa acute 
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pathogenicity. The authors reached this conclusion upon observing pathological 
changes such as a decrease in lung barrier integrity, increased apoptosis and 
differential cytokine secretion [249]. ExoY is toxic to the yeast Saccharomyces 
cerevisiae and induces cell rounding in eukaryotic immune cells [250], [251]. The role 
of these effectors in UTIs has not been widely studied. 
1.4.2.7 Chaperones 
Chaperones are cytosolic, small proteins which assist the assembly and the operation 
of T3SS secretion system [252]. Chaperones are classified into three classes 
dependent on the type of the protein it is associated with. Class I chaperones 
contribute to the formation of pores, class II assist in forming needle-like structures 
and class III chaperones are associated with effector molecules or the toxins [213]. 
The unifying role of the chaperone proteins are to ensure a functional system; 
however, this is achieved by different mechanisms [253]. For instance, Class I 
chaperones maintain the helical components of the needle by masking the binding 
domains which subsequently polymerise and further deliver proteins to the export 
channel [254]. Class II chaperones inactivate the toxicity of hydrophobic 
translocators, this prevents premature signalling within the bacterium when the pore 
is formed and ultimately, the injectosome is formed [254], [255]. Prior to the 
formation of the ring structure of the translocon, both translocator proteins PopB 
and PopD are chaperoned by PcrH [256]. Effector proteins are associated with type I 
chaperones, which interact with their cognate partner via the chaperone binding 
domain. For instance, chaperone SpcS folds ExoS and ExoT to achieve the full 
functional capacity leading to full secretion[257]. ExoU is chaperoned by SpcU but no 
chaperone has been identified for ExoY [253].  
1.4.2.8 T3SS and impact on disease  
T3SS is not essential for P. aeruginosa to establish an infection, however, its role in 
pathogenicity of P. aeruginosa has been well characterised in acute and chronic in 
vivo animal models [258]. Expression of the T3SS has been associated with a poorer 
prognosis, greater disease severity, and higher rates of mortality [213], [259], [260]. 
In a clinical study involving 108 patients, respiratory tract and blood P. aeruginosa 
isolates were examined by immunoblot analysis to detect T3SS proteins. Expression 
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of ExoS, ExoT, ExoU and PcrV was associated with a relative risk of 6-fold greater 
mortality [261]. A recent study analysing the association of virulence and T3SS 
expression observed that most virulent P. aeruginosa isolates possessed an exoU+ 
phenotype in a C. elegans bloodstream infection model [262].  Interestingly, clinical 
isolates expressing T3SS are predominantly found in acute infections rather than the 
chronic infections such as CF, indicating that T3SS virulence may play a bigger role in 
acute infections [213].  
The impact of T3SS on the pathophysiology of infection has several knock-on effects 
in the host, largely dependent on the site of infection. In respiratory tract infections, 
disruption of the host epithelial barrier increases susceptibility to infection due to the 
increased amount of asialoGM1 on the basolateral surface of epithelial cells [263]. 
Bacteria containing TS33 proteins bind to asialoGM1 and inject the effector proteins 
into the cytosol of the host cells which leads to tight junction disruption and further 
infiltration by invading P. aeruginosa cells [264]. Disruption of the epithelial and 
endothelial barriers allows P. aeruginosa dissemination into the bloodstream 
accompanied by secretion of pro-inflammatory mediators, resulting in eventual 
septic shock [264], [265]. In wound infections, ExoT causes delays in the healing 
process, potentially leading to invasion and dissemination into the blood stream 
[236].  
The impact of T3SS on the immune function of the host is profound. Pro-
inflammatory responses can be enhanced by T3SS due to the stimulation of IL-1β 
maturation leading to acute lung injury [244]. Neutralisation of alveolar macrophages 
and neutrophils in the lung by T3SS effectors also results in impaired bacterial 
clearance from the lung which further exacerbates the infection [213]. Failure to clear 
P. aeruginosa from the lung can lead to further secretion of effector proteins into the 
host cells and therefore a possible rise of pneumonia-like symptoms [266]. Hence,     
P. aeruginosa can self-promote this cycle by which pro-inflammatory responses are 
enhanced and innate response are neutralised, leading to further damage in the lung, 
bad prognosis and eventual mortality [213], [266].     
Knowledge of UTI P. aeruginosa isolates ability to utilise T3SS is scarce. Schaber et al, 
2004 found that the QS-deficient UTI isolate CI-5 did not possess either of ExoS or 
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ExoT [267]. In a recent study by Boulant et al, 2018, 339 isolates were obtained from 
invasive pulmonary infections, chronic CF infections, septicaemia, UTI, and isolates 
derived from environmental origins. PCR detection revealed that the prevalence of 
exoU was only 18.2% in 32 UTI isolates [268]. Tielen et al, (2011) detected 9 out of 30 
isolates (28%) which were exoU positive. Interestingly, 4 ExoU positive isolates were 
low in cytotoxic activity, potentially due to a loss of function mutation [90]. Currently, 
knowledge regarding the potential role for ExoU remains elusive [269]. As for ExoS, 
the levels of this effectors could increase over time in UTI setting and it could aid 
persistence and immune evasion [270]–[272]. ExoT could potentially aid immune 
evasion during invasion and colonisation of the urinary tract [271]–[273]. Currently, 
no clear evidence has been shown of the involvement of T3SS other Gram-negative 
uropathogens such as UPEC and P. mirabilis [207]–[210]   
1.4.2.9 Iron acquisition mechanisms 
Iron acquisition mechanisms are crucial for P. aeruginosa for invasion and 
colonisation of the urinary tract  [8]. P. aeruginosa utilises mechanisms to ensure its 
survival in different niches. Production of iron chelating molecules such as pyoverdine 
and pyochelin enables the bacterium to intake ferrous (Fe+3) from the host, 
particularly from transferrins and lactoferrins [274], [275].  P. aeruginosa can also 
hijack siderophores produced by other microorganisms such as the siderophore 
enterobactin from E. coli [276], [277].  P. aeruginosa produces other compounds that 
have iron chelating activity. This includes pyocyanin which can chelate ferrous iron 
(Fe+2) from the host (taken up by the Feo system) [278]. In addition, host 
haemoglobin can be targeted by haem proteins which are then transported through 
the Has and Phu iron uptake systems [279]. This will be discussed in detail in chapter 
5. 
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Table 1.3 A summary of the key virulence factors utilised by P. aeruginosa 
 
Virulence factor Structure and/or function Possible role in UTI pathogenesis 
Pilus and Non-
Pilus Adhesins. 
E.g. type IV pili 
(Tfp) and 
flagella. 
Cell Surface attachments: Pili play a role 
in attachment and invasion of host cells. 
Non-pilus adhesins binds to mucin. 
asthma [62], [63]. 
Involved in attachment to catheter 
surfaces and uroepithelial cells [280]. 
Pyochelin/ 
pyoverdine 
siderophores 
Extracellular Fe3+ chelating molecules 
scavenging scarcely available iron from 
host cells to ensure adaptability and 
survival [275]. 
May become more virulent in iron-
limited environments such as the 
bladder [280]. 
Pseudomonas 
exotoxin A 
Disrupts the function of protein synthesis 
by ADP-riboslation of Ef-2 elongation 
factor [281]. 
Causes multiple organ injury including 
the kidney [282]. 
Haemolysin Produced by multiple bacterial species, 
causes lysis of host red blood cells [283]. 
Implicated in renal colonization and 
tissue damage [280]. 
ExoU Type III cytotoxic phospholipase, 
Correlation exists between ExoU and 
acute cytotoxicity in the epithelium and 
macrophages [284]. 
Causes rapid necrotic cell death [270]. 
ExoT Bi-functional type III cytoxin with rhoGAP 
domain. Encoded by almost all strains, 
causes capsase cell dependent in strains 
producing ExoS with ExoT [49]. 
May protect against needle-mediated 
injury upon during its insertion in the 
host cell. Not proven in UTI isolates. 
Possible role in immune evasion. 
ExoS Bi-functional type III cytoxin with rhoGAP 
domain and. Responsible for disruption of 
cytoskeletal arrangements [285]. 
A potential role in macrophage 
evasion [286]. 
ExoY An adenylate cyclase that could disrupt 
actin cytoskeletons [270]. 
Function in UTI infection has not been 
established. 
Alginate An O- acetylated linear polymer 
composed of β-mannurate and L-
guluronate residues. Aids in biofilm 
adherence [287]. 
No fundamental role in biofilm 
formation in UTIs [288],[289]. 
Pyocyanin Nitrogen containing aromatic compound, 
a zwitterion that produces blue colour in 
neutral pH environments[134] . 
Can cause reduction in urothelial cell 
viability [168]. 
 
Hydrogen 
Cyanide 
Neutralisation of immune response and 
contributing to colonisation and virulence 
[204], [205]. 
Urothelial damage 
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1.5 Antimicrobial resistance  
1.5.1 Antimicrobial resistance: Overview   
Antimicrobial resistance (AMR) is major health-threat throughout the world and a 
great concern to health authorities and patients alike [290]. Antibiotics have been at 
the forefront of the success of modern medicine since Alexander Fleming discovered 
penicillin activity against S. aureus in 1928 [291]. With the dwindling efficacy and high 
rates of resistance in nosocomial settings, significant life-saving procedures such as 
surgery, transplantation and treatments of the immunocompromised are being 
compromised [292]. P. aeruginosa is a major cause of hospital-acquired infections. It 
is frequently found in burns, respiratory, urinary tract, bloodstream and device-
related infections [293]. The bacterium is resistant to multiple antibiotics, with a 
notable rise in resistance against β-lactams, cephalosporins and carbapenems [294].  
The majority of antibiotics need to penetrate the cell membrane of P. aeruginosa to 
be effective [295]. β-lactam antibiotics such as penicillins, cephalosporins, 
carbapenems and monobactams are comprised of a β-lactam ring (Figure 1.3) [296]. 
The antibiotics are designed to target and bind penicillin-binding proteins (PBP) 
produced by bacteria, and interfere with the synthesis of peptidoglycan [297]. 
Aminoglycosides used against P. aeruginosa include gentamicin, amikacin and 
tobramycin which inhibit protein synthesis upon binding to ribosomal 30S subunits 
[298]. Colistin, is a last resort antibiotic utilised to treat Gram-negative (including        
P. aeruginosa) MDR infections and belongs to the antibiotics class of polymyxins 
[299]. This class of antibiotics is comprised of polypeptides and targets bacterial LPS, 
resulting in increased outer membrane permeability [300]. Interference with DNA 
replication by targeting DNA gyrase and topoisomerase is another antibiotic action 
and this is utilised by quinolones such as ciprofloxacin and levofloxacin (Table 1.4) 
[301].     
31 
 
 
Figure 1.5 General chemical structure of antibiotics used for P. aeruginosa treatment, 
adapted from [302] 
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Table 1.4 A summary of major antibiotics used to treat P. aeruginosa infections, adapted  
from [303] 
 
1.5.2 Pseudomonas uropathogenesis and antimicrobial resistance 
The WHO has declared carbapenem resistant P. aeruginosa as a major and critical 
public health issue in need of developing therapeutic intervention [36].                           
The current new agents/combinations such as ceftolozane/tazobactam and 
ceftazidime/avibactam have increased the options with which the opportunistic 
Class Examples                                                 Resistance       
    Chromosomal                                              Acquired resistance  
Aminoglycosides  amikacin, 
tobramycin 
gentamicin 
• Increases efflux pumps 
such as MexXY-OprM  
• Causes reduction of 
transportation across the 
cytoplasmic membrane 
• Aminoglycoside-modifying 
enzymes (AMEs).  
• 16S rRNA methylases (extremely 
rare). 
Fluoroquinolones 
 
ciprofloxacin, 
levofloxacin 
 
• Induction of mutations in 
quinolone resistance 
determining region (QRDR) 
of gyrA, gyrB, parC, parE 
genes. 
 
• Increases efflux of 
MexAB-OprM, MexCD-OprJ, 
and MexXY-OprM pumps) 
• Aminoglycoside acetyltransferase 
variant aac(6’)-Ib-cr which 
promotes reduction to 
ciprofloxacin susceptibility.  
 
β-Lactams 
Carboxypenicillins 
Ureidopenicillins 
3rd generation 
Cephalosporins  
4th generation 
Cephalosporins 
Monobactams 
Carbapenems 
carbenicillin 
ticarcillin  
piperacillin 
ceftazidime  
cefepime 
cefpirome  
aztreonam 
meropenem 
imipenem 
doripenem 
• Increases efflux pumps, 
specifically the MexAB-
OprM pump which 
promotes resistance to all 
β-lactams except imipenem. 
• Induces intrinsic 
overexpression of AmpC β-
lactamase and promotes 
resistance to all β-lactams 
except carbapenems and 
carbenicillin.  
 
• Promotes lower outer 
membrane permeability via 
the loss of OprD porin, this 
results in resistance only to 
imipenem and reduced 
susceptibility to 
meropenem.  
 
• Acquired penicillinases e.g. TEM-
1, PSE-1 (confers resistance only to 
penicillins). 
• Extended spectrum β-lactamases 
e.g. PER-1, VEB-1 (confers 
resistance to all β-lactams except 
carbapenems).  
• Carbapenemases (resistance to 
most β-lactams including 
carbapenems.  
– Class A (e.g. GES-5) – Class B 
/MBLs (e.g. VIM, GIM NDM; 
enzymes not involved in resistance 
to aztreonam.   
– Class D (e.g. OXA-40-like; 
enzymes involved in carbapenem 
resistance. 
 
Polymyxins  
 
Colistin, 
polymyxin B  
 
Promotion of LPS modification via two component systems such 
as PhoQP and PmrAB  
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pathogen is treated [304] However, both treatments have already encountered  in 
vitro and in vivo resistance [304], [305]. Despite the emergence of potential new 
treatments in phase III clinical trials such as meropenem-vaborbactam, mipenem-
relebactam murepavadin and cefepime-zidebactam, the efficacy will not be assessed 
until prolonged period of consistent clinical use [306]–[308]. Thus, the current last 
resort for UTI treatment is colistin [309].     
1.5.2.1 Aminoglycosides 
Aminoglycosides are bactericidal agents used to treat P. aeruginosa infections by 
disrupting protein synthesis via binding 30S subunits [310]. Antibiotics such as 
streptomycin, gentamicin, amikacin and tobramycin are usually deployed with other 
β-lactams to increase the impact of bactericidal activity [311]. Multiple resistance 
mechanisms are involved in decreasing P. aeruginosa susceptibility such as decreased 
outer membrane permeability, efflux pumps and amino acid substitutions in 
ribosomal proteins [312].  
1.5.2.2 Fluoroquinolones 
Fluoroquinolones target DNA synthesis in bacteria by interacting with the enzymes 
DNA gyrase and topoisomerase IV [313]. Two members of this class of antibiotics are 
used to treat P. aeruginosa infections, ciprofloxacin and levofloxacin [314].                      
P. aeruginosa can develop resistance to this class of antibiotics by developing 
mutations on quinolone resistance genes in the (QRDR) region which encodes DNA 
gyrase (gyrA or gyrB) or topoisomerase IV (parC or parE) enzymes [315].                              
P. aeruginosa has also been identified with a transferable quinolone resistance 
determinant called aac(6’)-Ib-cr. This encodes the enzyme AAC(6’)-lb-cr. In 
comparison to AAC(6’)-Ib, AAC(6’)-lb-cr contains two amino acid substations which 
enables it to acetylate ciprofloxacin (not levofloxacin) and aminoglycosides [316], 
[317].   
1.5.2.3 β-Lactams  
β-Lactams are the largest class of antibiotics and these inhibit cross-linking of the 
peptidoglycan, a major component of the bacterial cell wall [318]. Inhibition 
mechanisms take place by targeting bacterial D-alanyl-D-alanine transpeptidase 
enzymes (PBPs) [319]. Many β-Lactams are ineffective against P. aeruginosa due to 
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the low membrane permeability, chromosomally encoded AmpC-type β-Lactamase 
and constitutive expression of efflux pumps [320]. See section 3.4.3 for detailed 
information on β-Lactamases classes.      
Effective antibiotics in this class which often neutralise P. aeruginosa include 
carboxypenicillins (e.g. carbenicillin), ureidopenicillins (e.g. piperacillin), some third-
generation (e.g. ceftazidime) and fourth generation cephalosporins (e.g. cefepime), 
monobactams (e.g. aztreonam) and carbapenems (e.g. imipenem, meropenem and 
doripenem only) [312]. For detailed information on resistance see section 3.4.    
1.5.2.4 Polymyxins 
The polymyxin class of antibiotics, consisting of colistin (polymyxin E) and polymyxin 
B, interfere with bacterial outer membrane binding by attaching to LPS [321]. The use 
of polymyxins dates to the 1940s, however their widespread use was unpopular due 
to nephrotoxic and neurotoxic side effects and the emergence of aminoglycosides 
and carbenicillin in the 1960s [322]. The rise in resistance, however, has meant that 
these antibiotics are being revisited and are particularly attractive due to the unusual 
mode of action. Delivery of colistin can occur two ways; intravenously and as 
nebulised drug for CF patients. The nebulised form is particularly attractive as safety 
issues are lessened due to the lower rates of absorption in other tissues [323], [324]. 
The vast majority of P. aeruginosa isolates are susceptible to colistin. However, 
resistance can occur due to LPS mutations and modified lipid A. In complicated UTI 
patients infected by XDR P. aeruginosa, colistin is used as a last resort antibiotic [309]. 
The commercially available form of this antibiotic for intravenous use is a prodrog of 
colistin called colistimethate sodium [325], which is eventually converted into colistin 
in the patient upon administration with 60%-70% immediate clearance in urine [326], 
[327].    
1.6 Hormones  
In addition to the wide spectrum of bacterial virulence factors that can affect the 
pathogenesis of infection, there are also important roles played by host factors. Host 
factors include many different components. However, in this thesis, I will be focusing 
on the impact of sex hormones.  
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1.6.1 Hormone classification  
Hormones are chemical mediators produced by humans, these signals are released 
by the hypothalamus-pituitary-gonads axis into the peripheral circulation [328]. 
Hormones perform several vital functions and aim to control homeostasis, 
development, reproduction, maintenance, energy use and growth [329]. Despite the 
small concentrations of hormones released into the blood, multiple tissues and cells 
in the body contain specific receptors which allow recognition and response [330].  
The impact of hormones varies amongst different tissues and cells, several examples 
of the impact of hormones on health and disease will be discussed further in this 
section.  
Three major classes of hormones have been recognized; Protein/peptide hormones, 
terpenes and amino acid derivatives hormones as shown in (Table 1.5). Sex hormones 
and steroids belong to the second class [331].   
Table 1.5 Classes of hormones and examples of each class. Sex hormones (steroids) are made 
by stimulation of hormones belonging to class one such as luteinising hormone (LH) and 
follicle stimulating hormone (FSH) 
 
1.6.2 Sex hormones  
Sex hormones are a group of hormones produced by male testes and female ovaries. 
In males, these hormones are known as androgens and testosterone is the main 
androgen. In females, two principal hormones are involved in promoting secondary 
female characteristics and reproductive functions. Each hormone will be discussed 
here and in further detail in chapter 5.   
Hormone class Hormone example 
 
Protein/peptide Regulating production (gonadotropins), Energy 
balance (insulin) and blood pressure regulation 
(angiotensin) Terpenes; Juvenile & Steroid hormones Sex steroids such as testosterone and 
oestrogen 
Amino Acid derivatives Serotonin and melatonin 
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1.6.2.1 The impact of luteinizing hormone and follicle stimulating hormone 
synthesis 
Human gonadotrophin hormones are comprised of three hormones: luteinizing 
hormone (LH); follicle stimulating hormone (FSH) and choriogonadotropin (CG) [331]. 
The latter is released by the placenta to aid pregnancy [332]. LH and FSH are released 
by cells in the anterior pituitary known as gonadotrophs, following exposure to 
gonadotropic releasing hormone (GnRH) from the hypothalamus [333]. Both 
hormones stimulate the gonads in male and female reproductive systems, 
specifically, the testes and the ovaries [334], [335]. The structure of both hormones 
comprises of alpha and beta chain subunits [331]. The alpha chains are identical, the 
beta chain is variable, and therefor determines the biological specificity of the 
hormones [336], [337]. In human males, the LH binds to receptors on Leydig cells in 
the testes to stimulate the production of testosterone [338], in females, testosterone 
is also produced in theca cells of the ovary prior to conversion to oestradiol by 
granulosa cells [339]. 
1.6.2.2 Testosterone   
Testosterone is structurally known as 17-beta-hydroxy-4-androstene-3-on [340]. The 
testes produce almost all testosterone in men from cholesterol and acetate. Smaller 
amounts are secreted by the zona reticularis of the adrenal gland [341]. Testosterone 
binds receptors in cells/tissue resulting in the promotion of protein synthesis [331]. 
Androgen receptors (AR) are the receptors that mediate the functions of 
testosterone [342]. Testosterone increases muscle strength and mass, bone density 
and stimulates male secondary characteristics such as growth of body hair and larynx 
enlargement. When males reach adulthood, major synthesis of testosterone takes 
place in gonads. Leydig cells produce testosterone in males while theca cells 
synthesise testosterone in the female ovarian follicle. In the latter, testosterone is 
converted into oestradiol by aromatase activity [343]. The placenta can also release 
testosterone [343].  
The synthesis of androgens in the gonads of both genders is regulated tightly by the 
secretion of GnRH [344]. This hormone (GnrH) is released from the hypothalamus 
and this leads to the stimulation of LH and FSH from the pituitary gland. LH then acts 
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by stimulating the synthesis of testosterone in the testicular male and ovarian female 
tissue. Testosterone inhibits GnrRH and LH release from the hypothalamus and the 
pituitary, respectively (Figure 1.4) [345].  
 
Figure 1.6 Testosterone production in humans. Negative feedback loop clarified as 
production of testosterone and inhibin by the testes inhibits the synthesis of LH, FSH and 
GnRH hormones. The process starts by secretion of GnRH from the hypothalamus. GnRH 
stimulates LH and FSH in anterior pituitary, which in turn, stimulate the production of 
testosterone 
1.6.2.3 Oestradiol   
Oestradiol is a central member of estranges family with oestriol and oestrone. 
Structurally, oestradiol contains two (OH) groups while oestrone and oestriol possess 
one and three (OH) groups, respectively [346]. The oestrogen derivatives fluctuate 
during the female lifespan as oestradiol is produced in higher quantities and is the 
principal oestrogen in the reproductive years [347]. All of these derivatives originate 
from endogenous and exogenous sources. The ovary, as an endogenous source and 
the principal producer of oestrogens, directly secretes oestrogens during the 
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reproductive cycle, and the adrenal secretory activity elevates conversion of 
androgens to oestrogen in the peripheral tissues [348]. Extragonadal sources such as 
the brain, liver, muscle and mesenchymal cells of adipose connective tissues, 
discharge small amounts in comparison to ovary [349], [350]. Upon progression to 
menopause, oestradiol starts to diminish [351]. Oestradiol promotes and maintains 
female secondary characteristic post-puberty such as breast growth, fat and bone 
deposition, and alterations in body shape. Oestradiol is discharged from the ovaries 
into the blood where coupling with sex hormone binding globulin occur, followed by 
cell entry to the nucleus to bind with DNA [331]. Oestrogen acts via intracellular 
receptors such as oestrogen-binding proteins ERα and ERβ [352]. The role of 
oestradiol in pregnancy is to maintain a balanced environment for the oocytes to 
thrive [353]. Oestradiol’s impact is not restricted to growth and reproduction only, it 
plays a major role in homeostatic feedback mechanisms. Indeed, oestradiol 
production inhibits GnRh/LH release in a process called a negative feedback loop in 
males and females. In the latter, however, oestradiol switches to positive feedback 
to generate a surge of GnRh/LH pre-ovulation (Figure 1.5) [354]. 
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Figure 1.7 The process of oestradiol production During the follicular phase, GnRH stimulates 
the production of FSH and LH from the pituitary. Both hormones lead to the stimulation of 
oestradiol from the production oestradiol from the ovaries. Oestradiol inhibits the 
production of GnRH from the hypothalamus and keeping the levels of LH and FSH low. 
Oestradiol acts on the endometrium and causes the endometrial arteries to constrict leading 
to menstruation 
1.6.2.4 Progesterone 
Production of progesterone occurs in the gonads and the adrenal cortex in males and 
females [355]. Progesterone is involved in pregnancy and fluctuates during the 
menstrual cycle in reproductive age women [356]. Structurally, progesterone is 
known as pregn-4-ene-3,20-dione [357] and it binds to progesterone receptors (PR). 
These receptors are expressed in the granulosa cells of preovulatory follicles of the 
ovary [358]. Low levels of progesterone are observed pre-pubescence and post-
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menopause. Physiologically, progesterone slows-down the pulsatile GnRH secretion 
by acting on the hypothalamus resulting in oestradiol priming [359]. In men, 
production of progesterone occurs in the testicles and the adrenal glands, and in 
contrast to women, serum levels of progesterone are not altered periodically or by 
age [360]–[362]     
1.6.3 Sex Hormones in disease 
Sex steroids impact on disease in some cases can be a clear, direct consequence of 
alteration in circulating hormones. This is exemplified by the protective effect of  
oestradiol to infections caused by Mycobacterium spp [363], [364]. Women are more 
susceptible to UTI and recurrent infections post-menopause [18]. In other diseases 
the link is less clear and is associated with increased risk but is not necessarily causal 
This will be discussed in detail in chapter 5, examples of sexual dimorphism and an 
overview of some of the roles those hormones plays are provided below.  
1.6.3.1 Oestradiol in disease  
Oestradiol has been linked to many disease conditions (Figure 1.6). Lack of oestrogen 
production in females is caused by conditions such as Turner syndrome [365]. Genetic 
defects in the adrenal and gonadal secretions impair fertility [366]. Oestradiol 
decreases the biomechanical stiffness of the cornea post-surgery [367]. In pulmonary 
disease, oestrogens including oestradiol are thought to predispose female patients 
to higher rates of morbidity and mortality, though the exact underlying mechanisms 
are not fully elucidated yet [368]. 
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Figure 1.8 Oestradiol deficiency impacts multiple organs in the females and acts on several 
systems and organs including the Central Nervous System (CNS), liver, β cells of the pancreas, 
adipocytes and skeletal muscles. As a result, metabolic syndrome, obesity and type 2 
diabetes develop [369]  
1.6.3.2 Testosterone in disease 
The association between testosterone and multiple health disorders is well-
documented [370]–[372].  Hypogonadism is a clinical syndrome in which the testes 
fail to produce sufficient levels of testosterone and sperm cells [373]. The disorder 
may arise either from a genetic origin (congenital) [374] or can be acquired [375]. 
Lower circulatory levels of testosterone lead to loss of male secondary 
characteristics, infertility and muscle weakness. The most common manifestation in 
congenital disorders is Klinefelter's syndrome [376]. On average, men lose 1%-2% of 
circulating testosterone every year with age progression [377]. Once serum 
testosterone levels drop from the adequate healthy male age reference, symptoms 
may rise and the onset of late-onset hypogonadism (LOH) is observed [378]. 
Symptoms such as depressions, loss of libido, fatigue, erectile dysfunction and 
reduced muscle strength may emerge [379].  Testosterone production is linked with 
multiple disorders such as diabetes mellitus, obesity, alcoholism, liver disease, 
hemochromatosis, and sickle cell anaemia [372].  Furthermore, diminishing serum 
testosterone levels are linked to the most health threatening non-communicable 
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disorders such as cardiovascular disease, the leading cause of mortality around the 
world [380].  
1.6.3.3 Progesterone in disease    
The role of progesterone in sexual dimorphism between men and women is less clear 
and not investigated as well as either oestradiol or testosterone [381], [382]. 
However, progesterone is involved in modulating the immune system heavily. It acts 
as a modulatory substance exerting its influence on intracellular and membrane-
associated progesterone receptors in immune cells, immune organs, and 
autoimmune disease tissues [383].  Evidence exists of the association of progesterone 
with autoimmune disease such as rheumatoid arthritis, where low progesterone 
levels are thought to be a contributing factor to this particular disease [384]. 
Progesterone was found to be associated with lung disease exacerbations [385]. 
Detection of nitric oxide in the lung is considered to be a biomarker of airway 
inflammation of asthma, which is positively associated with higher progesterone 
production levels [386]. Serum progesterone is positively associated with worsening 
condition in lung function of asthmatic women during the luteal phase, the phase in 
which serum progesterone reaches its peak [387].  
1.6.4 Accounting for sexual dimorphism in medical treatments 
Gender as a variable in contracting infectious diseases has been neglected in animal 
and clinical studies which aim to understand host-pathogen interactions and 
development of treatments [388], [389]. Animal studies usually exclude female 
subject, in part due to the fluctuating hormone levels during the estrus cycle [390]. 
Clinically, in 1977, FDA guidelines recommended the exclusion of productive age 
women from initial human clinical trials such as phase I [391]. This may have led to 
increased adverse events in women, which was observed between the years 1997-
2000 when 8 out of 10 withdrawn drugs resulted in greater health risks for women 
[392]. In 1994, the National Institutes of Health (NIH) issued new guidelines taking 
into account gender differences in conducting clinical trials [393]. Despite the 
relatively recent focus and effort on the inclusion of female subjects in clinical 
research, some drugs and therapeutic guidelines are exclusively based on clinical 
trials with males only [391], [394].      
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1.6.5 Therapeutic utilisation of sex hormones 
Therapeutic interventions using sex hormones were part of medical controversies 
since these treatments were recommended in 1992 [395] . Based on multiple 
observational and meta-analyses, hormone replacement therapy (HRT) was 
recommended for the treatment of coronary disease, dementia, osteoporosis for 
post-menopausal women by administrating estrogen [396]–[398]. The findings and 
recommendations were reversed earlier in the 21st century due to rising incidence of 
breast cancer, heart disease and osteoporosis [399], [400] . However, subsequent re-
analysis and further investigations concluded that HRT may be beneficial to women 
within the age of 50-59 years, suggesting that early administration is key to achieve 
disease prevention [401]. 
Testosterone replacement therapy can be administered to patients suffering from 
hypogonadism. Treatment is carried-out via multiple routes; oral, intramuscular, 
transdermal patches, and gels [375]. Concerns were raised regarding the oral 
prescriptions due to inability to control testosterone serum levels in the blood post-
administration, warnings were given of possible adverse events such as prostate 
cancer, sleep apnoea and erythrocytosis [402].  Other studies have demonstrated an 
increased risk of cardiovascular disease following the administration of testosterone, 
prompting the Food and Drug Administration (FDA) to issue consumer warnings 
[379].   
The FDA approved the use of progesterone, it can be administered via multiple routes 
[403]. However, it has not been effective in treating conditions such as acute 
traumatic injuries in phase III clinical trials [404] , due to lack of optimal dosing [405] 
and inaccurate inferences from pre-clinical data in designing clinical trials [406]. 
Sexual dimorphism in men and women in relation to infectious diseases will be 
highlighted in chapter 5 with examples of infections, immune modulation and the 
overall impact of hormones on experimental models and treatments.   
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1.7 Aims 
- To characterise genotypic and phenotypic traits in a panel of isolates 
sourced from the UK and the state of Kuwait 
- To establish the AMR profile of all clinical isolates  
- To assess whether AUM is an adequate in vitro laboratory model that 
recapitulates P. aeruginosa responses in human urine  
- To compare the proteomic profile of P. aeruginosa in AUM in comparison to 
LB and urine 
- To study the impact of sex hormones oestradiol, testosterone and 
progesterone on P. aeruginosa phenotypes.  
- To investigate the impact of sex hormones on the proteomic profile of 
clinical UTI P. aeruginosa  
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Chapter 2 
2 Materials and Methods 
2.1. UTI isolates storage and hormone stocks 
2.1.1 Bacterial isolates  
P. aeruginosa urinary tract isolates were sourced from the Royal Liverpool Hospital 
(n=15) and Kuwait (n=8) (Table 2.1). The average patient age on isolation was 70 years 
old and 47% were isolated from women in the UK panel. 8 isolates were sourced from 
Kuwait dating back to 2005, unfortunately, no other information was available. 
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Table 2. 1 Describes the main and known information of the P. aeruginosa strains and clinical 
isolates obtained for this study. N/A= not available, UK= United Kingdom, USA= United States 
of America 
Isolate 
Name 
Source Date Country of origin Gender Age Reference 
PAO1 Wound 1954 Australia N/A N/A [407] 
PA14 Burn 
Wound 
1977 US N/A N/A [408] 
LESB58 CF 1988 UK- Liverpool N/A N/A [409] 
133042 Urine 11-Oct-13 UK M 52 This study 
133043 Urine 16-Oct-13 UK F 80 This study 
133044 Urine 16-Oct-13 UK F 69 This study 
133065 Urine 18-Oct-13 UK F 70 This study 
133075 Urine 24-Oct-13 UK M 76 This study 
133082 Urine 25-Oct-13 UK M 89 This study 
133083 Urine 25-Oct-13 UK F 68 This study 
133090 Urine 25-Oct-13 UK M 83 This study 
133098 Urine 31-Oct-13 UK M 58 This study 
133099 Urine 31-Oct-13 UK F 61 This study 
133104 Urine 01-Nov-13 UK M 72 This study 
133105 Urine 01-Nov-13 UK M 50 This study 
133106 Urine 02-Nov-13 UK M 83 This study 
133117 Urine 02-Nov-13 UK F 61 This study 
133126 Urine 07-Nov-13 UK F 75 This study 
758 Urine 4-Jan-05 Kuwait N/A N/A This study 
783 Urine 10-Jan-05 Kuwait N/A N/A This study 
786 Urine 11-Jan-05 Kuwait N/A N/A This study 
864 Urine 18-Apr-05 Kuwait N/A N/A This study 
888 Urine 15-May-05 Kuwait N/A N/A This study 
902 Urine 22-May-05 Kuwait N/A N/A This study 
925 Urine 05-June-05 Kuwait N/A N/A This study 
1083 Urine 12-Nov-05 Kuwait N/A N/A This study 
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2.1.1.2 Isolate storage and culture  
All isolates were stored at -80 °C in Luria-Bertani (LB) (Sigma Aldrich) (W/V) 10% 
glycerol (Sigma Aldrich). Isolates were streaked onto LB Agar (Appleton woods) and 
grown overnight at 37 °C.  
A single representative P. aeruginosa colony was used to inoculate LB broth (Sigma 
Aldrich), artificial urine medium (AUM) or pooled human urine in glass or plastic 
universal tubes overnight. All cultures were grown at 37°C and shaking at 180 rpm 
unless otherwise stated. The use of glass tubes avoids adsorption of hormones to the 
vessel surface. 
LB agar (Sigma Aldrich) with the following formulation (agar, 10 g/L sodium chloride, 
5 g/L tryptone, 10 g/L, yeast extract, 5 g/L) was used. To prepare LB agar, 12g of the 
LB agar powder was dissolved in 500 ml of distilled H2o. Bacterial cultures were 
spread inoculated onto the agar and was allowed to grow overnight at 37 °C. 
2.1.1.3 Hormone Stock Concentrations  
Hormone stocks of oestradiol, testosterone and progesterone were prepared as 
following; for oestradiol, 2mM stock = 0.0136g (272.38g/mol) were added to 25ml 
filtered ethanol (Sigma Aldrich). Subsequently, 200µl of 2mM was added to 20 ml 
ethanol to make up 20µM working stock. The working solutions were used to reduce 
the concentration further to 20nM in LB. The same procedure was performed to 
testosterone (0.014g -288.42g/mol) and progesterone (0.0157g -314.46g/mol). In 
addition, the same procedure was followed to calculate 10µM hormone stocks. All 
hormones were stored in glass vials. 
2.2 Growth & Morphology characteristics  
2.2.1 Growth rate analysis  
To determine the bacterial growth rate in LB and AUM. Overnight cultures were 
diluted 1:100 in either LB broth, AUM or urine in polystyrene 96-well plates (Corning® 
Costar®). Bacterial growth curves were performed in media and with the addition of 
hormones; oestradiol, testosterone or progesterone. The hormones were added into 
LB to a final concentration of 20 nM. All assays were performed with four technical 
replicates and in quadruplicate biological replicates. The growth of each dilution was 
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monitored for 24 h at 37°C and the absorbance 600nm was recorded every 30 min by 
the Fluorostar Omega plate reader.  
2.2.2 Colony morphology  
To assess the morphology of colonies of UTI P. aeruginosa, bacteria from overnight 
liquid cultures were streaked on plates containing LB agar (Sigma-Aldrich) as shown 
in (Figure 2.1) to obtain single colonies. The colonies were allowed to grow in room 
temperature for 72h. Image analysis for morphological characteristics such as 
circular, raised, entire, mucoidy, colour and size (millimetre) was recorded. 
 
Figure 2.1 Streaking method conducted to study morphological characteristic of                              
P. aeruginosa UTI isolates 
2.3 Biofilm formation experiments  
2.3.1 Biofilm assay (Crystal Violet staining) 
The overnight cultures of the 15 clinical isolates were diluted 1:100 in LB or AUM. 
This was followed by the addition of 200µl of each P. aeruginosa containing-LB or 
AUM solution in quadruplicate to a 96-well plate (Corning® Costar®) and grown at 
37°C for 24h or 48h. After the incubation period, the broth was removed, followed 
by the application of 200µl of phosphate buffered saline (PBS) (Appleton Woods) to 
the wells twice to wash the biofilms. Removal of PBS was conducted and 200µl of 
49 
 
0.25% crystal violet (CV) w/v in dH2o (Sigma Aldrich) was added into each well for 10 
minutes. Removal of CV was performed, and the wells were rinsed and washed with 
tap water. Stained biofilms were solubilised by adding 200µl of 95% ethanol v/v 
(Sigma Aldrich) for 10 minutes and transferred to a new 96-well plate (Corning® 
Costar®). The absorbance was then measured at OD600nm on the Fluorostar Omega 
plate reader to determine the biofilm biomass. Hormones were added to some 
biofilm assays (where stated). In these assays, each isolate was grown as described 
above with the addition of oestradiol, testosterone and progesterone to a final 
concentration of 10nM. 
2.3.2 Biofilm laser confocal microscopy 
For biofilm microscopy, biofilms were prepared following the method described 
above using glass microscopy-compatible plates (Greiner high and medium binding 
96 well plates, Sigma-Aldrich). The biofilms were allowed to grow at 37°C for 24 h.  
Media and planktonic bacteria were removed gently without disrupting the bottom 
of the well. Each well was washed gently with LB and then removed. 3.58 ml of PBS 
was added with 5 µl of two dyes (SYTO 9 dye, 3.34 mM) and (Propidium iodide, 20 
mM) from the LIVE/DEAD® BacLight® Bacterial Viability Kit (Thermo Fischer 
Scientific). Only live cells/biofilms were included in the analysis. The dye solution was 
used to stain each well with 50 µl. The dye was kept in the wells for 30 minutes then 
transported to the Centre for Cell Imaging at the University of Liverpool where biofilm 
microscopy was performed. Specifically, Carl Zeiss microscope with 40x oil lens was 
used to image the biofilms in Z-stacks.  Upon producing 3D images using Imaris, 
measurement of biofilm structure was performed using Comstat [410]. This software 
measures multiple biofilm characteristics such as surface area, biomass, roughness 
co-efficient and maximum thickness. 
2.3.3 Pyocyanin assay 
To determine pyocyanin production, cultures were grown overnight at 37 °C shaking 
at 180 rpm. To extract the supernatant containing pyocyanin, 1.5 ml of culture was 
transferred to Eppendorf tubes and centrifuged at 13,000 for 2 minutes. 100 µl 
Supernatant was transferred to a 96 well plate and read at 695 nm by Fluorostar 
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Omega plate reader. For hormone treated cultures, 10 nM of oestradiol, testosterone 
and progesterone was used.  
2.4 Motility Assays 
2.4.1 Twitching 
To measure twitching motility of the isolates, a colony of P. aeruginosa was stabbed 
in the middle of an agar plate to the bottom. The colonies were then grown over-
night at 37°C. The agar was then removed, and the plate was subsequently stained 
with 0.25 % CV for 15 minutes. Twitching zones were measured using a ruler. The cut-
off point in which the isolate is considered motile is 5 mm in diameter.  
2.4.2 Swimming motility 
The methodology used is based on a swimming motility assay by Ha, et al, (2014) 
[411]. Briefly, media was prepared according to the protocol described. P. aeruginosa 
cultures were grown overnight in LB broth at 37 °C shaking at 180 rpm. Subsequently, 
a sterile toothpick was used to stab the agar from top to the near bottom of the plate. 
The agar plates were incubated at 37 °C for 18 h. Three biological replicates were 
performed for each isolate in the study. Millimetre measurements were taken to 
assess the diameter of swimming bacteria. To determine whether the isolate is 
motile, comparison with the reference laboratory strain PA14 were conducted.     
2.4.3 Swarming motility  
The swarming motility test was performed according the protocol established by Ha, 
et al, (2014) [411]. Once the preparations of plate cultures were completed, 2.5 µl of 
overnight of P. aeruginosa cultures were added to the top of the agar. The agar plates 
were incubated overnight at 37 °C for 18 h. Three biological replicates were 
conducted for each isolate. Measurements in mm were taken and the isolates were 
deemed motile/non-motile depending on the diameter of 6mm.  
2.5 Antibiotic resistance and genomic sequencing  
2.5.1 Disc diffusion assay  
Antibiotic susceptibility testing was carried out following the European Committee 
on Antimicrobial Susceptibility Testing  (EUCAST) protocol and cut-off points (Table 
2.2) [412]. Three biological replicates of each clinical isolate were grown overnight on 
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Mueller-Hinton agar with antibiotics disc (Thermo Fisher Scientific). The 
measurements in mm were determined and calculated as an average of three 
readings and compared to the published EUCAST breakpoints to determine if the 
clinical isolate is sensitive, intermediate or resistant. 
Table 2.2 Class of each antibiotic and dose used in this study. S= sensitive R=resistant 
Class Antibiotics Dose Zone diameter 
breakpoint 
(mm) 
        S ≥               R <  
Aminoglycosides Tobramycin TN 10 16 16 
Gentamicin GM 10 15 15 
Amikacin Ak 30 18 15 
Netilmicin NET 10 12 12 
Carbapenems Imipenem IMI 10 20 17 
Meropenem MEM 10 24 18 
Doripenem Dor 10 25 22 
Cephalosporins Ceftazidime Caz 30 17 17 
Cefepime CPM 30 21 21 
Ceftazidime/avibactam CZA 14 17 17 
Fluoroquinolones Levofloxacin Lev 5 22 22 
Ciprofloxacin CIP 5 26 26 
Monobactams Aztreonam ATM 30 18 18 
Penicillins Piperacillin PRL 100 18 18 
Piperacillin / Tazobactam PTZ 110 18 18 
Ticarcillin TC 75 18 18 
Ticarcillin with clavulanic 
acid 
TIM 85 18 18 
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2.5.2 Minimum inhibitory concentrations of antimicrobial agents 
Minimum inhibitory concentrations (MIC) for one clinical UTI P. aeruginosa isolate 
758 sourced from Kuwait, was determined using the microdilution method as 
described in the guidelines of the British Society for Antimicrobial Chemotherapy 
[413]. Briefly, 100µl of overnight culture of the isolate was diluted to OD600 of 0.05 
and was mixed with 100µl of serially diluted colisitin (512 - 0.5 μg/ml) (Sigma Aldrich, 
UK) in triplicate using cation adjusted MH broth. Microtitre plates were incubated    
for 1-2 days at 37 °C without shaking and bacterial growth was determined by 
measuring absorbance at OD600 with a FLUOstar® Omega microplate reader and the 
MARS Data Analysis Software test. 
2.5.3 Genomic DNA analysis 
All isolates in this study were sequenced following extraction by Wizard® Genomic 
DNA Purification Kit (Promega). Briefly, 1 ml of overnight culture was added to a 
1.5ml microcentrifuge tube. The sample was centrifuged at 13,000–16,000 × g for 2 
minutes in order to pellet the cells and the supernatant was removed. 600µl of Nuclei 
Lysis Solution was added and resuspended by gentle pipetting. The sample was 
incubated at 80°C for 5 minutes to lyse the cells, the sample was allowed to cool.  
Subsequently, 3µl of RNase Solution was added to the cell lysate, followed by tube 
inversion 2–5 times to ensure adequate mixing. The sample was incubated at 37°C 
for 15–60 minutes and cooled at room temperature. 200µl of Protein Precipitation 
Solution was added to the RNase-treated cell lysate, followed by vigorous vortexing 
at a high speed for 20 S. The sample was then incubated on ice for 5 minutes. Further 
centrifugation at 13,000–16,000 × g for 2 mins was conducted. The resulting 
supernatant containing DNA was transferred to a new 1.5ml microcentrifuge tube 
containing 600µl of temperature isopropanol. This was followed by mixing the tubing 
until the thread-like strands of DNA were visible from the mass. Subsequently, the 
supernatant tube was drained on a clear absorbent paper carefully. 600µl of room 
temperature 70% ethanol (Sigma-Aldrich) was added to the tube, followed by gentle 
inversion of the tube multiple times to wash the DNA pellet. The sample was 
centrifuged at 13,000–16,000 × g for 2 mins and ethanol was gently discarded. The 
pellet was allowed to dry after draining the tube on clean absorbent paper to air-dry 
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for 10-15 min. 100µl of DNA Rehydration Solution was added to the tube, followed 
by rehydration of the DNA at 65°C for 1h. The DNA was stored at 2–8°C in preparation 
for sequencing Centre for Genomic Research (CGR) at the University of Liverpool. 
Briefly, two isolates were sequenced for each sample in the panel. 100 bp paired 
reads were then generated from the ends of 500 bp fragments by utilising an Illumina 
HiSeq 2000 sequencer. FastQ containing sequenced read data were cut-off upon 
detection of Illumina adapter sequences by utilising Cutdapt version 1.2.1 [414]. This 
was followed by the selection of option -O 3, which resulted in trimming the 3’ of all 
reads that matched the adapter sequence of 3 bp or more. The Sickle version 1.2 was 
utilised, the minimum window quality of 20 was chosen as the score to further trim 
sequences shorted than 10 bp [415]. 
2.5.4 Identification of antibiotic resistance genes  
The Comprehensive Antibiotic Resistance Database (CARD; http://arpcard.mcmaster.ca) [7] 
was utilised to search for resistance genes on the sequences obtained from CGR. The 
sequences were inserted in the search tool of the Resistance Gene Identifier (RGI), 
and the following boxes were ticked prior to analysis were DNA Sequence, perfect 
and strict hits only, exclude nudge and High quality/ coverage.  
2.6 Polymerase chain reaction and RNA extraction for qPCR 
2.6.1 DNA extraction 
Promega’s Wizard® Genomic DNA purification kit was used to extract chromosomal 
DNA from all isolates included in this study. To summarise, overnight cultures were 
prepared by inoculating a single colony in 5 ml of LB broth. From this, 1 ml of was 
transferred to an Eppendorf tube and centrifuged at 13,000 rpm for 2 min to form a 
bacterial pellet. Resulting pellets were lysed with 600 µl of lysis solution and 
incubated in a water-bath for 5 min at 80°C. Lysed cells were subsequently treated 
with Rnase (12 µg) and 200 µl of protein precipitation solution. This was followed by 
centrifugation at 13000 rpm for 2 min, the accumulated supernatant was transferred 
to a clear tube consisting of 600 µl of propanol to precipitate the DNA. Further 
centrifugation at 13000 rpm for 2 min was performed, followed by washing the pellet 
with 70% of ethanol. Tubes containing DNA suspensions were stored at 4°C. 
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2.6.2 DNA amplification by PCR and gel electrophoresis  
GoTaq ®qPCR master mix was used to perform PCR reactions. Each reaction 
contained 25 µl of 1x flexi buffer, 200 µM of dNTPs (dntpA, dntpT, dntpC, DntpG), 
300 µM of each oligonucleotide primer, 2.5 mM of MgCl2 and 1.25 U Taq polymerase 
with (Table 2.3). 1 µl of PAO1 DNA was added to the master mix. 
 Table 2.3 Components used in PCR reactions 
Buffer 1X 5X Temperature Time 
DNTPs 0.05 2.5 95 C 3 min 
Buffer 5 25   
Forward 
primer 
0.75 3.75 94 C 20 s 
Reverse 
primer 
0.75 3.75 57 C 20 s 
Mgcl2 2 10 72 C 40 s 
Taq 0.1 0.5 72 C 1 min 
DEPC H2O 14.9 74.5   
DNA 1 ul -   
  
 
 2.6.3 Gel electrophoresis 
To produce agarose gel, agarose powder 1% [W/V] (Bioline) was mixed with TBE 0.5X 
in a volume of 150 ml, followed by the addition of 3 µl of a 10 mg/ml ethidium 
bromide solution.  5 µl of DNA produced by previous PCR reactions was loaded onto 
the gel for 1h to perform electrophoresis in 0.5 TBE solution. To compare sizes pf the 
bands produced, 1 µl of DNA marker (Invitrogen) was added to the both sides of the 
gel. (Gelrad-biodoc) translluminator was used to illuminate the bands and 
photograph the gel. 
55 
 
2.6.4 DNA Purification 
DNA was purified using QIAquick PCR purification kit (Qiagen) per manufactures 
instructions. In summary, 80 µl of Buffer PE (Qiagen) (equivalent to 5 volumes to 1) 
were added to 20 µl in column attached to a flow-through. The column was 
centrifuged at 13000 rpm 1 min to bind the DNA. Subsequent washing step was 
performed by adding 750 µl Buffer PE to the column, the sample was centrifuged at 
13000 rpm and eluted by 50 µl pf DEPC water (Invitrogen) into a clear a 1.5 ml tube.   
2.6.5 DNA Quantification  
Purified DNA samples were quantified using Qubit™ dsDNA BR Assay Kit (Fisher 
Scientific) per manufactures instructions. Master mix containing 0.5 % of Qubit™ 
dsDNA reagent and 95.5% of Qubit™ dsDNA BR buffer was prepared for subsequent 
additions of 2 µl of DNA into separate clear tubes. The concentration of DNA was 
measured in ng/ul with Qubit 3.0 fluorometer (Invitrogen).    
2.6.6 RNA Extraction and cDNA preparation  
Multiple steps were performed to extract and prepare cDNA for subsequent qPCR 
experiments.  1 ml of culture was dispensed into an RNAse free 1.5 eppendorf tube 
(Thermo Fischer Scientific) and subsequently centrifuged at 13,000 rpm for 2 min. 
The supernatant was removed, and the pellet was resuspended in 500 µl Triazole 
(Invitrogen) followed by using Direct-zol® RNA MiniPrep Plus (Zymo Research) kit, 
RNA extractions were performed in a fume hood. At the end of protocol, the samples 
were eluted by 50 µl of DEPC water and subsequently stored in a -80 freezer. The 
samples were quantified using The Nanodrop™ ND-1000 spectrophotometer at 260 
nM. Removal of genomic DNA was performed by Dnase using TURBO DNA-free Kit. 
cDNA synthesis was performed using SuperScript ® III First-Strand Synthesis SuperMix 
kit as instructed by the manufacturer, synthesis steps were carried out in GeneAMp 
PCR System 9700. The purity and amount of the yielded cDNA was once again tested 
by quantification using the Nanodrop™ND-1000 spectrophotometer at 260 nM. 
Samples were stored in -80° prior to qPCR analysis.  
2.6.7 RT qPCR analysis 
The mastermix solution for 72 reactions was prepared by mixing 937.5 µl SYBR green 
(Qiagen), 75 µl of forward primer and 75 µl (Sigma Aldrich) (Table 2.4) and 637.5 of 
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DEPC-treated water (Invitrogen). To calculate the standard curve, the specific DNA 
template was diluted (1 in 10) 9 times, the standards used would range from 10-4 to 
10-8. To conduct the reverse transcription, 23 µl of master mix was added into all the 
test tubes. Followed by adding 2 µl of standards, DEPC water (negative control) and 
cDNA samples into the allocated tubes. The samples were inserted into the Rotor Q 
PCR machine. Then they were preheated for 10 minutes then followed by 40 
amplification cycle with the subsequent order (95°C 10 S + 60°C, 15 S + 72°C, 20 S). 
The analysis was conducted by the Qiagen Rotor gene Q software and the 2-standard 
curves method.  
Table 2.4 Primers used in this study of genes involved in housekeeping, quorum sensing, 
biofilm formation and exotoxins 
Name Sequence Annealing 
Temp (©) 
Amplicon 
size (bp) 
 
Target 
site 
 
Reference 
proC F CAGGCCGGGCAGTTGCTGTC 74.6 180 
 
proC [416] 
proC R CGTCAGGCGCGAGGCTGTCT 74.5 180 
 
proC [416] 
rpoD F GGGCGAAGAAGGAAATGGTC 66.8 178 
 
rpoD [416] 
rpoD R CAGGTGGCGTAGGTGGAGAA 67.4 178 
 
rpoD [416] 
lasR F AAGGAAGTGTTGCAGTGGTG 62.8 67 
 
lasR [416] 
LasR R GAGCAGTTGCAGATAACCGA 63.0 67 
 
lasR [416] 
rhlR F AACGCGAGATCCTGCAATG 66.3 122 
 
rhlR [416] 
rhlR R GCGCGTCGAACTTCTTCTG 66.2 122 
 
rhlR [416] 
pqsR F TCGTTCTGCGATACGGTGAG 
 
66.3 168 
 
pqsR Unpublished 
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pqsR R GCACTGGTTGAAGCGGGAG 
 
68.3 168 
 
pqsR Unpublished 
algD F CGCCGAGATGATCAAGTACA 63.8 157 
 
algD [416] 
algD R TGTAGTAGCGCGACAGGTTCG 
 
67.4 157 
 
algD [416] 
pslA F GCAAGCTGGTGATCTTCTGG 
 
64.9 244 
 
pslA Unpublished 
pslA R TCCCGGAGAACTACAACTCG 
 
64.1 244 
 
pslA Unpublished 
pelB F AGCGCTTGCAACAGATTCTC 
 
64.6 113 
 
pelB [416] 
pelB R AACAGGTTCCAGTGGGTTTC 
 
62.8 113 
 
pelB [416] 
cif F TGAAGAACCAGGCCGACATC 
 
67.5 130 
 
cif Unpublished 
cif R GCACTGGTTGAAGCGGGAG 
 
67.1 130 
 
cif Unpublished 
mexX 
F 
AGCTGTTCAAGCAGACCCAGAACA 70.1 171 
 
mexX [417] 
mexX 
R 
AGGGTGTCGAAGATGTCGCTGAT 70.1 171 
 
mexX [417] 
mexB 
F 
CAAGGGCGTCGGTGACTTCCAG 75.4 272 
 
mexB [418] 
mexB 
R 
ACCTGGCAACCGTCGGGATTGA 73.9 272 
 
mexB [418] 
flgD F GTGCAGTCGCTGAACAAGAG 
 
63.9 159 
 
flgD [416] 
flgD R CATACGTTGCTGCTGGAGAC 
 
63.5 159 
 
flgD [416] 
phzF F GGAGATGAACCTGTCGGAGA 64.3 159 
 
phzF [416] 
PhzF R AGCCTGTCCTTGTCGGTCT 
 
63.9 159 
 
phzF [416] 
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2.7 AUM and Urine media  
2.7.1 AUM preparation  
A 1L solution of AUM was made using the chemical compounds in (Table 2.5). To start 
the process, all components were measured into a glass flask with the exception of 
lactic acid, calcium chloride and Iron II sulphate. Aluminium chloride and citric acid 
were added separately into the flask. 800 ml of distilled water (ddH2O) was added 
and stirred with a magnetic rod. As the components started dissolving, stock of 5 mM 
iron II sulphate was made by adding 0.139 g to 100 ml of ddH2o in addition to a stock 
with calcium chloride 12.5 mM. Subsequently, 1 ml of 5mM iron II sulphate were 
added to mixture followed by 199 ml of Calcium chloride 2H
2
O. The lactic acid was 
added at 0.1 g to dissolve and the pH of the solution was adjusted to 6.5. The solution 
was sterilised by filtration using a 0.2 µM vacuum filter. A single 500 ml DURAN® 
bottle containing AUM was stored and used for no longer than 10 days. 
2.7.2 Pooled Urine  
Urine was collected from healthy controls in accordance with ethical approval 
obtained from the University of Liverpool. Urine was collected from individuals 
following consent urine was pooled by combining equal amounts of urine from two 
males and two females using midstream urine. This was then mixed and filtered using 
a 0.2 µM vacuum filter. A single 1L DURAN® bottle containing urine was stored and 
used for no longer than 10 days. 
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Table 2.5 Contains the components of AUM used in this study with the source of each 
component  
Substance Quantity (g) Conc (mmol-1) Source 
Peptone L37 1 - Sigma Aldrich 
Yeast Extract 0.005 - Sigma Aldrich 
Lactic acid D 0.1 1.1 Sigma Aldrich 
Citric acid 0.384 2 
The British Drug 
House 
Sodium bicarbonate 2.1 25 Sigma Aldrich 
Urea 10.21 170 Sigma Aldrich 
Uric acid 0.067 0.4 Sigma Aldrich 
Creatinine 0.791 7 Sigma Aldrich 
Calcium chloride•2H
2
O 0.367 2.5 Sigma Aldrich 
Sodium chloride 5.259 90 Fisher scientific 
Iron II sulphate•7H
2
O 0.0014 0.005 Fisher scientific 
Magnesium sulphate•7H
2
O 0.492 2 Sigma Aldrich 
Sodium sulphate•10H
2
O 3.22 10 Sigma Aldrich 
Potassium dihydrogen 
phosphate 0.953 7 
Sigma Aldrich 
Di-potassium hydrogen 
phosphate 1.22 7 
Sigma Aldrich 
Ammonium chloride 1.34 25 
The British drug 
house 
Distilled water To 1L 
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2.8 Proteomic analysis  
2.8.1 Preparation of pellets for proteomic analysis  
To conduct proteomic analysis, isolate 133098 was chosen due to its consistent 
phenotypic characteristics and altered antimicrobial resistance in AUM compared to 
LB (data not shown). The isolate was grown in 7 ml of LB and AUM overnight shaking 
at 180 rpm and 37 °C. To assess the responses of P. aeruginosa to the environment 
in LB, AUM, and pooled urine media, 5 ml of 5 biological replicates of overnight 
culture were added to the corresponding media (Figure 2.2). Similarly, to investigate 
the impact of sex hormones on P. aeruginosa, stock solutions of ethanol (vehicle 
control, Sigma Aldrich) oestradiol, testosterone and progesterone hormones were 
added to the AUM to a final concentration of 20 nM (Figure 2.3). Growth curves were 
performed in order to determine the optical density in each media and continuously 
asses growth. Once the optical density of the cultures reached 0.25 +/- 0.05 OD600, 
the samples were centrifuged at 4500 rpm for 12 min to form a large pellet. The 
pellets were washed with PBS and stored at −80 °C before processing for proteomic 
analysis. Samples were then prepared for proteomic analysis by Dr Stuart Armstrong 
(University of Liverpool). Briefly, upon the initiation of proteomic analysis, samples 
were sonicated in 1% (w/v) sodium deoxycholate (SDC) in 50 mM ammonium 
bicarbonate to lyse the pellets. The samples were heated at 80 °C for 15 min, followed 
by centrifugation at 12,000×g to pellet debris. The resulting supernatant was 
retained, and the proteins were reduced with 3 mM dithiothreitol (DTT) (Sigma 
Aldrich) at 60 °C for 10 min. The sample was allowed to cool, followed by alkylation 
with 9 mM iodoacetamide (Sigma Aldrich) in the dark for 30 min with all steps 
conducted with intermittent mixing by vortexing. This was followed by the addition 
of proteomic grade trypsin (Sigma Aldrich) at a ratio of 50:1 and subsequent 
incubation overnight at 37 °C. The remnants of SDC were removed by the addition of 
trifluoroacetic acid (TFA) to a final concentration of 0.5% (v/v). Peptide samples were 
centrifuged at 12,000×g for 30 min to ensure full removal of remaining precipitated 
SDC. 
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Figure 2.2 The methodology used to inoculate overnight cultures of LB, AUM and pooled 
urine prior to proteomic processing. 5 ml of P. aeruginosa cultures were added to 45 ml of 
the corresponding media 
 
Figure 2.3 The methodology used to inoculate overnight cultures to AUM media prior to 
proteomic processing. 5 ml of P. aeruginosa cultures (A, B, C, D) were added to 45 ml of the 
corresponding media with 20 nM hormone concentration 
2.8.2 NanoLC MS ESI MS/MS analysis of peptides  
To initiate processing of the peptides, analysis by on-line nanoflow LC using a 
machine known as the Ultimate 3000 nano system (Dionex/Thermo Fisher Scientific). 
Samples of interest were loaded on the trap column with the following specifications 
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(Acclaim PepMap 100, 2 cm × 75 μm inner diameter, C18, 3 μm, 100 Å) at 
5 μl min−1).This was followed by addition of an acquis solution containing  0.1% (v/v) 
TFA and 2% (v/v) acetonitrile. Upon the 3 min mark, the trap column was set in-line 
analytical column with the following specifications (Easy-Spray PepMap® RSLC 
50 cm × 75 μm inner diameter, C18, 2 μm, 100 Å) and fused with to silica nano-
electrospray emitter (Dionex). The column was coupled with a Q-Exactive HF mass 
spectrometer under an operating constant temperature of 35 °C. The 
chromatography was conducted with 0.1% formic acid (Buffer A) and (Buffer B) which 
consists of 80% acetonitrile in 0.1% formic acid. Separation of peptides was 
performed by a linear gradient of 3.8–50% buffer B over a duration of 90 min with a 
flow rate of 300 nl per min. The mode of the Q-Exactive HF was set on the data-
dependent mode with survey scans obtained at the resolution of 60,000. The Isotope 
patterns were of the 10 most abundant patterns with charges ranging between +2 to 
+5 from the survey scan were chosen with an isolation window of 2.0  TH and 
separated to fragments with high and normalised energy dissuasion. Time for 
maximum injections of ion for survey scans was set between 100 and 45 ms, 
respectively. As for the ion target scan, the value was set to 36A for survey scans and 
1E5 for the MS/MS scans. The resolution with which MS/MS scans acquired were 
acquired at a resolution of 30,000. The dynamic exclusion feature was utilised by to 
minimise sequence repetitions for 20 s.  
2.8.3 Protein identification and quantification  
To identify and quantify the proteins. Thermo Raw files were transferred into the 
prognosis QI for proteomics (version 4.1, Nonlinear Dynamics). By utilising default 
settings and using selected runs as reference, the runs were time aligned. The 
software identified the peaks by using the default settings involving peaks between 
+2 and +7 charges only. These data were then converted to mgf files, and tagged for 
prognosis IQ for proteomics, this was followed by running the data search engine 
known as the mascot (version 2.3.02, Matrix Science). The translated open reading 
frames from the reference strain of P. aeruginosa were searched against tandem 
repeat data (Uniprot reference proteome, UP000002438, December 2016) and a 
contaminant database (cRAP, GPMDB, 2012) (combined 5733 sequences: 1,909,703 
63 
 
residues). Parameters used in this search were as follows, both of precursor mass 
tolerance and fragment mass tolerance were set at 10 p.p.m and 0.05 Da, 
respectively. In addition, two tryptic cleavages were allowed. Oxidation parameter 
was set at a variable modification while the carbamidomethylation was set at a fixed 
modification. To assess the validity of mascot results, the machine learning algorithm 
back up the results obtained. Upon utilising the Mascot decoy database function, the 
false discovery rate was less than 1% and the individual percolator ion scores 
recorded >13, which indicates to the identify or extensive homology with a (p < 0.05). 
Upon the transferring the mascot search results to Progenesis QI for proteomics, the 
files were converted to XML files. The intensities of the peptides were normalised 
against a reference utilised by Progenesis QI for proteomics, the intensities were 
utilised to emphasize the relative differences in the expression of proteins in the 
treatment groups. Identification of proteins was restricted only to 2 or more peptides 
include in this set of data. Again, Prognosis QI for proteomics was utilised to perform 
statistical analysis which identified statistically significant proteins with p < 0.05, 
q ≤ 0.05, and relative fold change of ≥ 1.5 of differentially expressed proteins. The 
Principal component analysis (PCA) plots were generated by using ClustVis proteins 
which included proteins with 2 or more identified peptides along with q < 0.05. 
Scaling was conducted by applying unit variance to rows; amputated SVD was used 
to calculate PCA. 
2.9 Therapeutics 
2.9.1 Bacteriophage-inhibition of P. aeruginosa assay 
To test the ability of bacteriophages PELP20, PMN, PT6 and 42/1 to infect our panel 
of UTI isolates, a mixture of 3.5 ml pf liquid top agar (0.6% agar) (Fisher Scientific) and 
150 µl of P. aeruginosa grown in either LB) (Appleton woods) or AUM was prepared. 
The mixture was used to inoculate LB agar plates. Phage stocks were adjusted in 
concentration to 200 plaque forming units per 10 µl to perform a spot assay. 10 µl of 
each phage was inoculated onto the lawn of P. aeruginosa and the plates were 
allowed to grow overnight at 37 °C. Clear zone formation indicated that the isolate 
was susceptible to that phage. 
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2.10 Statistical analysis  
All statistical analyses (unless otherwise stated) were performed using Sigma Plot 14 
software. Distribution was determined using Shapiro Wilk normality test. Growth 
curves, biofilm assays were analysed using Kruskal-Wallis analysis of variance and 
Holm-Sidak post hoc test for nonparametric data and Brown-Forsythe test for 
Pairwise comparison. MIC data were analysed using Kruskal-Wallis analysis of 
variance and Brown-Forsythe test.  
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Chapter 3 
3 Characterisation of a Panel of Urinary P. aeruginosa Isolates 
3.1 Introduction  
3.1.1 P. aeruginosa characteristics in different human niches 
P. aeruginosa is a highly adaptable and versatile opportunistic pathogen with a large 
genome (5.5 Mb to 7.0 MB). This is larger than other Gram-negative uropathogens 
such as  UPEC (5.2 Mb) [419], K. pneumoniae 5.2Mb [420] and P. mirabilis 4.063 Mb 
[421]. P. aeruginosa can undergo adaption that enhances survival and virulence in 
the host. It can act as a pathogen in many different infection types including 
respiratory, burns and wounds, keratitis as well as urinary tract infections. 
3.1.1.1 Respiratory infections 
P. aeruginosa can cause chronic respiratory infections in patients with CF, non-CF 
associated bronchiectasis and patients on ventilators. Infection in CF patients is a 
prime example of the pathogen’s capability to cause severe damage to the 
respiratory system, leading to increased morbidity, compromised life quality, and 
eventual mortality [422]. Upon establishment in the CF lung, P. aeruginosa can 
become impossible to eradicate, due to high levels of antibiotic resistance and rapid 
adaptation to the host environment [423]. Numerous alterations of phenotypic and 
genetic characteristics take place over the course of the infection to allow the 
bacteria to further adapt [424], [425]. P. aeruginosa secretes important virulence 
factors such as QS-regulated elastase, pyocyanin and proteases [426], and other 
factors such as the siderophore pyoverdine [427]. P. aeruginosa can lose motility 
[138] and convert to a mucoid phenotype [426], [428]. Hypermutator strains have 
been identified and are thought to contribute to adaptation in the CF lung. These 
isolates have also been linked to the development of antibiotic resistance [424], 
[429], [430]. For an extensive review on CF pathogen-host interactions see Malhotra 
et al, 2019 [431]. 
Non- CF bronchiectasis is another situation whereby chronic respiratory infection by 
P. aeruginosa can occur. Bronchiectasis is characterised by the existence of a cough 
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and sputum that is difficult to clear [432]. It is often exacerbated by the continuous 
cycle of infections which lead to lung damage, dilation and failure [433]. Risk factors 
of bronchiectasis consist of old age, poor lung function and prolonged P. aeruginosa 
colonisation [434]–[436]. A meta-analysis conducted on 3683 adult patients revealed 
that P. aeruginosa is associated with increased hospital visits, morbidity, and 
mortality [437]. Varga et al, (2015) analysed a hyper-mutator strain PAHM4 isolated 
from a chronic bronchiectasis patient and distinguished the similarities and 
differences between this strain and CF isolates [438]. The role of  P. aeruginosa in 
bronchiectasis has been reviewed recently by Chai et al, (2019) [439].   
3.1.1.2 Burns and wound infections 
P. aeruginosa can cause nosocomial burns wound infections [440]. Severe burns lead 
to devascularisation of the wound environment, which leads to difficulty in clearing 
bacterial infection due to the inhibition of neutrophils migrating to the wound [441]. 
Burns patients suffer from an increased susceptibility to infection arising from the 
breached skin barrier. Such infections can lead to a pro-inflammatory response which 
is initiated by IL-6 and TNF-α followed by an anti-inflammatory response (IL-10,IL-4) 
.The avascular nature of the wound decreases oxygen levels and diminishes the 
nutrient supply to host tissues [442]. Despite these limitations, P. aeruginosa can 
thrive and invade damaged tissues and from here, potentially access the bloodstream 
[443]. Heparinase produced by P. aeruginosa appears to contribute to bloodstream 
survival and is associated with 100% mortality in a mouse model of burn wound 
infection. Conversely PA14 lacking hepP (which encodes heperinase) were associated 
with only with 7% mortality of infected mice [444].  Elastase and protease contribute 
to the breach of host physical barriers through enzymatic action on collagen, thereby 
further disrupting the integrity of the host membrane defences [445]. Other                    
P. aeruginosa virulence factors involved in burn wound pathogenesis are LPS, 
phospholipase C, ferripyochelin binding protein and effectors of the type III secretion 
system [445]. As in other types of P. aeruginosa infections, antibiotic resistance is a 
concern and requires immediate development of more therapeutic options. For 
further recent published literature on the rise of antimicrobial resistance in burn 
wound patients see [446].  Alternative therapeutics potentially embedded in wound 
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dressings should be developed to treat/limit P. aeruginosa infections in these 
patients. 
3.1.1.3 Keratitis 
P. aeruginosa can cause keratitis which is defined as inflammation of the eye due to 
infection. This can result in the rapid destruction of the cornea [447]. P. aeruginosa 
is the leading cause of bacterial keratitis around the world and a major cause of 
corneal ulcers in developing countries [448]. P. aeruginosa has been associated with 
contact lens use and the incidence of this infection has increased since the 
introduction of contact lenses in 1971 [449], [450]. Ocular surgery, trauma and viral 
infections are predisposing factors [451]. Furthermore, P. aeruginosa can be resistant 
to disinfectants and can adhere to plastic surfaces and form biofilms on contact 
lenses, intraocular lenses and lens storage cases [452], [453]. Upon infection of the 
eye, P. aeruginosa invades the corneal epithelium and subsequently moves into the 
corneal stroma. The bacteria binds to corneal epithelial glycoproteins through 
attaching via pili [453]. LPS also mediates adherence to the cornea or contact lenses 
[454]. Flagellar motility plays a major role in the dissemination of infections, mutants 
in flagellar motility genes are attenuated in their ability to colonise the corneal 
epithelium [455].  Biofilm formation and maturation on the surface of the cornea has 
been reported [456], [457]. However, the host-pathogen interactions and the role of 
biofilms has not been extensively researched in ocular infections. 
3.1.1.4 Urinary tract infections 
In contrast to CF infections caused by P. aeruginosa, there is a paucity of information 
in the literature that address P. aeruginosa UTIs. Infections impacting the urinary 
tract account for the majority of infections in Europe at 40% of all nosocomial 
infections [458]. Most infections cause inflammation of the bladder, but in some 
cases, infections can progress to the kidney (pyelonephritis), and particularly in 
patients suffering from vesico-uretric reflexes (VUR). Patients affected by this 
disorder could further experience complications such as kidney scarring and failure. 
UTIs can also be recurrent and persistent, causing more severe infections. 
Furthermore, dissemination of bacteria into the bloodstream (bacteraemia) and 
sepsis may lead to fatal infections. One third of bacteremia cases are caused by E. coli 
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in England with over 50% of these are associated with UTI .Uropathogenic                          
P. aeruginosa is not as widespread, however, it is frequently detected in complicated 
UTI such as CAUTI, it has been reported that it is the third most common cause of 
CAUTI [47]. Multiple virulence factors participate in UTIs, elastase and protease have 
proteolytic and elastolytic activity in UTI infections and are produced in higher levels 
than isolates obtained from burn wound infections, skin wounds infections and acute 
pneumonia [175]. Hamood et al, (1996) examined the production of enzymes such as 
elastase, phospholipase C, toxin A, and exoenzyme S, quantified and compared from 
isolates derived from trachea, wounds and urinary tract. Most isolates produced all 
toxins but in different quantities based on the site of infection. Wound and UTI 
isolates produced significantly higher levels of exoenzyme S than tracheal isolates.  
As for elastase and phospholipase C, they were produced by most isolates from 
trachea, wound and urinary tract [180]. Ciragil et al, (2004) investigated the 
production of virulence factors alginate, elastase and alkaline protease from isolates 
derived from the airways of CF patients and blood, lungs, and urine from non-CF 
patients [148]. It was observed that UTI isolates produced the least amount of 
alginate and the highest levels of alkaline protease compared to the other isolates. 
This may suggest a role for alkaline protease in degrading C2 component of 
complement system and inhibiting associated phagocytosis [459].  Iron acquisition 
mechanisms are indispensable for P. aeruginosa and the role of siderophores have 
been reported in CF and burn infections [460], yet their role remains unclear in P. 
aeruginosa uropathogenesis. Pyoverdine and pyochelin are two siderophores 
produced by P. aeruginosa in order to facilitate uptake of iron from the environment. 
Upon characterisation of 30 UTI and CAUTI isolates, Tielen et al, (2011) reported the 
detection of pyoverdine [90]. Although the majority of P. aeruginosa isolates produce 
these two types of siderophore, a study by Visca et al, (1992) revealed that some 
isolates appeared to rely on only one siderophore as some strains did not produce 
both siderophores (2.4% and 7.4% were defective in pyochelin and pyoverdine, 
respectively) [461]. P. aeruginosa UTI isolates that produce high levels of haemolysin 
have been associated with higher bacterial counts and renal colonisation in a mouse 
model of infection [462]. These findings suggest that P. aeruginosa UTI pathogenesis 
could involve several mechanisms to acquire iron from the host. Other uropathogens 
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such as UPEC utilise siderophores enterobactin, yersiniabactin, and salmochelin to 
survive in the urinary tract [463], [464]. For detailed analysis on siderophores and 
iron acquisition mechanisms see chapters 4 & 5.  
P. aeruginosa UTI pathogenesis has recently been reviewed by Newman et al, (2017) 
[269]. Despite the reported genotypic and phenotypic characterisation of P. 
aeruginosa UTI isolates in the literature, this field of interest remains relatively 
underreported.  
3.2 Biofilms 
Formation of biofilms is a crucial factor in establishing colonisation and survival in 
multiple host niches. Biofilm formation on urinary catheters make up 40% of 
nosocomial infections and are the most common source of Gram-negative 
bacteraemia in patients [465]. One of the main drawbacks of utilising urinary 
catheters is the resulting compromise of the natural barriers such as the urethral 
sphincter [466]. Thus, catheters serve as a basis for biofilm formation and provides a 
focal point for replication and dissemination of bacteria into the bladder [467]. 
Treatment is becoming increasingly difficult due to reduced antibiotic susceptibility 
of biofilms, contributing to the persistence of CAUTI [468]. This is attributed to poor 
antibiotic penetration, slow growth, nutrient limitation, and the existence of persister 
cells [469].  
P. aeruginosa can possess different biofilm formation characteristics depending on 
the site of infection. For example, CF isolates produce the exopolysaccharides 
alginate, Pel and Psl and this has been shown to be important in both in vitro biofilm 
formation assays [470] and in vivo [428]. Furthermore, mucoid isolates have been 
identified that overproduce alginate and these have been linked to chronic infections 
[471], [472]. Once colonisation occurs and the biofilm is fully established within the 
respiratory tract, treatment with antibiotics cannot eradicate the infection [473]. 
Constant immune recruitment of PMNs to surround P. aeruginosa biofilms, 
ultimately leads to lung damage and respiratory failure due to the aggressive 
inflammatory response [474]. P. aeruginosa biofilms are also implicated in chronic 
wound infections, where penetration of deep layers occurs [475]. Infections with           
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P. aeruginosa present in a biofilm often cause larger wounds than infections caused 
by other bacteria such as S. aureus and thus can be highly problematic in the healing 
process [475], [476]. Biofilms on urinary catheters vary in size, as many as thousands 
of bacteria per ml ( >105 CFU/ml) can cause infection around the catheter and induce 
chronic inflammation [477]. The inflammation is driven by recruitment of PMNs and 
complement components [478]. Gram-negative bacterial uropathogens start 
developing biofilms upon the colonisation of the catheter [479]. P. aeruginosa can 
utilise flagella to initiate attachment to the catheter. Cellular secretions of bacterial 
cyclic di GMP then promote formation of biofilms and suppresses multiple cellular 
functions such as motility. C-di-GMP is considered as a switch between a motile and 
sessile bacterial lifestyles [77]. Indeed, c-di-GMP binds and acts on the transcriptional 
regulator FleQ to suppress flagellar movement and inhibits FimX to repress type IV 
pilus involved in twitching motility [75], [480], [481].  As a secondary messenger, c-
di-GMP activates both of the psl and pel exopolysaccharide operons in vitro by 
binding to the FleQ master regulator [76]. Thus, transforming motile bacteria to 
sessile biofilms is governed by multiple actions of c-di-GMP acting in concert to 
promote biofilm formation. Cole et al, (2014) examined the ability of PA14 and PA14 
mutants in alginate production, to from CAUTI in a mouse model. The findings 
indicated that c-di-GMP promoted biofilm formation independent of alginate and pel 
exopolysaccharides, followed by colonisation of the bladder and subsequently, the 
kidneys [56]. Therefore, the importance of exopolysaccharides in the context of 
catheter biofilms in unclear. 
As well as bacterial-derived factors that promote initial colonisation, P. aeruginosa 
can also utilise host factors to aid this process. P. aeruginosa attach to secreted host 
proteins present on the catheter surface [466]. Tamm-Horsfall protein (THP) is a 
glycoprotein secreted by kidney tubular cells and the most abundant protein present 
in urine [482]. THP exists in the mucosal slime and provides protection against 
invasive E. coli in the urinary tract. Mice mutants lacking THP do not clear UPEC as 
efficiently as the wild-type [483]. However, some studies conducted in vitro and in 
vivo found the opposite effect. Harjaj et al, (2005) utilised THP-coated P. aeruginosa 
and injected it in murine bladder via urinary catheters, and observed increased 
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bacterial load and tissue pathology of ascending acute pyelonephritis [462]. THP has 
also been found to bind to catheters and promotes P. aeruginosa biofilm formation 
[484]. Therefore, the exact role of this host protein remains unclear although it may 
promote bacterial persistence in the presence of an indwelling catheter.  
Urea is another major component of urine which has been shown experimentally to 
be a contributing host factor which promotes biofilm formation [56]. As the primary 
solute in urine, urea has been shown to induce the release of eDNA from a subgroup 
of P. aeruginosa cells within the biofilm [56]. Thus, biofilms can be formed in the 
lumen of catheter without the expression of exopolysaccharides such as Pel and Psl. 
Alterations of QS systems las and rhl were mediated by urea and urine, suggesting 
that urine acts as an inhibitory substance [485]. This indicate that quorum sensing 
may not be essential during CAUTIs. Further discussion on the role of eDNA and 
pyocyanin will follow in chapter 4.  
3.3 P. aeruginosa motility  
As discussed previously (section 1.3.2), motility is important in the initial stages of 
infection in various human niches. P. aeruginosa possess several different modes of 
motility. The exact role in UTIs is unclear. 
3.3.1 Swimming motility  
Motility is utilised by multiple bacterial species to reach new environmental niches 
and this includes movement to a potential infection site. P. aeruginosa can execute 
at least 3 types of motility; swimming, twitching and swarming [69]. Swimming 
motility in liquid is promoted by a single polar flagellar and allows rapid movement 
[486]. This movement is powered by a motor complex where energy for rotational 
torque is provided by flagellar subunits. The energy propels the bacterium in a 
direction controlled by the rotor [487]. Swimming motility is linked with immune 
activation by TLRs, neutrophil phagocytosis and NETs in the host [488].  As a potential 
survival strategy in the respiratory tract of CF patients, loss of flagella is common and 
has been found to confer resistance to phagocytosis and aid in the establishment of 
chronic infection [489].  
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3.3.2 Twitching motility  
Twitching motility allows movement across solid and semi-solid surfaces and is 
dependent on type IV pili, fibrous appendages on the cell surface. This process 
involves repeated extension, tethering and retraction of the pili that results in a jerky 
movement [490]. Each bacterial cell can have many of these pili appendages that can 
extend and retract independently, or in a coordinated manner [491].  Despite having 
pili at each pole, P. aeruginosa cells normally utilise one pole to direct movements 
[491]. Type IV pili are responsible for allowing P. aeruginosa to adhere to a diverse 
range of surfaces such as glass, stainless steel and mammalian buccal epithelial cells 
[492], [493].  Twitching motility, is hence, considered as a virulence factor promoting 
micro-colony formation (through initial attachment) and host cell adhesion [492]. 
This form of motility is utilised to counteract iron depletion/scarcity in mammalian 
hosts [494]. In the respiratory tract of CF patient, loss of type IV pili has been 
identified as a possible evolutionary adaptation during chronic infection, perhaps in 
part mediated as a defence from temperate phage infection which often utilise pili 
as a receptor. Currently, the role of type IV pili is unclear in P. aeruginosa UTI motility, 
however, adhesive organelles such as the fimbriae in UPEC has been shown to play a 
role in urothelium adhesion [495].   
3.3.3 Swarming motility   
Swarming motility is the movement of bacteria across semi-fluid surfaces. It is 
regarded as the fastest mode of motility to expand and colonise environments and 
host tissues surfaces [496]. This type of movement is not exclusively dependent on a 
single organelle or biochemical pathway, instead it involves multiple coordinated 
cellular activities. P. aeruginosa utilize type IV pili, flagella and biosurfactants in this 
process [492], [497],. Rhamnolipids are the main biosurfactants produced by                    
P. aeruginosa and RhlA is the major protein [498]. Current evidence suggests that 
swarming motility may affect biofilm architecture. Hyper-motile strains form flat 
biofilms while strains with lower levels of swarming tend to aggregate and form 
micro-colonies [499], [500]. To address the complexity of the multi-factorial 
regulation of P. aeruginosa swarming motility, Yeung et al, (2009) performed 
insertional mutations in PA14. The study identified 35 transcriptional regulators 
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involved in in swarming motility and multiple two-component-systems. An inverse 
relationship between biofilm formation mutants and swarming motility deficient 
mutants was observed [501].           
In contrast to CF infections caused by P. aeruginosa [489], [502], motility profiles of 
UTI isolates are not widely reported. Tielen et al, (2011) investigated 30 UTI isolates 
of P. aeruginosa and found that catheter-associated isolates displayed reduced 
motility in comparison to P. aeruginosa isolated from mid-stream urine [90]. 
However, no correlation was found between each type of motility and biofilm 
formation. In this study, 90% of isolates displayed swimming, 70% could twitch and 
60% showed an ability to swarm [90]. Keratitis isolates showed a similar degree of 
motility. A study by Priya et al, (2005) which analysed the phenotypic differences 
between 17 ocular P. aeruginosa isolates found that 100% possessed the ability to 
swim, 82% twitched and 64% swarmed in vitro [503].  Cigana et al, (2016) examined 
a panel of 338 P. aeruginosa CF isolates, most of which were assigned to the most 
prevalent (P) subtypes identified in an Italian population of CF patients [504]. The 
majority of P1 isolates were able to twitch (62%) and swim (75%). Other subtypes (P6 
and P14) isolates lacked both twitching and swimming.  Another study in Italy of 135 
CF isolates found that again, motility was generally lower in CF isolates (swimming 
isolates [40%], twitching [50%] and swarming [45%]) [505].   
3.4 Antimicrobial resistance  
3.4.1 Intrinsic resistance 
3.4.1.1 Efflux pumps  
Intrinsic resistance is defined as the innate ability of a given microorganism to 
withstand the efficacy of antibiotics through existing structural or functional traits 
[506]. The outer membrane of P. aeruginosa contributes to intrinsic resistance owing 
to its low permeability  to multiple types of molecules, including antibiotics [507].The 
outer membrane of P. aeruginosa is highly restrictive, compared to that of E. coli, (12-
to 1000- fold less permeable) [507], [508]. Efflux pumps play a crucial role in 
transporting a few antibiotic classes out of the bacterial cell. The protein pumps 
belong to the resistance nodulation division (RND) super-family of efflux pumps 
[509]. These are comprised of cytoplasmic membrane transporters, linker 
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cytoplasmic proteins and outer membrane porin channels [510]. Several efflux 
pumps contribute to resistance to different antibiotics, for example, MexAB-OprM 
contributes to the expulsion of β-lactams and quinolones [511], [512]. MexCD-OprJ 
ejects β-lactams [513]. MexEF-OprN pumps out quinolones [514]. While MexXY-
OprM is involved in extruding aminoglycosides [515]. In addition to their baseline 
activity, mutations can occur that lead to overexpression of efflux pumps. This has 
contributed substantially to the increasing burden of AMR [516]–[518].    
3.4.1.2 Antibiotic inactivating enzymes 
Inactivation of enzymes by modifying and breaking down antibiotic molecules is 
another method by which intrinsic antibiotic resistance is achieved [519]. Numerous 
antibiotics contain amides and ester chemical bonds which are susceptible to 
hydrolysis by bacterial enzymes such as β-lactamases enzymes modifying of 
aminoglycosides [311], [520], [521]. The intrinsic resistance of P. aeruginosa is 
enhanced by the existence of naturally occurring AmpC, a β lactamase that is 
encoded chromosomally [520]. AmpC utilizes hydrolysis to prevent antibiotic 
molecules of penicillin and cephalosporins from reaching their targets [522]. AmpC 
benefits from its location in the periplasm and can be induced using subinhibitory 
concentrations of β-lactams [522], [523]. In addition, other β-lactamases are 
chromosomally encoded, and these enzymes can be classified into four groups (A, B, 
C, D) based on amino acid sequences according to the ambler classification (Table 
3.1). 
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Table 3.1 Ambler classification of β-lactamases and examples of intrinsic enzymes involved 
in P. aeruginosa antibiotic resistance 
Ambler class β-lactamases Active site 
agent 
Examples References 
A Penicillinases Serine Unknown _ 
B Metallo-β-
lactamases 
Zinc Pib-1 [524] 
C cephlaosporinases Serine AmpC [520] 
D Oxacillinases Serine OXA-50 [525] 
 
3.4.2 Acquired resistance 
In addition to intrinsic resistance, bacterial isolates can acquire further resistance to 
antibiotics either by mutational alterations or gaining resistance genes via horizontal 
gene transfer [526]. The combination of intrinsic and acquired resistance complicates 
potential treatment of P. aeruginosa infections [527]. 
3.4.2.1 Acquired resistance by mutations   
Mutational changes reduce susceptibility to antibiotics by, for example, influencing 
modification of antibiotic targets, overexpression of efflux pumps and antibiotic 
inactivating enzymes [528]. The mutations occur randomly but can be selected for 
due to antibiotic pressure during treatment. Furthermore, inactivation of                          
P. aeruginosa DNA oxidative repair mechanism through mutations in mutT, mutS and 
mutY can increase mutational frequencies (hypermutability), which in turn can 
increase resistance by causing mutations. For example, mutations that enhance  β-
lactamase production or overexpression of the efflux pump MexCD-OprJ [529].  
Mutations affecting bacterial membrane permeability can lead to enhanced 
resistance to antibiotics [530]. This occurs due to spontaneous mutations to porins, 
which are water-filled that allow hydrophilic antibiotics to pass [530], [531]. OprD is 
such a porin and loss of this channel increases resistance to carbapenems [532], 
[533]. Fang et al, (2014) collected and analysed 61 clinical isolates from different 
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sources, six of which were from mid-stream urine. The study found that 50 isolates 
displayed resistance to imipenem by the loss of OprD function either by frameshift 
mutation or a premature stop codon while the rest of the 11 isolates displayed either 
reduced oprD expression or undetectable OprD porin [95]. Ochs et al, (2000) revealed 
that two loops (2 and 3) contained the entry and binding points for imipenem, 
mutations in either or both loops lead to conformational changes and increased 
carbapenem resistance [534].  
Efflux pumps eject toxic materials out of the cells to avoid the build-up of harmful 
molecules such as antibiotics [509], [516]. Overexpression of efflux systems such as 
MexXY-OprM has been shown to result from gene mutations of the transcriptional 
regulators, mexR, nalR, nalC and nalD, contributing to reduced susceptibility to β-
lactams and fluoroquinolones (FQs) [535]–[538]. Mutations occurring in the mexZ 
gene (a repressor) was also reported to alleviate the levels of overexpression of 
MexXY-OprM to a few classes of antibiotics, namely, aminoglycosides, β-lactams, and 
FQs in P. aeruginosa clinical isolates [417], [539], [540]. Another efflux system, 
MexCD-OprJ was found to be overexpressed in several P. aeruginosa strains due to 
mutations in the nfxB gene, giving raise to resistance to carbapenems and FQs [513], 
[541].   
Mutational changes can play a role in the protection and modification of bacterial 
target sites [528]. For instance, alterations of DNA gyrase (GyrA-GyrB) and 
topoisomerase (ParC-ParE) subunits by chromosomal mutations are one of the 
common resistance mechanisms to FQs [301]. The mechanisms of action for 
quinolone antibiotics depend on the inhibition of bacterial DNA replication by 
affecting DNA gyrase and topoisomerase [542]. Thus, reduction of the binding affinity 
reduces susceptibility of P. aeruginosa to FQs [543]. Polymyxin, which is the last 
resort class of antibiotics to treat P. aeruginosa infections, can be resisted by the 
bacterium via different mechanisms [544]. First, by modifying and adding 4-amino-L-
arabinose (L-Ara4N) to the phosphate group within the lipid A moiety of LPS [545]. 
Alterations in the two component systems PhoPQ and PmrAB via specific mutations 
lead to P. aeruginosa conferring resistance to cationic polymyxins [546], [547]. 
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3.4.2.2 Acquisition of resistance of genes  
P. aeruginosa can acquire further resistance via obtaining transferrable resistance 
genes. Resistant genes on mobile genetic material such as plasmids, integrons, 
transposons and phages may be transferred to and between the same or different 
bacterial species via conjugation, transformation and transduction [430]. Integrons 
are genetic elements which capture small genetic material called cassettes via site-
specific recombination and insert them into a specific location [548]. Integrons have 
been shown to play a crucial role in disseminating resistance genes between                   
P. aeruginosa strains around the world [549]–[552]. Acquisition of β-lactam and 
aminoglycoside- resistance genes have been reported by several studies worldwide. 
For instance, several genes have been identified as Class B metallo-beta-lactamases, 
(MBLs) [553]. Genetic elements such as integrons and plasmids are involved in the 
transmission of MBLs [554], [555]. A single integron can carry multiple resistance 
genes. This is demonstrated by two aminoglycoside resistance genes aacA29a and 
aacA29b, both are located at the 5’ and ‘3 end on the hydrolysing beta-lactamase 
VIM-2 gene cassette in P. aeruginosa clinical isolates [556]. VIM-2 has been reported 
in many countries around the world such as Argentina, France, Greece, India and 
Japan and Spain [557]. In Spain, detection of the MDR and XDR strains carrying VIM-
2 with the integron structure IntlI-VIM2-aac6'Ib-qacEΔ1 has been reported [558].   
3.4.3 Resistance to β-lactams 
3.4.3.1 Extended spectrum β-lactamases  
As previously mentioned in section 3.4.1.2, β-lactamase enzymes are classified 
according to amino acid sequence into 4 sub-groups; A, B, C and D. The enzyme 
classes A, C and D target an active site of serine for hydrolysis. Group B β- lactamases 
are metalloenzymes that depend on bivalent zinc for its activity. MBLs resist all β-
lactam class antibiotics except for monobactams. In the past few decades,  UTI-
related extended-spectrum β-lactamases (ESBL) in Enterobacteriaceae and non-
fermenting bacterial pathogens such as P. aeruginosa and Acinetobacter baumannii 
have been on the rise, particularly in the developing world [559].  
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3.4.3.2 Class A β-lactamases 
Class A β-lactamases are serine enzymes which include K. pneumoniae 
carbapenemases (KPC) enzymes and Guiana extended-spectrum (GES) variants [560]. 
Transmissible elements such as plasmids and transposons carry KPC encoding genes 
are on Enterobacteriaceae species such as K. pneumoniae [561]. Detection of                   
P. aeruginosa carrying KPC enzymes has been reported in China, the Caribbean region 
and South America, and rare reports from the United States of America [557], [561]. 
GES enzymes detected in Spain, Turkey, China, and Brazil [557].  
3.4.3.3 Class B β-lactamases 
Class B β-lactamases, also known as MBLs, are common throughout the world 
amongst P. aeruginosa isolates and the most reported carbapenemases. Unlike other 
classes of β-lactamases with serine activity, MBLs contain Zn2+ ion on the active site 
and possess strong inhibition via metal chelators. MBLs can hydrolyse carbapenems 
efficiently and the rest of β-lactams except for monobactams. P. aeruginosa 
containing MBLs are not affected by  β-lactamase inhibitors such as tazobactam and 
clavulanic acid [553]. Integron gene cassette are encoded on genes related to mobile 
elements and exhibit different compositions, MBL genes occupy these compositions 
[562]. The most common MBLs are Imipenamases (IMP) and Verona integron-
encoded metallo- β-lactamases (VIM) which were discovered in the 1990s in Japan 
and Italy, respectively (Table 3.2) [563], [564]. These discoveries were followed by 
more reports of additional MBL-types such as GIM-,SPM,KHM-, NDM-, AIM-, DIM-, 
SIM-, FIM- and TMB- [557], [565]. , This study will only discuss VIM-type resistance, 
For extensive reviews on all types see Potron et al, (2015) and Hong et al, (2015) 
[553], [557]. 
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Table 3.2 Example of the epidemiology of MBLs around the world 
 
3.4.3.4 Verona integron-encoded MBLs 
VIM-type P. aeruginosa is the most widespread MBL and has been involved in 
multiple outbreaks around the world [570]. The subtype VIM-2 is the most reported 
in this opportunistic pathogen [570]. VIM-1 has been reported in Italy upon its 
detection from a surgical wound [564], followed by further detection in France in four 
isolates, one of which was isolated from urine [571]. In Greece, a UTI isolate amongst 
5 other isolates carrying blaVIM were found to be resistant both to imipenem and 
meropenem [572]. In the same country, VIM-4 was isolated from a ventriculo-
peritoneal catheter and the cerebrospinal fluid. VIM-4 differs from VIM-1 by a single 
nucleotide and may have diverged from the same ancestor [573]. VIM-4 was also 
reported in a urine sample isolate collected from a Greek patient in Sweden [574] 
with further reporting from a children’s hospital in Poland, (5 VIM-4 positive                       
P. aeruginosa urinary isolates) [575].  VIM-2, it is closely related to VIM-1 as they both 
share 90%  amino acid identity [570] and is disseminated throughout the world and 
is known to be the most widespread MBL in P. aeruginosa [553].  For example, VIM-
Metallo-β-lactamases Example encoding gene Reference 
Imipenemases (IMP) blaIMP-1 [553] 
Verona integron-encoded 
metallo-β-lactamase 
(VIM) 
bla VIM-1 [564] 
San Paulo metallo-β- 
lactamase (SPM) 
blaSPM-1 [566] 
Germany imipenemase 
(GIM) 
blaGIM-1 [567] 
New Delhi metallo-β- 
lactamase (NDM) 
bla NDM-1 [568] 
Florence imipenemase 
(FIM) 
blaFIM-1 [569] 
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2 producing P. aeruginosa has been isolated from a urine sample belonging to a Saudi 
patient diagnosed with prostatitis [576] and from Tunisia from blood and urine 
samples [577]. In the far east, a South Korean tertiary hospital identified 43 VIM-2 
producers over a period of six years mostly from urine and sputum samples [578]. 
VIM-2 producers have also been detected in Venezuela from blood and respiratory 
tract samples [579]. In Germany, VIM-2 was isolated from a blood sample of a cancer 
patient [580]. The first report of outbreak of VIM-2 North America (USA) was 
published in 2005, where five isolates, one of which was obtained from urine, were 
identified [581]. In 2004, a novel MBL, VIM-7 was detected. This MBL shares 77% and 
74% identity to VIM-1 and VIM-2, respectively [570]. A P. aeruginosa pulmonary 
invasive sample from a cancer patient that carries VIM-7 was identified in the USA 
[582]. Ever since the discovery of VIM-type MBLs in Italy, they have been reported 
repeatedly around the world (Table 3.3 ) [553].  
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Table 3.3 Examples of variants of VIM- producing P. aeruginosa isolates reported around the 
world since its discovery in Italy in 1999 
VIM enzyme Type Country of isolation Sample type Reference 
VIM-1 Italy 
 
Surgical wound [564] 
VIM-2 Tunisia Blood, urine, Catheter [577] 
VIM-3 Taiwan Blood, urine, Catheter [583] 
VIM-4 Greece Ventriculo-peritoneal 
catheter 
[573] 
VIM-5 Turkey Respiratory tract [584] 
VIM-6 South Korea Wound, soft tissue [585] 
VIM-7 USA Invasive pulmonary 
sample 
[582] 
VIM-8 Columbia Sputum, urine [586] 
VIM-9 UK Not specified [557] 
VIM-10 UK Not Specified [587] 
VIM-11 Malaysia Respiratory tract, 
abdominal swabs, 
catheters, blood, urine 
[588] 
VIM-13 Spain Not Specified [589] 
VIM-14 Spain Not Specified [557] 
VIM-15 Bulgaria Urine [590] 
VIM-16 Germany Urine [590] 
VIM-17 Greece Not specified [591] 
VIM-18 India Sputum [592] 
VIM-20 Spain Urine, surgical wound, 
catheter, bone, abscess 
[593] 
VIM-28 Egypt Not specified [594] 
VIM-30 France Not specified [557] 
VIM-36 Belgium lower respiratory tract [595] 
VIM-37 Poland Skin [595] 
VIM-38 Turkey wound, blood, sputum [596] 
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3.4.3.5 Ambler Class D  
Ambler class D β-lactamases contain OXA-type or oxacillinases are represented by 
more than 350 genetically diverse enzymes, which are extensively disseminated in 
Gram-negative bacteria [597]. Generally, OXA-type β-lactamases are categorised     
into narrow-spectrum and extended spectrum β-lactamases. Narrow-spectrum 
oxacillinases such as OXA-2 and OXA-10, confer resistance to penicillins and early 
cephalosporins but can also confer resistance to 2nd generation cephalosporins such 
as ceftazidime by amino acid substitutions [598], [599].  
P. aeruginosa  expresses oxacillinases which are β-lactam hydrolysing enzymes [600]. 
For example, OXA-10, which can be identified in P. aeruginosa, hydrolyses 
cephalosporins, cefotaxime, ceftriaxone, and aztreonam but fails to neutralise 
ceftazidime and carbapenems [601]. Formerly known as PSE-2, OXA-10  nucleotide 
sequence was identified by Huovinen et al, (1987) [601]. Other examples of 
oxacillinases include OXA-18 and OXA-198 [602] [603]. In 2018, a study by Bonnin et 
al, (2018) published the detection of three more OXA-198 P. aeruginosa tracheal 
isolates carrying the blaOXA-198 on a 49-kb plasmid. All three patients were deceased 
in the same hospital [604].  
3.4.4 Prevalence of antibiotic resistance and geographical distribution of resistance 
Epidemiological studies on AMR in Gram-negative uropathogens show variation in 
resistance worldwide. For example, lower levels of MDR were found in England than 
in Eastern Europe, the Middle East and South America [559], [605]. However, in 2000, 
a multicentre (including hospitals in England) study based on the SENTRY 
antimicrobial resistance surveillance revealed that uropathogenic P. aeruginosa is a 
cause for concern. This was in part due to P. aeruginosa showing less susceptibility to 
carbapenems at 89.3%, compared to UPEC at 99%. The study, however, does not 
specify the proportion of isolates originating from England [606]. In the latest 
surveillance report by SENTRY, which was conducted between 2012-2015 on urinary 
and intrabdominal P. aeruginosa isolates, a total of 64 isolates were collected from 
the UK and were found to be susceptible to ceftolozane/ tazobactam (100%),  
ceftazidime (90.6%) and meropenem (84.4%) [607]. Ironmonger et al, (2015) 
conducted the first antimicrobial resistance surveillance in the Midlands (UK) to 
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detect resistance patterns of uropathogens, one of which was P. aeruginosa. The 
study was performed over a period of 4 years on a population of 5.6 million and 
collected a total of 786 of Pseudomonas spp isolates (4.08% of total uropathogens), 
detecting 5.7% carbapenemases producers [605]. Public Health England (PHE) started 
a surveillance program in 2013-2018 to monitor P. aeruginosa resistance to 
ceftazidime and carbapenems in bloodstream infections. The report found that AMR 
resistance in bloodstream infections remained stable over the period of the study. 
The report did not specify the percentage of P. aeruginosa and their role in 
bloodstream infections [608]. 
 3.4.4.1 Antimicrobial resistance in the Gulf corporation council  
The Gulf Corporation Council (GCC) is comprised of six countries that function as a 
political and economic union; The state of Kuwait, Kingdom of Saudi Arabia, Kingdom 
of Bahrain, State of Qatar, United Arab Emirates and Sultanate of Oman (Figure 3.1) 
[609]. 
Antibiotic resistance is on the rise across the region. This is attributed to multiple 
factors, one of which is travelling, a known risk factor for acquisition and transmission 
of antibiotic resistant bacteria [610], [611]. Increased travel is driven primarily by a 
large boom in the tourism industry, large inward migration of expatriate workers, and 
hosting religious pilgrimages such as the Haj and Umra [559], [612], [613]. In addition, 
multiple studies have been conducted to assess the contributing factors of the rise of 
antimicrobial resistance in the region. These factors include the high use of antibiotics 
[614], [615], lack of regional and legislative guidelines for bacterial infection 
treatments [614], [616], and purchase of antibiotics from pharmacies without 
prescriptions in certain countries [609], [617].   
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Figure 3.1 The countries of the Gulf Corporation Council comprise of six countries; Kuwait, 
Saudi Arabia, Qatar, Bahrain, United Arab Emirates [609] 
Environmental factors such as naturally occurring high temperatures between 38 °C 
and 48 °C during the summer months can promote and increase the rate the of 
horizontal gene transfer between microorganisms carrying AMR genes [618]–[620]. 
Another concerning factor is the exacerbation of temperatures by climate change and 
anthropogenic activities, for instance, sea temperature at the Kuwait bay is rising 
three times the global average [621].  
As a result, multiple studies have described the presence of AMR bacteria such as 
ESBL producing E. coli [622], [623], carbapenem resistant A. baumannii [624], [625], 
and pan-drug resistance K. pneumoniae [626].  
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As for P. aeruginosa, a retrospective study conducted by al-johani et al, (2010) found 
that P. aeruginosa is the second most isolated carbapenem resistant bacteria in an 
intensive care unit (ICU) in a Saudi hospital. The study also observed a decline in 
susceptibility from 66% to 24% over a period of 5 years [627]. Carbapenem resistance 
in the GCC states appear to be associated with VIM-type and IMP-type MBL enzymes 
[622], [627], [628]. Zowawi et al, (2018) carried-out a regional study on P. aeruginosa 
clinical isolates collected from all GCC countries and found that high-risk clones are 
now detected, particularly, blaVIM- was found in 39% of 95 isolates in the study [629].  
3.4.4.2 Prevalence of UTI antibiotic resistance in Kuwait  
Kuwait is located in the eastern tip of the Arabian (Persian) Gulf [621]. The country 
possesses five large district hospitals which provide tertiary care services [630]. 
Surveillance programmes for AMR are lacking [609].However, sporadic reports of the 
emergence of AMR bacteria have been on the rise particularly for pathogens such as 
A. baumannii and ESBL-producing Enterobacteriaceae [631], [632].   
The first of report of resistant UTI clinical isolates was published in 1986 in E. coli and 
P. mirabilis. The authors reported resistance to ampicillin, sulphonamide and 
trimethoprim/sulphamethoxazole [633]. In 1997, a study reported multiple resistant 
uropathogens including UPEC, K. pneumoniae, P. mirabilis, and P. aeruginosa in 
complicated UTIs isolates from 225 patients in a district hospital in Kuwait. In the 10 
detected P. aeruginosa UTI isolates, aminoglycoside resistance was more common 
than ceftazidime and piperacillin [634]. Dimitrov et al, (2004) conducted a study on 
community acquired UTI over a period of 7 years between 1995 and 2001 and 1606 
isolates were collected. Amongst those, 74 (4.8%) P. aeruginosa isolates were 
reported, with two displaying imipenem resistance [635].  In 2004, 265 (7.5%) of 3592 
Enterobacteriaceae and P. aeruginosa were found to be ESBL producers.                                     
35 P. aeruginosa ESBL were detected, of which 14 were isolated from urine [636]. Al 
Sweih et al, (2005) reported further 193 P. aeruginosa uropathogens found to be 
sensitive to amikacin, ciprofloxacin and piperacillin in two large hospitals in 2002 
[637]. In addition, a study conducted over a period of three years (2005-2007) in one 
of Kuwait’s largest hospitals, found that 9.8% of P. aeruginosa UTI was acquired in 
the hospital, in contrast to 4.3% isolated from outpatients. The percentage resistance 
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of hospital-acquired isolates was 15% and 14% to amikacin, piperacillin and 
Tazobactam, respectively [638]. These studies provide primary information on UTI      
P. aeruginosa but lack comprehensive analysis on the type of genes responsible for 
resistance and the emphasis on the role of mutations which increase AMR.  
3.5 P. aeruginosa genomics 
3.5.1 Sequencing of reference strains PAO1, PA14, LESB58 
Due to rapid advances in the last two decades, genome sequencing has been 
extensively used to enhance our understanding of pathogen diversity and adaption 
[639]. The emergence of high powered and in depth sequencing technology has led 
to cheaper ‘per genome’ costs and this has enabled scientists to sequence many 
pathogens of the same species as opposed to focusing on sequencing genetically 
distant organisms only [640].  
The PAO1 P. aeruginosa laboratory strain was isolated from a wound infection in 
Australia and the genome was subsequently sequenced in the year 2000 using Sanger 
sequencing  [641], [642]. The large and complex genome of P. aeruginosa contributes 
to survival and adaptation in different niches and environments. The size of this 
genome was 6.3 million base pairs, which is larger than many other bacteria [642], 
[643]. PAO1 contains 5,557 open reading frames, four putative chemotaxis systems 
and a great number of genes participating in control systems such as environmental 
signals and transcriptional regulators [642]. A second commonly used reference 
strain called PA14 was subsequently sequenced and was found to have 6.5 million 
base pairs [644], [645]. PA14 contains two pathogenicity islands that may be 
responsible for the virulence in a wide range of hosts including models such as the 
nematode C. elegans, the insect larvae Galleria mellonella, the plant Arabidoopsis 
Thaliana, and mice [646]–[648]. A third important strain related to CF pathogenesis 
called the Liverpool Epidemic Strain B58 (LESB58) was shown to be transmissible in a 
landmark paper using molecular methods. Prior to this discovery, the belief that each 
CF patient harboured individual specific strains was widespread [125]. The reference 
LESB58 was the earliest LES isolate to be sequenced. The analyses revealed multiple 
large genomic islands such as prophage clusters, a defective pyocin prophage cluster, 
and non-phage islands [131].  
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The genome of P. aeruginosa is comprised of a core genome and accessory genome 
[649]. The core genome is a highly conserved and therefore common to all isolates. 
The accessory genome includes flexible genes (of which there may be several 
variants) and mobile genetic elements such as plasmids, transposons, phages and 
genomic islands. These can play a significant role in determining the pathogenicity in 
microorganisms, including P. aeruginosa  [649].  
Genomic islands are defined as chromosomal regions which are often strain-specific 
[650]. Many islands are identified by the atypical G+C content. Pathogenicity islands 
are genomic islands that encompass distinct genetic elements which encode 
virulence proteins [650]. The variation observed between P. aeruginosa genomes is 
largely dependent on genomic islands and prophages [651]. Mathee et al, (2008) 
conducted a comparison between the genomes of PAO1 and PA14 to three other P. 
aeruginosa strains isolated from CF patients identified as PA2192, PAC52 and C3719 
[652]. The genomes of PA14 and PA2192 were larger and distantly related to the rest 
of the isolates [652]. The analysis revealed a total of 5021 genes conserved in the 
genomes possessed by these strains, whereas 52 regions of gene plasticity (RGB) 
were detected. RGBs allow for the insertion of genomic islands and bacteriophages 
or removal of DNA segments [652].  
3.5.2 Next Generation Sequencing (NGS)  
Next Generation Sequencing (NGS) methods are becoming cost-effective and have, 
in some situations, been used in clinical investigations into transmission and AMR 
[653]. NGS methods are comprised of two types: short-read sequencing and long-
read sequencing. Short-read sequencing (such as Illumina) is considered useful for 
population-level research with low cost and high-accuracy performance. Long-read 
methods (such as PacBio) is powerful in de novo gene assembly and using this, 
assemblies of one complete contig are possible.  
3.5.3 Population genomics of P. aeruginosa  
P. aeruginosa populations have been described as displaying an epidemic population 
structure [654]. Wiehlmann et al, (2007) developed a microarray genotyping 
platform that included analysis of the core and the accessory genome. The paper 
analysed 240 isolates from diverse habitats and found that the PA14 clone was the 
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most abundant genotype [645]. The increased availability and utilisation of 
sequencing has enabled further in-depth studies. The Pseudomonas Genome 
Database (www.Pseudomonas.com) contains 335 complete genomes and 4512 draft 
genomes (as of the 2nd of September 2019) [655]. The database provides researchers 
with genome annotations, cellular components, molecular functions and biological 
processes [655].  It contains genomes of taxonomical outliers such as PA7, a multi-
resistant strain from Argentina, and since its typing and annotation, more isolates 
were categorised as PA7-like [656], [657]. Population structure of P. aeruginosa 
consisted of group 1 (PAO1-like) and group 2 (PA14-like) and the outlier group PA7-
like [658]. LESB58 clusters in group 1. A multi-group study by Freschi et al, (2015) 
characterised 389 strains and found that 309, 68 and 12 strains belonged to groups 
1,2 and 3, respectively [658]. Kos et al, (2015) utilised NGS to link the genomes of 390 
isolates to resistant phenotypes. These clinical isolates were sourced from diverse 
range of infections including UTIs (n=86) and from different geographical locations 
around the world [659]. Phylogenetic tree analysis of the isolates revealed a 
heterogenous population and genome size ranging from 6.0 Mbp to 7.4 Mbp, with 
PA01-like isolates making up the majority of the samples [659]. The population 
structure has been recently redefined by utilising NGS sequencing and analysing the 
pan-genome, leading to the addition of a fourth and fifth group of P. aeruginosa 
isolates [660]. 
3.5.4 Genomic studies in P. aeruginosa UTI infections 
The database of sequenced isolates of P. aeruginosa isolates appears to be biased 
towards respiratory infections such as CF. This presumably reflects the amount of 
research and funding available in this area. Sequenced UTI isolates of P. aeruginosa 
are scarce and this is a potential limitation in current datasets. 
Using Single nucleotide polymorphism (SNP) Tielen et al, (2011) investigated the 
genomic variability and the relationship between 30 urethral isolates which led to the 
detection of 21 genotypically different groups. This suggests that, like P. aeruginosa 
isolates from other sources, the UTI population is highly heterogenous [90]. As 
mentioned earlier in section 3.5.3, Kos et al, (2015) sequenced 86 UTI isolates and 
found that the average genome size of the isolates was 6.8 Mbp [659]. A UTI isolate 
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from Germany (called MH38), has been sequenced revealing a 6,889,973 base pair 
genome. MH38 contains 6,089 protein-coding sequences (CDS)s 254 were found to 
be unique (Table 3.4). From the unique CDS,  59 phage and 5 transposon associated 
genes were identified [661]. RN21 was isolated from an acute UTI and was found to 
have a 7.0 Mbp genome including, again, unique phage-related genes. Some of the 
phage-related gene displayed strong similarity to the transposable phage D3112. 
CRISPR phage immunity sequences were also identified [662]. Further genomes from 
CAUTI isolates have been reported between 6.6-7 Mbp, these strongly suggest that 
UTI isolates could be a rich source of unique genes, particularly with reference to 
prophage sequences. Furthermore, although isolates numbers are low, it appears 
that UTI isolates can contain large genomes of over 7 Mbp. 
Genome sequencing has also revealed genes associated with heavy metal and 
antimicrobial resistance.  A Sudan based-study described a draft genome of a multi-
drug resistant isolate with an estimated genome size of six mb carrying multiple β-
lactamases genes such as blaVeb-1, blaPAO and blaOXA-50 [663]. Overall, UTIs are 
an understudied source of P. aeruginosa isolates and WGS of further UTI isolates may 
contribute to the population structure and identification of antibiotic resistance 
genes.  
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Table 3.4 Draft genome of 4 UTI isolates elucidating key genotypic and phenotypic 
characteristics such as genome size, GC content and reported key features 
 
P. aeruginosa contributes to the overall morbidity and mortality of UTIs, with the 
emergence of highly resistance strains that are specifically involved in CAUTI [665]. 
Paucity of information regarding P. aeruginosa genomics may be detrimental in 
combating the rise of AMR strains and developing therapeutic options to tackle this 
threat. Current sequencing projects have resulted in a database that is extensive 
however, it is biased both geographically (Western origin) and in terms of infection 
site (respiratory) and therefore additional sequencing could be employed in order to 
represent these different niches. 
In this chapter, the findings will be discussed in relation to reported virulence 
characteristics in P. aeruginosa uropathogens and isolates sourced from other types 
of infections. 
Isolate Genome 
size 
GC content Key features Reference 
MH38 6.9 Mb 65.83% Metal resistance 
Antibiotic resistance 
Type IV secretion 
system 
[661] 
MH19 7.1 Mb 65.95% Metal resistance 
Antibiotic resistance 
Evolutionary 
homologues of toxins 
[664] 
RN21 7.0 Mb 65.88% Phage encoded genes [662] 
UTI 6.0 Mb 64.6% Antibiotic resistance [663] 
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3.6 Aims 
 
1). To phenotypically characterize a panel of urinary tract samples obtained in the 
United Kingdom. 
 
2). To determine the levels of antimicrobial resistance to 17 anti-Pseudomonal 
antibiotics of UTI isolates from the UK and the State of Kuwait. 
 
3). To determine the genomic profile of the isolates and the genetic basis of AMR. 
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3.7 Results 
3.7.1 Morphological and growth characteristics 
3.7.1.1 Growth of P. aeruginosa UTI isolates 
Growth curves were performed in order to determine growth patterns over 24 hours 
for 15 UK clinical isolates and the two reference isolates PA14 and PAO1 (Figure 3.2). 
The growth of the UTI isolates were highly variable and strain dependent. 
Comparisons were performed at 4 time points (6,12,18, and 24 h). The only significant 
difference was observed at the 18h point where the optical density of PAO1 was 
significantly higher than 133042 (P=0.047). The growth rates and maximum cell 
density vary between all the UTI clinical isolates  
 3.7.1.2 Morphology imaging 
In other infections, particularly respiratory, colony morphology has been linked to 
features such as chronic infection (mucoidy), persistence (small colony variants) and 
alterations in quorum sensing (metallic phenotype). In order to study the colony 
morphology of the isolates, 23 clinical UTI P. aeruginosa isolates (from the UK and 
Kuwait) were grown over 72 h. These were originally isolated from two different 
geographical locations; the United Kingdom and the state of Kuwait. Phenotypic 
characteristics may give an indication of possible mutations in QS regulatory genes 
such as mutations in lasR or energy acquisition mechanism [666]. For instance, the 
mucoidy phenotypes are associated with alginate overproduction in P. aeruginosa 
and wrinkly shaped colonies indicate an adaptive response linked to oxygen uptake 
[667]. Colony images were taken after 72 h (Table 3.5). From the UK panel of clinical 
isolates; isolate 133042 exhibited a pigmented morphology that developed into a 
wrinkly colony type over time. None of the isolates displayed a mucoid phenotype. 
The majority of isolates were yellow however blue-green pigmentation was also 
identified (Isolates 133042, 133065, 133075). The metallic phenotype was observed 
in isolates 133117, 133042 and 133065. Most isolates maintained a circular shape 
during growth.  Colony size displayed variation from 1-5 mm. 
As for isolates sourced from Kuwait (Table 3.6), all isolates exhibited the same circular 
shape and the yellow pigmentation except isolates 925 and 1083, with both 
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demonstrating grey and creamy pigments. No mucoidy or wrinkly colonies observed, 
all isolates appear to have closely similar phenotypes. 
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Figure 3. 2 Growth of 14 UTI isolates and 2 references isolates PAO1 and PA14 over 24 h. Optical density was measured at OD600. Pairwise comparison of all 
isolates involved at 6,12,18 and 24h. Three biological replicates were performed, and points represent the mean (with standard deviation bars)
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Table 3. 5 Morphology of the UK panel of isolates after 72 hours.  C-circular, Con-convex, E-
entire, NM-non-mucoid, R-raised, I-irregular 
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Table 3.6 Morphology of Kuwait panel of isolates after 72 hours.  C-circular, Con-convex, E-
entire, NM-non-mucoid, R-raised, I-irregular 
 
3.8. Biofilm Formation  
3.8.1 CV staining  
Biofilm formation is one of main, problematic features in CAUTI in nosocomial 
settings [56], [280]. P. aeruginosa is often used as a model to study biofilms [668]. 
By studying this panel of isolates, the in vitro biofilm formation ability of the UTI 
isolates was determined and compared to laboratory reference strains PAO1 and 
PA14. Using a 96-well assay to study biofilms adhered to polystyrene wells, it was 
found that the total biomass of all isolates, apart from 133105, was reduced 
compared to PAO1. Isolate 133044 displayed a significant reduction in biofilm 
formation (P=0.036) (Figure 3.3). In comparison to PA14, 5 isolates (133075, 
133082,133083, 133105, 133117) formed more biomass, although these differences 
were not statistically significant. These results show that the majority of isolates are 
capable of biofilm formation in this assay, however, the extent of the biofilm is 
variable. 
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Figure 3.3 Biofilm formation across all clinical isolates. Dunn’s statistical test showed a statistically significant difference in the biomass between 
PAO1 and 133044 only as P= 0.036 which is shown by the asterisk
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3.8.1 Biofilms microscopy   
Further assessment of biofilm morphology was conducted using confocal microscopy 
(Figure 3.4). Biofilm microscopy provides further insight and information on the 3D 
architecture and development of these sessile microbial communities by conducting 
post-analyses by a software called COMSTAT. Specifically, the software quantifies and 
compares biofilm structures formed by all the 15 clinical isolates and the reference 
isolates.  
COMSTAT consists of 10 different features which analyses the biofilm quantitatively. 
5 variables were chosen in this study; biomass, maximum thickness, roughness co-
efficient, surface to biofilm ratio and surface area. The roughness coefficient 
parameter distinguishes between rough and smooth biofilms. The parameter of 
surface:biofilm ratio indicates to which fraction of the biofilm is exposed to nutrient 
flow. As for the biomass; Hydorn et al, (2000) defined the biomass as the total volume 
of the biofilm. Maximum thickness covers a given area regardless of the pores or the 
holes in the biofilm and correlates inversely with surface to biofilm ratio. The surface 
area is defined by Heydorn as ‘’ The area summation of all biomass voxel surfaces 
exposed to the background’’ [410]. 
In terms of biomass, all the UTI isolates produced a greater biomass than the 
reference isolates except for 133105 (0.92 µm^3/µm^2) (Figure 3.5). This highlights 
inconsistencies between the microscopy and staining method. Using the staining 
method, isolate 133105 produced the highest biofilm formation of all of the UTI 
isolates. Using microscopy, isolate 133075 recorded the highest biomass (3.17 
µm^3/µm^2) followed by Isolates 133044 and 133098 (2.73 and 2.84 µm^3/µm^2, 
respectively). Again, this highlights the inconsistency as both of these isolates were 
very low biofilm producers in the staining assays. Furthermore, the variation between 
replicates of the same isolate was very high suggesting that these measurements can 
be inconsistent and thus, this data must be interpreted with extreme caution.  
No significant differences were identified between isolates for any of the microscopy 
measures. In brief, 60% of all clinical UTI isolates displayed higher surface to biofilm 
ratio with the highest value recorded by isolate 133090 (26.84 ratio) and the lowest 
was 133104 (6.14) ratio. No statistical significance was identified (P = 0.934) (Figure 
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3.6-A). The surface area covered, although identified as higher in 93% of all UTI 
isolates in comparison to PAO1, there was no statistical difference (P = 0.974) (Figure 
3.6-B). There was no significant difference in the biofilm roughness coefficient (P = 
0.351) (Figure 3.6-C) or the maximum thickness (P=0.802) (Figure 3.6-D). 
 
Figure 3.4 Biofilm morphology of UTI isolates of P. aeruginosa. Images obtained with Carl-
Zeiss confocal microscope at 40X magnification of biofilms formed by the UK panel of                  
P. aeruginosa isolates. The images were processed using Imaris and can be used to calculate 
different parameters of biofilms such as biomass, maximum thickness and surface area by 
COMSTAT. The scale of the images is 20 µm. A: The panel include strong biomass formers. B: 
Intermediate biofilm producers. C: Weak Biofilm producers
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Figure 3.5 The total biofilm biomass of clinical isolates after 48 h growth in LB. Biomass was calculated using Comstat. There are no statistically significant 
differences between reference and all clinical isolates (n=5) (P = 0.985). Statistical test performed by Kruskal–Wallis test analysis of variance on values 
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Figure 3.6 The graphs display four parameters calculated by COMSTAT post-microscopy. A): Surface to biofilm ratio with a P = 0.946. B) Surface area of biofilm, 
P= 0.974. C) Roughness co-efficient with P=0.802. D) Maximum thickness with no significant P=0.351. No statistically significant difference found between 
reference and clinical isolates. Statistical test conducted by Kruskal–Wallis test analysis of variance on values 
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3.9 Production of the virulence factor pyocyanin 
Pyocyanin is a potent virulence factor utilized by P. aeruginosa in urinary tract 
infections and other types of infection such as CF and keratitis [156]. All the UTI 
isolates showed decreased pyocyanin production compared to LESB58, which is a 
known hyperproducer of pyocyanin. For four isolates (133083,10090, 133042 and 
133065) the reduction was significant (P=0.003, P=0.015, P= 0.031 and P= 0.041) 
(Figure 3.7). None of the UTI isolates exhibit the pyocyanin over-production 
phenotype. There were no significant differences in pyocyanin production between 
the clinical isolates and PAO1 or PA14. Isolate 133083 displayed the lowest levels of 
pyocyanin production at 0.002 (absorption at A695). This low level may be indicative 
of a mutation in the QS system or phenazine production genes [669]. The average 
production of all clinical isolates is 0.04 (standard deviation of 0.02), which is higher 
than PAO1, though is less than PA14 (0.063). 
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Figure 3.7 Mean pyocyanin production from the clinical UTI isolates of P. aeruginosa. Pyocyanin production was determined through measurement 
of absorbance at 695nm of supernatants. * denotes statistical significance between LESB58 the isolates P <0.050 
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3.10 Bacterial motility of UTI isolates 
3.10.1 Swimming motility  
Swimming motility is facilitated by polar flagella present on some P. aeruginosa isolates. The 
flagellum is a virulence factor utilised in swimming but also to initiate biofilm formation [71]. 
Overnight bacterial cultures were grown in LB medium shaking at 180 rpm and 37°C. By 
utilising a plate-based method [411], the ability of the 15 UK UTI isolates to swim was analysed 
in comparison to the reference strain PA14. Based on this, three UTI isolates were significantly 
reduced in comparison to PA14 (133044,133083 and 13099 with the following respective P 
values, P= 0.011, 0=0.46 and 0.046). These were classed as non-motile. Thus, 80% of the 
clinical isolates (n=11) displayed an ability to swim through aqueous media (Figure 3.8 & 3.10).  
 
 
Figure 3.8 Swimming motility of PA14 displayed on image (A). The mean distance travelled by isolate 
133106 is the most (20 mm) (image B) and the least travelled is isolate 133099 (4 mm) (image C) 
3.10.2 Twitching motility  
Twitching motility is facilitated by type IV pili which allows the bacteria to move across 
surfaces and colonize the host [670]. Twitching motility is involved in forming biofilms. 
Examination of this type of motility may clarify whether these isolates have the potential to 
utilize motility to aid CAUTI. The method used was based on Fonseca et al, (2004) [671], where 
CV was utilised to detect twitching movement by staining the bottom of the agar after 
inoculating with P. aeruginosa. The mean distance travelled by all the 15 clinical isolates is 6 
mm SD=+/-0.75 mm (Figure 3.11). The cut-off was exceeded by all the UTI isolates except 
133044 and 133105 which were non-motile (1 mm). Thus, 86.6% UTI isolates in this study can 
perform twitching motility. 
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3.10.3 Swarming motility 
Swarming motility is considered the fastest movement across semi-fluid surfaces by P. 
aeruginosa [69]. The average mean distance travelled by the UTI isolates was 12 mm (sd +/- 
1.75 mm). The cut-off used to define motile and non-motile isolates was 6 mm. All but two 
UTI isolates (133083 and 133099) demonstrated the ability to swarm. The greatest swarming 
was observed for isolates 133082 and 133098, travelling 26 mm and 22 mm, respectively 
(Figures 3.9 & 3.12).    
 
Figure 3.9  A sample of 3 isolates that poses the capacity to perform swarming motility. Strain PAO1 
(A) displayed moderate swarming capability, isolate 133098 (B) is the 2nd most motile in the panel, 
while isolate 133082 (C) is an example of a moderate isolate 
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Figure 3.10 The mean value of distances travelled (mm) by swimming in each isolate from the point of inculcation is displayed on the Y axis. The 
asterisk indicates to a statistically significant difference P< 0.050 between the annotated UTI isolates and PA14    
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Figure 3.11 Twitching motility. The horizontal line at 5 mm denotes twitching motility and is reached by the two references isolates PAO1 and PA14 
and 12 clinical isolates
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Figure 3.12 The mean average of distance travelled (mm) by swarming motility. The horizontal line is at 6 mm, the cut-off of which an isolate is recognised as 
motile. 13 UTI isolates can perform swarming motility
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3.11 Antibiotic susceptibility testing (AST) 
3.11.1 Disc diffusion assay  
To examine the ability of the UTI isolates to resists the action of antibiotics, an 
extensive panel of antibiotics were chosen to test all clinical isolates and the two 
reference strains PAO1 and PA14 according to clinical breakpoints points published 
by EUCAST [672]. Table 3.7 shows the results for this susceptibility testing of the UK 
UTI isolates. Only one isolate, 133044, displayed resistance to aminoglycosides. This 
isolate showed no zone of inhibition for tobramycin and gentamicin but was 
susceptible to amikacin. The rest of the isolates displayed zones of susceptibility 
ranging from 18 to 30 mm to tobramycin, gentamicin and amikacin. Carbapenems 
are widely used to treat as a last line of treatment of P. aeruginosa infections around 
the world. For imipenem, 2 isolates showed intermediate resistance (133044 and 
133105). Furthermore, isolate 133105 was also resistant to meropenem and 
doripenem, therefore, this one isolate displayed at least some resistance to all three 
clinically relevant carbapenems. The panel was generally susceptible to 
cephalosporins.  
Ciprofloxacin is a fluoroquinolone antibiotic and is used to treat P. aeruginosa 
infections. 22.6% of the clinical isolates were not susceptible to ciprofloxacin, with 
isolate 133126 exhibiting intermediate susceptibility and isolates 133065, 133099 
and 133126 categorised as resistant. Resistance to levofloxacin (another quinolone) 
was detected (5/15 isolates with three of these isolates showing no zone of 
inhibition).  Aztreonam targets PBP3 and is classified as a monobactam. 133105 is the 
only isolate resistant (0 mm) to aztreonam while the rest of isolates displayed 
inhibition zones ranging from 19 to 30 mm. The isolates were generally susceptible 
to antibiotics form the penicillins class. However, isolate 133105 was resistant to 
piperacillin (16 mm), piperacillin Tazobactam (18 mm), ticarcillin (0 mm), ticarcillin 
with clavulanic acid (0 mm). Other isolates exhibiting resistance to antibiotics in the 
penicillin class were 133044, 133099 and 133104.  
A multi-drug resistant (MDR) isolate is classified as such when resistance occurs to 
one antibiotic in three or more classes [559]. Although six isolates showed resistance 
to at least one antibiotic, based on the criterion, only two UK UTI isolates can be 
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classified as MDR, 133099 and 133105. Overall, these results indicate that although 
resistance was detected in the isolates, the isolates are susceptible to some of the 
antibiotics and therefore there are potential treatment options.   
In contrast to the UK isolates, the isolates from Kuwait displayed more resistance to 
antibiotics (Table 3.8). If an isolate is resistant to all antibiotics except two or fewer 
classes, it is defined as an extensively drug resistant (XDR) bacterial isolate [673]. 75% 
of the Kuwaiti clinical isolates are classified as XDR (Table 3.8). Isolates 758 and 783 
were resistant to all the antibiotics tested. Isolate 786 was only susceptible to 
imipenem. Isolate 888 was only susceptible to some cephalosporins and 
tazobactam/piperacillin and isolate 925 was only susceptible to fluoroquinolones 
(levofloxacin and ciprofloxacin) and gentamicin. Isolate 864 was MDR and displayed 
resistance to antibiotics from carbapenems, cephalosporins, monobactams and 
penicillins. The only isolate not classed as resistant was 1083. For this isolate, 
intermediate levels of resistance were observed to netilmicin. To assess whether 
isolate 758 is resistant to polymyxins such as colistin, an MIC experiment was 
conducted. Both isolates were sensitive to colistin at 2 mg/L suggesting that it could 
be a last resort antibiotic used for treatment against these isolates.  However, 2 mg/L 
represents the cut-off for classification as sensitive (sensitive ≥2, resistant <2) and 
therefore these isolates must be deemed as a high potential for pan resistance. 
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Table 3.7 AMR in UK P. aeruginosa isolates from UTIs. Size (mm) of zone of inhibition following disk diffusion assays are reported. Resistance is colour coded 
in red while intermediate values appear in orange 
 Aminoglycosides Carbapenems Cephalosporins Fluoroquinolones Monobactams Penicillins 
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 TN GM AK NET IMI MeM Dor Caz CPM CZA Lev CIP ATM PRL PTZ TC TIM 
Dose 10 10 30  10 10 10 10 30 30 14 5 5 30 100 110 75 85 
133042 24 21 26 18 29 34 35 29 28 28 35 26 30 27 26 26 28 
133043 24 23 21 17 25 27 35 23 30 22 32 24 20 22 24 25 20 
133044 0 0 18 0 18 28 31 27 22 27 29 24 22 18 25 0 26 
133065 26 25 29 22 31 31 40 26 28 27 21 12 22 28 27 33 27 
133075 28 28 31 22 25 33 32 25 32 25 37 30 19 24 27 23 21 
133082 23 24 27 18 27 26 28 25 25 25 35 28 21 20 27 24 21 
133083 22 22 22 19 26 37 35 25 29 25 33 23 26 22 24 28 21 
133090 25 23 25 19 27 29 31 26 32 28 34 25 27 22 29 25 22 
133098 26 26 27 22 27 38 32 26 30 26 33 30 29 28 26 28 24 
133099 21 18 20 12 29 28 28 24 24 25 0 0 20 18 26 23 19 
133104 21 18 20 12 29 28 28 24 24 25 0 0 24 18 26 23 19 
133105 21 18 20 4 27 28 28 22 22 22 32 0 0 19 23 22 26 
133106 25 25 21 20 24 34 34 23 30 23 33 23 25 24 27 21 23 
133117 20 20 19 10 28 20 30 24 23 21 0 0 25 20 26 22 21 
133126 22 19 21 16 27 36 35 24 31 25 26 26 25 24 27 27 25 
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Table 3.8 AMR in Kuwait P. aeruginosa isolates from UTIs. Size (mm) of zone of inhibition following disk diffusion assays are reported. Resistance is colour 
coded in red while intermediate values appear in orange 
 Aminoglycosides Carbapenems Cephalosporins Fluoroquinolones Monobactams Penicillins 
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 TN GM AK NET IMI MeM Dor Caz CPM CZA Lev CIP ATM PRL PTZ TC TIM 
Dose 10 10 30  10 10 10 10 30 30 14 5 5 30 100 110 75 85 
758 
0 11 0 0 9 0 0 0 6 0 0 0 10 0 0 0 0 
783 
0 10 0 0 10 0 0 0 5 0 0 0 10 0 0 0 0 
786 
0 0 14 3 24 16 16 10 11 11 0 0 3 9 12 0 0 
864 
20 20 25 17 11 0 15 15 20 16 25 12 16 14 14 11 8 
888 
0 0 0 0 0 11 14 23 24 23 0 0 18 7 19 14 7 
902 
20 20 25 17 25 20 21 10 16 8 22 11 9 0 9 6 0 
925 
0 17 11 0 10 10 14 0 12 0 24 25 24 0 11 0 0 
1083 
19 18 20 12 20 29 31 21 22 25 27 20 23 25 27 24 22 
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3.11.2 Detection of resistance elements 
Following WGS, post-analysis was performed using the CARD database to identify 
genomic determinants of AMR. Overall, as expected, almost all the isolates in both 
UK and Kuwait panel contained multiple genes encoding efflux pumps (mex) and 
porins (opr) (Table 3.9). Resistance to aminoglycosides was found in isolates from 
Kuwait, particularity the XDR isolates 758 and 783, the most resistant isolates in both 
panels (Table 3.10). These isolates contained AAC (6’)-ii and aaA61, (encoding an 
aminoglycoside transferase enzyme and an aminoglycoside adenylyltransferase 
respectively), which both inactivate aminoglycoside antibiotics by enzymatic 
modification. In addition, APH(3’)-Ib, which is a plasmid-encoded phosphotransferase 
in E. coli , was found in both isolates. Other Kuwaiti isolates (786, 888, and 925) also 
harboured this gene and displayed resistance to aminoglycosides. Isolate 888 
contained five aminoglycoside resistance genes; AAC (6’)-ii, aadA11, ANT(2’’)-Ia, 
APH(3’)-Ib, and APH(3’)-Via. In the UK panel of isolates, only 133044 contained genes 
conferring resistance to aminoglycosides, namely, APH(3’’), APH(4), APH(3’)-Iib and 
APH(6)-Id. This correlated with the observed resistance using the disk diffusion tests. 
Genes conferring quinolone resistance such as crpP were found in isolates 133042, 
133075, 133117 and 925 (Kuwait isolate). The enzyme product CrpP  is a novel 
ciprofloxacin modifier and has been described recently by Chávez-Jacobo et a, (2018) 
[674]. Ciprofloxacin resistance was found in only one isolate 133117 (crpP+) in disk 
diffusion testing. Specific mutations in gyrA confer resistance to fluoroquinolones 
was detected mostly in isolates sourced from Kuwait (62.5%).  
 
Genes carrying β-lactamases are detected across all isolates in both UK and Kuwait. 
OXA-50 is chromosomally encoded and is found on all isolates. The other OXA-type 
identified was OXA-10, which is a resistance gene detected in only one isolate, 786. 
PDC  β-lactamases are class C AMR genes that can be found in P. aeruginosa [418]. 
All isolates contained a single PDC enzyme or more, although the type differed. These 
include PDC-1, PDC-2, PDC-3, PDC-4, PDC-5, PDC-7, PDC-8, PDC-9, PDV-10 and PDC-
86. PDC-2 is present is 26 % of the total UTI isolates tested, followed by PDC-3, which 
is only detected in Kuwaiti isolates 758,783,786 and 888. PDC-5 and PDC-9 were only 
present in UK isolates, the former is detected in 133044, 133082, and 130083 while 
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the latter was found in 133042, 133099 and 133117. The rest of the isolates carried 
PDC-1 (133090, 864), PDC-10 (133065,133098,), PDC-7 (133106) and PDC-86 (902). 
 
A single VIM type gene was identified in three isolates. VIM-28 was detected in these 
isolates and this gene is highly uncommon in P. aeruginosa isolates. Other resistance 
genes identified were sul1 which is acquired via horizontal gene transfer and 
integrated in the bacterial genome [675]. The gene was originally detected in E. coli 
and confers resistance to sulphonamide antibiotics. It is detected in 62% of the 
isolates sourced from Kuwait, however, was not detected in the UK panel of isolates.
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Table 3.9 Genes involved in resistance-nodulation-cell division (RND) antibiotic efflux pump and their respective percentage identity in both of the UK and 
Kuwait isolates 
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Table 3.10 Antimicrobial resistance genes identified in P. aeruginosa UTI isolates through whole genome sequencing and analysis using the CARD database. 
Percentage sequence identity is reported. These genes are involved in promoting resistance to multiple of classes of antibiotics such as aminoglycosides 
(Blue), Fluoroquinolones (green), trimethoprim (yellow) and β-lactamases (orange) in UK & Kuwait isolates with resistance induced by C= Chromosome, 
I=Integrons=Transposons, IN=Integrative element 
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3.12 Genomic DNA analysis 
To investigate the genomic background of UTI isolates in this study, Illumina 
sequencing was conducted to determine the population of structure for both the UK 
and Kuwait isolates. In both groups, PA14-like isolates were more prevalent at 66.6% 
and 62.5%. This is in contrast to isolates in the database in which group 1 (PAO1-like) 
isolates are more prevalent. However, the panel is small and therefore may be 
skewed by these limited numbers. To demonstrate the distribution of the these UTI 
isolates, a phylogenic tree was drawn to display the distribution of the population 
(Figure 3.14). The isolates were spread across both group 1 and group 2. No PA7-like 
(group 3) isolates were detected. Three isolates from Kuwait were clustered on the 
same arm of the phylogenetic tree and are very closely related.    
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Figure 3.13 Phylogenic tree of the UK and Kuwait panel of isolates according to the genomic 
composition. This was created by Dr Sam Haldenby at the Centre for Genomic Research, 
University of Liverpool. The main (PAO1, LESB58, and PA14) strains are colour-coded in red, 
UK isolates in yellow and isolates sourced from Kuwait in orange 
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3.13 Discussion  
P. aeruginosa has been highly studied yet there are still many gaps in the literature. 
Many databases and studies are skewed by isolate origin, both geographically and 
infection site. There is little data on P. aeruginosa isolates from UTIs and even less 
data on isolates sourced from the GCC countries. In this chapter, I have characterised 
isolates from UTIs using both genotypic and phenotypic methods.   
Studying growth in laboratory conditions gives an insight into the behaviour and 
fitness of the bacterial isolates. Isolates from some sources such as chronic lung 
infection in CF have been reported as slow growing in the laboratory environment. In 
this study, the UTI isolates displayed differences in their speed of growth with some 
isolates growing very fast (133065, similar to the laboratory reference strain PAO1) 
and others growing much slower and failing to reach a high final density (133117). 
Many different factors can affect the growth rate of P. aeruginosa. Schaber et al, 
(2007) compared growth rates of 5 QS-deficient clinical isolates sourced from 
respiratory, wound and UTI to PAO1, with no major differences observed at lag, log 
and exponential phases [676]. It can be concluded that UTI isolates are heterogenous 
in their ability to grow in the laboratory environment.  
Overexpression of alginate exopolysaccharides is a common feature in CF chronic 
lung infections and has been linked to the inability to clear the bacteria from the 
respiratory tract [677]. UTI derived mucoid isolates have been previously reported 
[678], [679]. Like many CF isolates, these isolates were identified as carrying a 
mutated version of the mucA gene. This suggests that the conversion to mucoidy can 
follow a similar pathway regardless of infection site [677]. However, alginate over-
producers are not commonly found in UTI infections, with studies reporting a level of 
around only 1- 3% [90],[680], [681]. In our study, none of the 25 UTI P. aeruginosa 
isolates displayed the mucoid phenotype, further solidifying previous findings that 
mucoidy may not play a major role in UTIs due to the possible absence of mucA 
mutations [677].  
Colony morphology can also be affected by a variety of other factors including the 
production of pigments. P. aeruginosa can produce a number of coloured compounds 
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including pyoverdine, pyomelanin, pyorubin and pyocyanin. Dietrich et al, (2008) 
suggested that colony morphology in P. aeruginosa can be affected by phenazines 
production. Smooth colonies have been linked to the production of phenazines 
whereas isolates lacking this ability can grow as wrinkly colonies [667]. Isolate 133042 
exhibited a wrinkly phenotype, which has been attributed to an adaptive response to 
maximise oxygen uptake by increasing the surface area of the cell [682]. In addition, 
mutations in the QS regulator gene lasR have been associated with a metallic sheen 
phenotype on nutrient rich media such as LB [666]. This isolate produced very little 
pyocyanin. Isolate 133117 from UK panel and isolate 925 from Kuwait’s panel 
produced metallic colonies, and this may indicate a possible loss of lasR function. 
However, isolate 133117 could still produce some pyocyanin at a similar level to 
PAO1. Such mutation confers a growth advantage with carbon and nitrogen sources 
with the catabolic pathway [666]. QS mutants have been identified in isolates from 
many different sources. However, they have been linked to adaptation during chronic 
infection. No information is available on the length of time these patients had been 
infected for and it would be incredibly interesting to determine whether QS mutants 
begin to appear in patients with chronic UTIs, similar to that since in CF lung infections 
[666].    
Biofilm formation has been implicated in 65-80% of all microbial and chronic 
infections [140]. P. aeruginosa utilises urinary catheters as a focal point to establish 
UTI and persist, leading to complicated infections, morbidity, and mortality [56]. 
Biofilms are commonly involved in CAUTI and they have also been identified in the 
urothelium and on prostate stones [683].  P. aeruginosa is a model organism in which 
to study biofilm formation and therefore, there is a wealth of literature describing 
factors associated with this process [118], [684], [685].  
Biofilm formation assays grown in 96-well plates and stained using CV, provide a 
method to measure biofilms that are easy to execute and therefore commonly used 
[686]. This method was utilised to quantify biofilm for 15 UTI isolates and compared 
them to reference strains PAO1 and PA14. The biofilm formation of each isolate was 
determined at 24h [137]. Our results suggest that similar variation exists in this panel 
of UTI isolates. Isolate 133105 produced the highest level of biofilm, and this 
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exceeded the amount produced by PAO1 although there was no significant 
difference. The other isolates produced less biofilm to PAO1 however this was only 
significant for 133044 (P=0.036). The results in this study indicate that the UTI isolates 
produce variable levels of biofilms that are isolate-dependent.   
Several studies have reported biofilm formation of P. aeruginosa isolated from 
multiple infection sites. P. aeruginosa can cause otitis media ear infections in patients 
with cholesteatoma, (25%-35% of infections) [687], [688]. P. aeruginosa isolates from 
otitis media appear to be good biofilm producers, with 83% of isolates forming 
significantly higher levels than PAO1. The authors of this study suggested that the 
ability to form biofilms may play a role in persistent infections in patients with 
cholesteatoma [689]. A recent study in Calgary, Canada by Doung and colleagues 
analysed biofilm formation of 108 CF isolates classified as Prairie Epidemic Strain 
(PES), other epidemic strains (OES) (including 6 LES isolates from the UK) and local 
non-epidemic isolates. This study demonstrated that local non-epidemic strains 
produced the highest mean of biofilm biomass followed by PES and OES, respectively 
[690]. PAHM4, a non-CF bronchiectasis strain forms significantly less biofilm than 
PAO1 [438]. A study of 101 keratitis isolates found that they produced 17% to 242% 
of the PAO1 control and the ability to form biofilms was correlated with worse vision 
outcomes [691]. The Schaber et al, (2007) study compared 5 QS-deficient isolates 
derived from respiratory, wound and UTI to PAO1 to assess biofilm development, the 
UTI isolate CI-5 was derived from 82-year patient who suffered sepsis secondary to 
CAUTI. Upon CV staining and comparison of all isolates, the UTI isolate produced the 
highest biomass amongst all QS-deficient isolates and up to 82% capacity of PAO1 
[267].  A study examining uropathogenic P. aeruginosa serotypes and their ability to 
form biofilms in vitro via CV staining found variation between the different serotypes. 
Specifically, O11 serotypes produced the strongest biofilms and were more likely to 
be resistant to antibiotics while strains belonging to serotype O6 produced the 
weakest biofilms [692]. The ability of CAUTI P. aeruginosa was assessed by Vipin et 
al, (2019) all isolates formed biofilms varying in intensity between 0.20 and 1.11 
(ODOD580), indicating the diversity amongst these clinical isolates [693].  
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Although this method of biofilm quantification is relatively easy and high throughput, 
the method is limited as it does not provide information on the biofilm architecture 
or bacterial viability [694]. Biofilm formation in vivo does not always involve the 
formation of the mushroom-shaped structures. Microscopy has been used previously 
to assess biofilm formation of UTI P. aeruginosa [676], [693] . Here, we used confocal 
microscopy on UTI P. aeruginosa to assess biofilm architecture analysed with the 
post-imaging software COMSTAT [410]. This method of analysis allows the study of 
different parameters related to biofilm architecture [410]. Five parameters were 
studied in the reference and UTI isolates; biomass, maximum thickness, surface area, 
and surface to biofilm ratio. One of the main measurements in COMSTAT, is the 
measurement of biomass [410]. Despite the different time period of incubation (24h 
for the plate assay and 48 h for the microscopy), in each assay there was no significant 
difference between PAO1, and the majority of the isolates tested (14/15 for the plate 
assays and 15/15 for the microscopy). Furthermore, the results across the two assays 
were not consistent and isolates that produce the most biofilm in one assay did not 
in the other. Furthermore, the variability in the biological replicates for both assays, 
and particularly the microscopy, was large and in hindsight, this variability may have 
affected these results. It has been shown previously that upon reaching biofilm 
maturation, some microbial cells disperse due to nutrient depletion and decreased 
oxygen uptake [695]. Time-dependent analysis of PAO1 biofilm formation in a micro-
device control flow system revealed alteration of biomass over a period of a week 
which resulted in subsequent reduction and dispersal of biofilms after stage V 
maturation [696]. This phenomenon may have a role in explaining any disparity 
observed between the plate assay and the microscopy measures of biofilm. To study 
this further, a time course with points over a 48h period using both methods could 
be employed. 
Biofilm architecture is also known to show variation depending on isolate. PAO1 has 
been described as producing a mushroom type biofilm [697], whereas other isolates 
produced much flatter biofilms. In order to determine differences in the architecture, 
measurements such as roughness, surface area, thickness and biofilm:surface area 
ratio were analysed. Of particular interest was the roughness coefficient. This is a 
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dimensionless value which provides a description to variability across a given biofilm 
[410]. This parameter provides a measure of structural heterogeneity as it 
differentiates between rough and smooth biofilm.  The former has pillars, interstitial 
channels, and towers of cells separated by spaces lacking any bacterial cells, while 
the latter is composed mostly of homogenous single layer of cells [698], [699]. No 
significant differences were observed but again, the variation between replicates was 
high. This may be due to the time point chosen (48 h). This was chosen to enable the 
study of a mature biofilm. However, earlier time points may allow more 
reproducibility and consistency of the results.  In our study, based on the roughness 
coefficient values, no UTI isolates formed rough biofilms in comparison to the rest of 
isolates, indicating that the biofilm architecture does not differ significantly between 
isolates. The QS-deficient UTI isolate CI-5 studied by Schaber et al, (2007) was also 
analysed using confocal microscopy and COMSTAT [267], [676]. The analysis after 7 
days of biofilm growth revealed a higher maximum thickness parallel to PAO1 by the 
UTI isolate CI-5 and produced unique towering structures [676]. In our study, 
maximum thickness was found to be higher in 9 UTI isolates, although the parameter 
was not significantly higher than PAO1. The consensus in the studies conducted 
measuring prokaryotic and eukaryotic (fungal) biofilm thickness suggest thicker 
biofilm tend to give an advantage for the pathogen [676], [700]–[702]. Biofilms may 
play a role in UTIs however, the methods used in this study are limited to the 
measurements of biofilm attached to an abiotic surface. P. aeruginosa biofilms can 
also exist in other forms such as aggregates at the air-liquid interface [703] and 
microcolonies [704], [705]. Most UTI isolates in this study possess intermediate ability 
to form biofilms, since most isolates registered between 0.1 and 0.2 A600, a similar 
outcome was observed by Tielen et al, (2011) [90]. 
Motility is a prominent virulence factor utilised by P. aeruginosa to cause multiple 
types of infections [72]. Tielen et al, (2011) reported that UTI isolates derived from 
mid-stream urine were more likely to able to swim than CAUTI isolates, 90% of 30 
isolates were able to swim [90]. A study conducted in the Czech Republic revealed 
that more than 95% of CAUTI isolates have the functional capacity to swim [706].  
This was consistent with the findings in this study as 80% exhibited the ability to 
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swim. Swimming motility initiates attachment and adherence on abiotic surfaces that 
can lead to biofilm formation including on surfaces such as urinary catheters [67]. 
Twitching motility is facilitated by type IV pili and is used to move across solid and 
semi-solid surfaces [492]. Olejnickova et al, (2014) examined 139 P. aeruginosa UTI 
isolates for twitching motility which led to the discovery that 75% were capable of 
twitching [706]. Winstanley et al, (2005) tested 63 keratitis isolates for twitching 
motility, 90% out of the isolates exhibited the ability to twitch in vitro [707]. 
Furthermore, mutants defective in twitching motility were not able to colonise the 
cornea [708]. In our study 86.6% were able to twitch, indicating that this is another 
common feature in UTI isolates. Our panel of UTI isolates demonstrated a high degree 
of swarming motility (86%). Swarming hyper-motile strains tend to form flat biofilms 
[499]. High percentage (up to 95%) of swarming-motile P. aeruginosa CAUTI isolates 
have been reported [706]. Interestingly, swarming is a key feature for another urinary 
pathogen, P. mirabilis [39]. This may suggest that swarming is a beneficial trait in the 
urinary environment.   
P. aeruginosa produces pyocyanin, an effective phenazine toxin [154]. P. aeruginosa 
UTI isolates consistently produce the most potent pyocyanin compared to isolates 
derived from other sites of infection. [709]–[711]. Pyocyanin  has been shown to be 
associated with biofilm formation in the urinary tract [168]. Pyocyanin intercalates 
with eDNA to form biofilms in UTIs thereby promoting cell to cell interactions and 
affecting cell surface properties. The correlation between pyocyanin and                            
P. aeruginosa UTI isolates  producing biofilms has been assessed in the Vipin et al, 
(2019) study [693]. In our study, we did not observe a positive relationship between 
strong biofilm and pyocyanin producers and while none of the UTI isolates we tested 
were found to over-produce pyocyanin (like the CF strain LESB58), the majority of 
isolates produced comparable levels to PAO1 and PA14. Tielen et al, (2011) showed 
that 5 -15% of UTI isolates do not produce pyocyanin [90]. In this study, the isolate 
133104 produced the highest level of pyocyanin and isolate 133083 produced a very 
low level of less than 0.01 (A695nm). This low level is comparable to isolates 
previously identified with mutations in their QS genes (lasR) from the CF lung [669].  
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P. aeruginosa strains are diverse in terms of its population structure. Here we report 
that the vast majority of isolates are PA14-like. Although the sample size is relatively 
small, more isolates fall in Group 2. This contrasts with the largest population 
structure studies which reported that PAO1-like P. aeruginosa isolates are the most 
widespread in the environment [658]–[660]. Further studies could involve analysing 
a much larger panel of isolates to determine if there is link between Group and UTIs. 
PA14 is thought to be more virulent than PAO1 in invasion models and has been used 
extensively in in vivo infection models [712]. Three isolates from Kuwait cluster very 
closely on the phylogenetic tree based on the core genome. Little is known about the 
epidemiology of these isolates and therefore surveillance of strain types circulating 
in Kuwait may provide insight into outbreaks or common circulating clone types. This 
is particularly important in light of the extreme AMR observed. A similar finding was 
observed by Tielen et al, (2011) upon conducting SNP chip typing on 30 P. aeruginosa 
uropathogens, and found 21 different clones [90]. The Kos et al, (2015) study 
sequenced 390 isolates containing 86 UTI isolates, the study did not discuss the 
relatedness to UTI to either PA01, PA14 and PA7-like groups [659].  
 
The WHO has identified carbapenem resistant P. aeruginosa as a critical issue in need 
of intervention by developing new antimicrobial agents [36]. Upon searching for 
specific information on the P. aeruginosa AMR UTI isolates in both regions covered 
in this study, it was found that information is either scarce or reported briefly in larger 
UTI Gram-negative AMR studies [605], [636]–[638].  Based on these results, extreme 
resistance was identified in isolates from Kuwait and therefore Kuwait may be a hot 
spot for resistance. However, there may be some bias in isolate selection and 
therefore a wider study should be implemented. Lack of surveillance programmes, 
inadequate use of antibiotics, travelling and climate change are contributing factors 
to the rise of AMR in this region [609]. Genome sequencing of the isolates obtained 
from Kuwait showed higher resistance than those collected from the UK. Multiple 
isolates in the panel exhibited resistance to tobramycin, gentamicin and amikacin. 
This was consistent with the genomics analysis of these isolates as they contained 
modifying enzymes conferring resistance to aminoglycosides such as AAC (6’)-ii, 
aadA11, ANT(2'')-Ia and APH(3')-Ib. Some of the acquired genes are plasmid-borne 
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and may have been transferred by horizontal gene transfer. In addition, gyrA 
mutations and plasmid associated crpP enzyme were involved in promoting 
resistance against ciprofloxacin and levofloxacin in several isolates [674]. dfrB1is  a 
plasmid-associated trimethoprim-resistant dihydrofolate reductase which was 
initially discovered on in Bordetella bronchispetica bacteria, suggesting it might have 
been transferred at some point to P. aeruginosa [713]. Resistance to β-lactamases in 
the Kuwaiti panel can be attributed to the presence of ESBLs such as PDC-2 and PDC-
3. VIM-type resistance has previously been reported in P. aeruginosa in the GCC 
region [629]. VIM-28, an MBL which was first detected in Egypt recently, was found 
in isolates 758, 783 and 925. VIM-28 gene contains an unusual integron arrangement 
in the structure, with the gene cassette located downstream of the “intI1” gene [594]. 
Egyptian nationals are one of the largest ethnic minorities in Kuwait [634], [714]. 
Movement between the two countries may help explain the identification of bla-VIM-
28 in the two areas.  In addition to the intrinsic OXA-50 Class D β-lactamase, which is 
found in all isolates, OXA-10 was detected in only one isolate 786. To the best of my 
knowledge, this is the first report of OXA-10 in bacterial isolates from Kuwait.  Isolates 
758 and 783 are sensitive to colistin using MIC broth microbdilution assay, therefore, 
there is one antibiotic that could be used to treat infections caused by these bacteria. 
Due to the extended resistance and the genes identified, it may be plausible that 
these isolates carry MDR plasmids. Recent studies on isolates from Thailand revealed 
P. aeruginosa carry MDR megaplasmids [715]. Further analysis of the genome 
sequence data would provide insight into this. The implications of these findings are 
alarming and require extensive surveillance and AMR stewardship programmes.  
 
Isolates sourced from the UK in this study were much more susceptible to antibiotics 
with only two MDR isolates detected. The prevalence of AMR P. aeruginosa 
uropathogens is generally considered to be low [55]. Surveillance is not 
comprehensive. This could be attributed to stricter policies of antibiotic stewardships 
and wider knowledge amongst the public with antibiotic misuse [716]. According to 
Ironmonger et al, a 4-year long surveillance study detected only 45 non-susceptible 
P. aeruginosa uropathogens to carbapenems in a total of 6985 isolates sourced from 
the Midlands region of England [605].     
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 The results from this chapter have provided insight into the genomic and phenotypic 
variation of P. aeruginosa isolates from UTIs. The data has highlighted that UTIs can 
be caused by a diverse selection with regards to both phenotype and genotype. This 
is not surprising as the P. aeruginosa population is diverse, and patients would 
presumably acquire individual strains from an environmental source. However, this 
may differ in the hospital setting for patients with long term catheters. The 
sequencing data has provided information on the population structure of the UTI 
isolates and further analysis could be performed on virulence genes and mobile 
genetic elements (such as prophages). This is unfortunately beyond the scope of this 
thesis. A large variety of antimicrobial resistance genes were identified through 
sequencing and furthermore, resistance to every class of antibiotics was identified in 
the UTI isolates using disk diffusion assays.  This is of course alarming, particularly the 
extremely high level of resistance identified in isolates from Kuwait. The exact basis 
for picking these isolates has been difficult to determine and the isolates were now 
obtained some years ago. A new study aimed at determining the current prevalence 
of antimicrobial resistance, both in the UK and in Kuwait, would provide important 
missing epidemiological data and ensure less biases (or at least known biases). The 
identification of highly resistant strains of P. aeruginosa from UTIs requires further 
research. In addition, further understanding of how P. aeruginosa responds to the 
urinary environment would allow a deeper analysis of the basis of bacterial 
pathogenesis and potentially help identify new therapeutic interventions. 
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Chapter 4 
4.Artificial Urine Medium as a Model for UTIs 
4.1 Introduction  
4.1.1 Components of Urine 
Urine is defined as a ‘ transparent, sterile, amber-coloured fluid generated by the 
kidneys’ [717]. Urine formation occurs via the secretion of waste from the 
bloodstream into the tubular filtrate along with glucose, excess water, and other  
waste compounds such as hydrogen ions and drug metabolites [718]. The primary 
route of excretion of soluble waste in humans is through the urinary tract [717]. 
According to the urine metabolome database, 4000+ elements and compounds have 
been detected in urine derived from healthy and ill individuals [719]. Metabolomics 
is the study of chemical products or metabolites made by cells [720]. This approach 
has been used in drug discovery, disease marker identification [721]. Previous studies 
have also utilised 2D-electphoresis in order to construct a urine proteome map [722]. 
Thus, classification of urine components was established based on functional criteria. 
These functional groups constitute of 9 groups; kidney secretory and structural 
proteins, serum  and transport proteins, coagulation factors, complement fractions, 
immunoglobulins with heavy and light chains, proteases and inhibitors, enzymes, 
metal binding proteins and lipoproteins (Table 4.1) [722]. Urine contains high levels 
of urea as a by-product of amino acid metabolism [723]. High concentrations of 
inorganic salts such as sodium, chloride and potassium are found in urine [724]. 
Furthermore, ammonia, creatinine, organic acids, soluble toxins, haemoglobin 
derivatives such as urobilin are detected[717], [725]. Hormone and drug metabolites, 
including these with low molecular weight, have been identified through 
metabolomics [726].   
4.1.1.1 Factors affecting Urine Composition 
Urine composition is highly variable amongst healthy and ill individuals and in the 
same individual over periods of time [727]. Urine is more concentrated in the 
morning and is influenced by fluid intake, surrounding temperatures and exercise 
[728], [729]. The normal urinary pH is typically 6.0 to 7.5 but can vary between pH 
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4.5 to 8. UTIs can also affect the pH of urine which can raise to 9.5. This can be 
indicative of the presence of bacterial species such as Proteus spp and Klebsiella spp 
as a result of urease activity and the generation of ammonia [730], [731].   
Table 4.1 Functional classification of components detected in urine using 2-D gel 
electrophoresis [722] 
Functional classification Examples 
Kidney secretory and structural proteins Uromodulin (Tamm-Horsfall protein), Epithelial-
cadherin, Polymeric immunoglobulin receptor, 
Stomatin-like protein. 
Serum constitutional and transport proteins Albumin, Vitamin D binding protein, Leucine-rich 
α2 glycoprotein, Transthyretin monomer multimer. 
Coagulation factors Fibrinogen α chain, Kininogen, Fibrinogen β chain, 
Fibrinogen γ chain. 
Complement fractions Complement factor B (Complement factor Bb, 
Mannan-binding lectin serine protease 2 
Immunoglobulins with heavy and light 
chains 
Ig α-1 chain C region, Ig γ-3 chain C region, Ig γ-2 
chain 
Proteases and inhibitors α1 Antitrypsin and α1 Antitrypsin fragment, 
Pancreatic α amylase; α1 Antichimotrypsin/ 
Enzymes Trehalase Ribonuclease, Prostaglandin-H2-
isomerase, Dimethylargininase-2 
Metal binding proteins Serum transferrin, Ceruloplasmin, α HS 
glycoprotein, Copper transporting ATPase 1 
Lipoprotein metabolism Clusterin, Apolipoprotein D, Ganglioside GM2 
activator 
 
Dietary habits are known to impact the composition of urine. Siene et al, (2002) 
conducted a study of 10 healthy male subjects consuming a western meat-based diet, 
compared with those consuming a normal mixed diet and those on an ovo-lacto-
vegetarian diet [732]. The study showed that the secretory profiles of urine 
components were altered, in particular, calcium secretions were highest in 
participants taking western diets (21%) compared to 13% in people consuming a 
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vegetarian diet. This suggested that the risk of urolithiasis (formation of stones within 
the urinary tract) in those consuming a Western diet was increased [732]. In addition 
to diet, several other metabolic and dietary factors affecting urine composition and 
renal calculi formation have been implicated (Table 4.2) [722].  
Table 4.2 Dietary factors involved in changing urine composition 
 
 
 
 
 
 
 
4.2 Current understanding of bacterial metabolism in urine 
Little is known about the behaviour of uropathogenic P. aeruginosa and its traits 
which enable colonisation and infection of humans. However, knowledge gained 
from studying host-pathogen interactions in E. coli has provided insight into 
mechanisms which may be important determinants of pathogenicity, as they are 
shared by several Gram-negative bacteria [269]. Bacteriuria is the presence of 
bacteria in urine and a marker of symptomatic UTI, higher levels of bacteriuria 
contribute to the of severity of infection [740]. Progression of the infection depends 
on the survival and fitness of the uropathogen as well as factors impacting the host. 
Most patients who suffer from persistent UTI are infected with different bacterial 
strains over time [741]. Interestingly, long-term bladder colonisation appears to 
select for UPEC with attenuated virulence phenotypes [742]. Different 
microorganisms have variable fitness which determines their potential to survive in 
the harsh urinary tract environment [743]. Patients with previous E. coli infections 
are more susceptible to infection and can be colonised by the same or a different 
uropathogen [744]. Antimicrobial peptides are another defence mechanism which 
colonising uropathogens must overcome (See section 4.3.1) [745]. In addition, factors 
Dietary factors affecting urine References 
Decreased fluid intake [733] 
High or low calcium intake [734] 
High intake of oxalate [735] 
Animal protein [736] 
Sodium [737] 
Refined sugars [738] 
Potassium [739] 
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such as defects in TLR receptor signalling, genetic immunodeficiency, recurrent 
infection or serotype/type replacement influence bacterial progression in the urinary 
tract. [745], [746]. Survival and growth in urine ensures persistence of uropathogens 
regardless of the ability to adhere to the urothelium or the dynamics of the inflowing 
urine, including voiding and the rates of urinary flow rates. Indeed, non-voided 
uropathogens, which exist in the remnants of urine, grow and multiply to propagate 
the infection [745]. ABU E. coli isolate 83927 has been studied to understand bacterial 
fitness in the urinary tract, this strain can outcompete UPEC strains 536, CFT073, 
NU14, and 1177 [747], [748]. The identified adapted metabolic behaviours include 
alterations in transport and degradation pathways for compounds such as 
glucuronide, galactonate and galacturonate [747]. In addition, antioxidant defence 
mechanisms are of paramount importance for survival in the host [749]. ABU E. coli 
83927 was shown to acquire mutations to adapt its metabolic profile. In an unusual 
therapeutic approach, Zdziarski et al, (2010) inoculated the bacteria into six patients 
and recaptured the isolates from urine at different time points over several months. 
Subsequent transcriptomic and proteomic analysis revealed shifts in diverse 
metabolic pathways such as those utilising amino acids, hexuronates or (deoxy-) 
ribonucleosides [750]. Genes guaA and argC were shown to be essential for guanine 
synthesis in UPEC using transposon mutagenesis. Mutants were found to show 
attenuated virulence in mouse models of UTI [751]. In addition, argC and carAB 
mutations in another transposon study resulted in reduced growth ability of E. coli, 
highlighting the need for arginine to support growth in urine [752]. 
As for P. aeruginosa, utilisation of nutrients can be partially dependent on oxygen 
availability and limitations in the urinary tract [753]. In aerobic environments, 
different sugars from carbon sources are utilised by the Entner-Doudoroff-Pathway 
to perform oxygen respiration through numerous terminal oxidases [754], [755]. The 
versatile metabolic adaptability of P. aeruginosa allows this bacterium to process 
nitrate or nitrite by denitrification in environments lacking oxygen [756], [757].              
P. aeruginosa can also produce energy by fermenting arginine in media lacking 
electron acceptors [753]. In anaerobic conditions, P. aeruginosa utilises mixed acid 
fermentation which prolongs anaerobic survival and assists in the formation of 
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microcolonies [758]–[760]. In the urinary tract, citrate, lactate and amino acids can 
be utilised as carbon sources [753]. Tielen et al, (2013) investigated the metabolomic 
profile of PAO1 biofilms grown in AUM under anaerobic conditions [753]. The authors 
observed that P. aeruginosa adapted its central metabolism is favour of utilising 
citrate, lactate and multiple amino acids derived from peptone. This study identified 
that genes involved in the tricarboxylic acid cycle such as gltA/prpC which encode 
citrate synthetase 1 and 2, were induced under these conditions. P. aeruginosa also 
appeared to synthesise higher concentrations of amino acids including                             
alanine, β-alanine, aspartate, glutamate, glutamine, serine and ornithine                                           
within intracellular metabolome in AUM biofilms compared to biofilms grown in                                                      
10-fold diluted LB. In contrast, fatty acid biosynthesis was reduced as genes                   
accA, accB, accC, fabAB, fabGD were downregulated in AUM [753]. Berger et al, 
(2014) utilised 13C-metabolic flux analysis to study PAO1 and 17 other UTI clinical 
isolates, which were universally able to catabolise glucose by the Entner-Doudoroff-
Pathway. The study also reported over-production of NADPH for anabolism by 
additional supplementation of NADPH, which can be useful against oxidative stresses 
derived from the host. In addition, the authors concluded that biosynthesis using the 
tricarboxylic acid cycle , pyruvate metabolism, and the glycoxylate shunt was variable 
amongst the UTI isolates [761]. These findings provide a good insight into the 
pathogenic behaviour of P. aeruginosa, however, it does not address the similarities 
and differences of planktonic and biofilm growth of P. aeruginosa between AUM and 
urine. The virulence profile between P. aeruginosa grown in urine and AUM may be 
different. Thus, we will try to address this disparity by conducting growth rate, biofilm 
formation, gene expression and proteomic analysis between LB medium, AUM and 
human urine. 
4.3. Immunity in the urinary tract   
4.3.1 Immune system components in urine 
Immune components in urine and the urinary tract determine the way by which an 
individual deters UTI [762]. Urine contains several compounds and antimicrobial 
peptides participating in fighting infections, such as lysozyme, defensins, lipocalin, 
cathelicidin, lactoferrin, ribonuclease-7 and uromodulin (THP) and these can 
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eliminate bacteria via multiple pathways [17], [762], [763]. The presence of innate 
immune white blood cells such as neutrophils, macrophages, Natural killer (NK) cells 
with the related pro-inflammatory cytokines, complement systems and scavenging 
receptors can help control and clear UTIs (Table 4.3) [762], [764], [765].  
Table 4.3 Urine and urinary tract components which confer immunity to uropathogens such 
as antimicrobial peptides: defensins, lipocalins, cathelicidins, ribonuclease 7. Other 
compounds with immune functions are featured such as lactoferrin and uromodulin 
 
4.3.1.1 Toll-like receptors 
TLRs on the surface of immune cells or the epithelia lining the urinary tract recognise 
conserved molecular patterns known as PAMPs on the uropathogen and drive innate 
and adaptive immune responses by producing pro-inflammatory cytokines [773]. 
Four TLRs have been associated with host defences against uropathogens; TLR2, 
TLR4, TLR5 and TLR11 [774]. TLR2 is an immune receptor to bacterial lipoteichoic acid 
or lipoprotein and is found in the kidneys and expressed constitutively in the proximal 
Immune components Function Reference 
Lysozyme Cleavage of Gram-positive bacterial cell wall [766] 
Defensins Antimicrobial activity against bacteria, 
chemoattractant for dendritic cells 
[767] 
Lipocalin Sequesters iron to prevent bacterial 
utilisation 
[768] 
Cathelicidin Antimicrobial activity against Gram-positive 
and Gram-negative bacteria, 
chemoattractant for neutrophils and 
monocytes 
[769] 
Lactoferrin Limits proliferation and adhesion of bacteria, 
sequesters iron to prevent bacterial 
utilisation 
[770] 
Ribonuclease 7 Antimicrobial activity against uropathogens, 
disruption of the microbial membrane 
[771], 
[772] 
Uromodulin (Tamm-
Horsfall) protein 
Interfering with the ability of uropathogens 
to bind to the epithelium 
[767] 
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and distal-collecting tubules [775], [776]. An in vivo study involving control and TLR2-
deficient mice presented evidence of reduced pro-inflammatory response and 
leukocyte infiltration in the latter [777]. TLR4 is one of the key TLRs contributing to 
immune responses against uropathogens. This occurs upon the recognition of LPS of 
bacteria such as UPEC by TLR4 on bladder cells, which in turn activates neutrophils 
[778]. TLR4 also recognises UPEC Type I pili which leads to the transcription of genes 
encoding  Il-6 and IL-8 [17], [779]. TLR4 has been shown to interact with the FimH 
adhesin of UPEC in human embryo kidney cell lines along with animal models [780]. 
TLR5 recognises flagellin, a structural protein in UPEC’s flagella, which triggers the 
innate immune response in the bladder and kidneys. The importance of this cascade 
in host defence has been demonstrated in TLR5-defiecent mice, which exhibit a 
higher bacterial load than wild type mice infected with E. coli strain CFT073 [781], 
[782]. TLR11 is not expressed in the urinary tract of humans or any anatomical 
location in the body [783]. Zhang et al, (2004) characterised TLR11 in mice, and 
generated mutants mice lacking TLR11 and challenged them with UPEC strain 8NU, 
knockout mice showed higher bacterial load in the bladder and kidney upon 
examination the respective homogenates [784].  
4.3.1.2 Adaptive immune response 
Adaptive and acquired immunity can also play a significant role in combating UTIs. 
Mice lacking  B and T lymphocytes were more vulnerable to UTIs than wild type mice 
[763], [765]. Carson et al, (1999) infected mice lacking γδ -T cell by UPEC strain 1677, 
and found they were more susceptible to UPEC compared to wild-type mice [785]. 
Conversely, introduction and restoration of T lymphocytes in the spleen and inactive 
serum transfer from infected mice to naïve mice enhanced resistance to the 
colonisation of UPEC isolate NU14  [778], [786]. Studies aimed at designing vaccines 
against UPEC suggest an important role for humoral and cell mediated immunity via 
the production of cytokines interferon gamma (IFNϒ), IL-4 and IL-17 in UTI eradication 
[787]–[789]. The expression of multiple immune components can be variable 
depending on anatomical location within the urinary tract. For instance, secretory IgA 
may be the most effective immune component against bacterial colonisation in the 
bladder, lack of secretory IgA in the urinary tract may lead to recurrent UTIs [763], 
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[765], [778].  In contrast, systemic production of T lymphocytes appears to be more 
significant in kidney defences [790].      
4.4 The urinary tract microbiome  
4.4.1 The urinary microbiome in health and disease 
For over a century, the scientific community believed in the dogma of the sterility of 
the urinary tract and urine [740]. This notion has been challenged in the last decade 
with emergence of advanced molecular and sequencing techniques aimed at 
understanding the complex microbiome found in the urinary tract [791]. The current 
gold standard for urinalysis is the examination of urine culture due to the highest 
accuracy in which aerobic prototypic phenotypes are identified [792]. Routine culture 
techniques may not be able to detect fastidious anaerobic uropathogens such as 
Ureaplasma and Corynebacterium [740]. Modern sequencing technologies, such as 
16S rRNA sequencing, allowed the detection of a diverse urobiome in individuals 
[793]. The findings of such advanced techniques are supported by modified and 
enhanced quantitative urine culture protocols leading to the detection of up to 80% 
of previously undetectable bacteria by the standardised routine protocols, including 
Actinomyces naeslundii, Fusobacterium nucleatum, Gardnerella vaginalis. 
Furthermore, microbiome alterations have been detected in certain urinary diseases. 
In interstitial cystitis (IC), which is a chronic condition identified by persistent pain 
and at least one symptom such as bladder pain or frequent urination, alterations in 
the microbiome have been observed [794]. The abundance of Lactobacillus is found 
in 90% of IC samples in comparison to 60% abundance in healthy individuals [740].  
4.5 In vitro infection models 
4.5.1 The aim of artificial mediums in vitro    
It is widely accepted that laboratory methods based on the utilisation of nutrient rich 
LB media are not representative of P. aeruginosa infections or the pathophysiology 
of other common uropathogens [795], [796].  Media have been developed in vitro to 
better mimic the conditions in the host. Here we discuss some of the experimental 
tools developed to enhance our understanding of P. aeruginosa infections in other 
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host tissues, and their importance in our understanding of the use of artificial urine 
medium (AUM) to study UTIs.  
4.5.2 Artificial sputum medium (ASM) 
The rise in antimicrobial resistance has led researchers to question the 
methods/conditions used for in vitro studies such as  diagnostic testing of planktonic 
P. aeruginosa [797]. For example, P. aeruginosa grows in mostly microaerophilic 
biofilms in chronic infections in the CF lung, calling into question whether the 
methods of diagnostic testing are representative of  the actual infection environment 
[704]. Many groups have developed and used specific media such as artificial sputum 
in order to recreate physiologically relevant conditions [798], [799]. These studies 
provide clear evidence for the application of in vitro models that recapitulate the host 
environment, particularly in the development of novel therapeutics.   
 4.5.3 Artificial Urine Medium (AUM) 
The changing urinary composition in humans can pose a challenge for laboratory 
investigations of UTI [727]. Typically, urine is pooled from several individuals [800] 
which could affect the reproducibility of results due to the variability in the proteomic 
and metabolic profile of urine between individual donors. To combat these effects, 
Brooks et al, (1997) devised artificial urine medium (AUM) to allow a more consistent 
approach to the investigation of UTI pathogenesis. AUM contains basic urine 
components such as urea, uric acid and sodium chloride along with other 
components  [800]. 
4.5.4 AUM as an experimental medium 
The importance of AUM as a medium used for research purposes is highlighted in the 
broad array of applications found in published literature. AUM has been used to study 
diagnostic tools to uropathogenesis, host-pathogen interactions and the 
development of therapeutics related to the treatment of UTI. AUM has been used to 
investigate factors that contribute to UTIs [731]. For example, struvite stones are one 
of the most common urinary stones and are comprised of magnesium ammonium 
phosphate (MgNHPO4·H2O). These stones constitute about 10 to 15% of all urinary 
stones identified in patients globally and are produced by urease producing 
uropathogens [801]–[803]. The formation of struvite crystals in AUM by 
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uropathogenic P. aeruginosa is inhibited in the presence of vitamin C at 0.5 mg/mL 
or 1 mg/mL over 15 days, suggesting a strong modulatory effect by ascorbic acid 
[804]. P. mirabilis also induces struvite formation by urease production, whereas 
aminophosphinic urease inhibitors prevent formation of struvite in AUM [731]. 
Several studies have used AUM with small differences in its composition, to assess 
the efficacy of novel antimicrobials targeting Gram-negative uropathogens. AUM 
containing chitosan (1% chitosan solutions ranges from 50 and 150 kDa) 
demonstrated antimicrobial capacity to inhibit adhesion of E. coli and K. pneumoniae 
on Foley urinary catheters and also prevented the re-growth of both uropathogens 
[805]. Campana et al, (2017) developed biofilms of these uropathogens on urinary 
catheters for 48 and 72 h in AUM with different chitosan molecules based on 
molecular weight at pH 5.0, and observed 90.4% and 89.7% removal of biofilm 
followed by inhibition of regrowth on catheters [806]. Biodegradable ciprofloxacin- 
incorporated waterborne polyurethane polymers are found to be effective in 
preventing P. mirabilis biofilm formation in AUM and in an artificial bladder model, 
which consisted of a glass flask maintained at 37°C in a water jacket with a catheter 
inserted to the base through a silicone tubing [807], [808]. Urease inhibition has also 
been investigated in UTI-causing Gram-positive uropathogens, where               
treatment   of  S. saprophyticus in AUM by urease inhibitors cetohydroxamic acid or 
fluorofamide causes a temporary delay in the raise of pH associated with urease 
activity [803]. AUM has also been used to test products sold for UTI treatment. 
However, these over-the-counter plant preparations have shown limited 
effectiveness in reducing growth of S. saprophyticus in AUM [801].     
AUM has been involved in studying host-pathogen interactions. Urease causes 
encrustation on urinary catheters and stents by converting urea to carbon dioxide 
and ammonia [809]. Encrustation of medical devices can lead to several concerning 
issues; hindrance of urinary flow, biofilm formation and device-removal associated 
mucosal damage [810], [811]. Removal of urinary catheters can be performed with 
ease, but in the case of other medical devices such as urinary stents, surgical removal 
is required [812]. In vitro, AUM containing urease has been utilised as the ideal 
medium to perform initial research on therapeutic options for biofilm inhibition 
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treatment, despite the use of urine in some experimental setups. As discussed 
previously, experimentation with urine has inherent limitations caused by variable 
composition between healthy and diseased hosts as well as physiological changes 
that occur with time in the same individual [727], [813]. Assessment of E. coli 
adaptation to the urinary tract and its low metabolite availability has revealed, by 
qRT-PCR, that nucleotide salvage pathway genes are upregulated in the presence of 
uracil, xantham and hypoxanthine by using an AUM model [814]. AUM has also been 
to investigate the link between biofilm formation and UTI antimicrobial resistance. A 
study conducted in Japan investigated the correlation between biofilm formation in 
AUM and MBL uropathogenic P. aeruginosa and found a significant increase in biofilm 
formation in MBL producing strains than the non-producers [815]. To characterise 
the transcriptomic, metabolomic and proteomic profile of PAO1 P. aeruginosa in 
conditions mimicking the UTI environment, Tielen et al, (2013) compared biofilm 
formation in AUM medium and a 10-fold diluted LB media, to utilise it as a control 
and maintain the growth rates similar to AUM [753]. Transcriptomic analysis revealed 
that 1019 genes were differentially expressed in AUM while proteomic and metabolic 
analysis found 19 proteins and 34 metabolites expressed differentially. The dominant 
response observed at the transcriptomic and proteomic level was to iron limitation 
as the Fur regulon was upregulated which includes 19 sigma factors and an estimated 
80 targeted operons and genes [753].  
More recently, there has been a shift towards the use of AUM in diagnostic testing of 
uropathogens. Laboratory testing of urine specimens produce negative cultures in up 
to 80% of the tested samples, causing additional workload and significant loss of 
resources [816]. Most importantly, using urine culture as the diagnostic gold standard 
causes delays up to two-three days to detect causative agents and antimicrobial 
susceptibly patterns [817]. Thus, rapid and efficient standardised detection methods 
are needed. One of the most recent advances in this field is the application of 
isothermal microcalorimetry (IMC), using AUM as a standardised medium [818]. This 
study examined four uropathogens in AUM; E. coli, P. mirabilis, S. aureus and E. 
faecalis with IMC, all were detected between 4 to 10 hours after inoculation in AUM 
[818]. By utilising a portable bacteria-grasping surface-enhanced Raman scattering 
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(SERS) method, detection of E. coli, P. mirabilis and P. aeruginosa was significantly 
faster in LB and AUM (1.5 h) than traditional screening methods. With the electro 
adsorption principle, researchers managed to grasp the positively charged NH3+ on a 
portable chip with the negatively charged microorganisms [819]. AUM has also been 
used in cell culture. Madin-Darby Canine Kidney (MDCK) cell polarisation using 
Transwell™ were optimised using this method. This resulted in more complete 
polarisation of MDCK renal tubular cell by production of greater levels of tight 
junction proteins occuldin and ZO-1 [820]. These findings together suggest that AUM 
maybe a more suitable media to study a wide-variety of related aspects of UTIs such 
as diagnostic tools, host-pathogen interactions and the development of therapeutics. 
4.6 Phages as novel antimicrobials 
AUM has previously been used to study bacterial virulence but also the action of 
antimicrobials. With the rise of resistance, novel antimicrobials are being developed 
and these could potentially be used to treat UTIs. However, in the development 
pipeline, it is important to be able to test the activity of any new antimicrobial agent 
in relevant conditions. Thus, in conjunction with studying changes in bacterial 
characteristics in physiologically relevant media, it can also be used as a platform in 
which to assess new therapeutics. Here, I discuss the use of bacteriophages (phages) 
and will study their activity in AUM. 
4.6.1 Therapeutic application of phages against P. aeruginosa   
Bacteriophages (phages) are one of the most widespread and ubiquitous biological 
entities in the environment [821]. Phages are classified into lytic and temperate 
(lysogenic) according to their lifecycle [822]. Lytic phages infect their host (bacteria) 
and can replicate producing progeny [823]. The process of phage invasion of its host 
is initiated by adsorbtion to the host cell surface, followed by injection and replication 
of the phages DNA, eventually resulting in induction of cell lysis and subsequent 
phage replication and invasion of neighbouring cells [824]. Temperate phages 
integrate their DNA into the bacterial chromosomal DNA establishing a relatively 
stable relationship. At later stages during the life cycle these phages can transform 
into the lytic life cycle [825]. Due to their inability to integrate into host bacteria, 
currently only lytic phages are of therapeutic interest.  
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The term “phage therapy” was first coined by Félix d'Hérelle in 1917 [826], followed 
by early successes in the therapeutic application of phage to treat infections [827]. 
The use of phages, however, was abandoned in the Western world following the 
discovery and implementation of antibiotics post World War II [823]. The focus on 
phages has shifted back considerably due to the emergence of MDR bacterial 
pathogens and limited therapeutic options [828]. Bacteriophages targeting                     
P. aeruginosa were first described in 1960 by Holloway et al, (1960) [829] and as of 
January 2015, 137 complete phage sequences were reported [827].  
The vast majority of phages (94%) which target P. aeruginosa belong to the order of 
caudovirales, which consists of 3 families Podoviridae, Myoviridae and Siphoviridae 
(Table 4.5) [821], [830]. The taxonomical distinction is based on the shape of the tail 
[830]. Sequencing analysis revealed that the majority (85%) of Pseudomonas phages 
of caudovirales are P. aeruginosa specific. Amongst these phages, it is estimated that 
60% are lytic phages while 21.8% are temperate and 18.2% are yet to be classified. 
These phages have been isolated worldwide from multiple sources with the most 
common isolation places being wastewater treatment plants and hospitals [827]. 
Table 4.4 Taxonomy and characteristics of largest order of phages involved in invading               
P. aeruginosa  
 
The efficacy of lytic phages as a therapeutic option against P. aeruginosa infections is 
of continued interest to the field. Fur et al, (2010) pre-treated hydrogel urinary 
catheters with Myoviridae lytic phages two hours in advance before inoculating the 
catheters with P. aeruginosa which led to the reduction of 2.8 log in comparison to 
untreated control catheters after 24 hours. The results were reversed between 24-
Phage order Family Tail 
description 
Genome size 
(Kb) 
Nucleic acid 
Caudovirales Podoviridae Short 
noncontractile 
41.6 - 74.9 dsDNA 
Myoviridae long and 
contractile tail 
64.1- 309.2 kb dsDNA 
Siphoviridae long and 
noncontractile 
tail 
34.5 - 61.1 dsDNA 
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48 hours of growth in the treated biofilms prompting the investigators to isolate          
the resistant P. aeruginosa cells and study their susceptibility patterns [831]. This 
allowed them to construct a strategy in which a cocktail of 5 phages applied to pre-
treated catheters, resulting in a 3-log reduction of the same P. aeruginosa biofilm 
population versus the untreated controls [831]. Pires et al, (2011) utilised two phages 
(phiIBB-PAA2 and phiIBB-PAP21) capable of reducing the biomass of planktonic cells 
to infect and reduce biofilms. Upon infecting biofilms with one type of phage, the 
biofilm was reduced after 2 h and further inhibition took place after 6 h. However, 
biofilm cells of strain PAO1 developed a resistant phenotype to phiIBB-PAP21 after 
24h [832].  
In addition to using phages on their own, research has been conducted into 
combining phages with existing antibiotics in order to potentially enhance any 
synergistic effect. Torres-Barceló et al, (2014) allowed PAO1 to grow for 6h to reach 
the exponential phase then introduced either streptomycin and/or Podoviridae 
phage LUZ7. Cultures were studied for up to 70 h to assess whether the use of phages 
can contribute to a reduction of antibiotic doses below the standardised MIC. The 
results suggested that combination therapy with both the phage and streptomycin 
was more effective than the individual treatments alone [833]. Knezevic et al, (2013) 
further expanded on this approach by performing kill-curves on P. aeruginosa treated 
with a combination of phages belonging to Podoviridae and Myoviridae classes 
coupled with subinhibitory concentrations of ciprofloxacin, gentamicin, ceftriaxone, 
and polymyxin B. The only effective combination found to inhibit P. aeruginosa 
growth was ceftriaxone and Siphoviridae phage σ-1, suggesting that cell is disrupted 
by the antibiotic paving the way for the phage infection [834]. Zhang et al, (2013) 
extracted RNA phages from wastewater in Missouri, USA and challenged                           
P. aeruginosa biofilms with chlorine, the synergistic impact of both treatments 
proved more effective than individual treatments [835]. Phage cocktails appear to be 
more effective in a wide range of hosts, simultaneous administration of multiple 
phages may results in higher reduction of bacterial load [836], [837]. 
Lehman et al, (2015) investigated the utilisation of a multiday model of continuous 
flow in an in vitro model of AUM, to assess the effect of pre-treated hydrogen coating 
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silicon catheters with mixed P. aeruginosa and P. mirabilis phages. The application of 
a cocktail of phages isolated from sewage water was effective in reducing biofilm 
formation in both pathogens. The authors concluded that AUM is a valid alternative 
to urine to study the impact of phages on P. aeruginosa [838]. This remains the only 
report which used AUM to study the impact of phages in the urinary tract. Therefore, 
more research is warranted to assess whether AUM is a viable option for testing 
phage efficacy. 
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4.7 Aims 
-   To compare growth and virulence characteristics of P. aeruginosa in AUM with 
both nutrient rich LB broth and human urine  
-  To study P. aeruginosa proteome changes in AUM compared to urine and a 
standard laboratory media. 
-  To compare the resistance of P. aeruginosa to therapeutics in AUM to existing 
nutrient rich laboratory media. 
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Results 4.8 
4.8.1 Growth kinetics of P. aeruginosa are similar in urine and AUM 
In order to study the factors that might regulate the growth dynamics of                             
P. aeruginosa, growth rates of P. aeruginosa UTI isolates were measured and 
compared over a 24 hour period in either AUM, pooled human urine or nutrient rich 
laboratory media, LB. 3 clinical isolates (133043, 133065 and 133098) (Figure 4.1) 
were selected as representative strains that demonstrate the global growth patterns 
observed across the entire isolate panel described in Chapter 3.  
 
Figure 4.1 Growth curves of 3 representative P. aeruginosa UTI isolates chosen from a panel 
of 15 UTI isolates in LB broth (black circle) artificial urine media (AUM) (grey triangle) and 
pooled human urine (black square) over 24 hours at 37°C. Significant differences to the 
growth in LB are shown using **P<0.001 
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Isolates grown in LB media showed a rapid increase in cell density over the first 12 
hours and reached optical densities >1.8 (A600nm). Growth in AUM was significantly 
lower in comparison to LB. However, this was highly similar to the increases in growth 
measured in human urine (Figure 4.1). The cell density for all isolates increased to 
0.4-0.5 that (A600nm) over the first 6 hours. These data suggest that AUM supports 
similar levels of growth to pooled human urine. 
4.8.2 Biofilm formation in urine is better represented by AUM  
As previously discussed in chapter 3, biofilm formation is essential in establishing 
CAUTI [56], [280]. Thus, to determine whether there are differences in P. aeruginosa 
biofilm formation when grown in AUM, compared to urine or LB, CV staining was 
performed to estimate the biomass under each condition. For almost all isolates, the 
highest biofilm formation was observed when grown in LB (Figure 4.4). However, for 
PA14, the highest amount of biofilm at both 24 h and 48 h could be seen in AUM. At 
24 hours, 13/18 isolates showed a significant reduction in biofilm formation in AUM 
compared to LB. All isolates had reduced biofilm in urine compared to LB at both 24 
h and 48 h (Figure 4.2). However, this apparent difference in biofilm formation could 
be attributed to the differences in growth observed in Figure 4.1. To account for this, 
the data was reanalysed to correct for total bacterial growth and expressed as per 
capita biofilm production (Figure 4.3).  
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Figure 4.2 Biofilm assay of P. aeruginosa UTI isolates in LB (black), artificial urine media (AUM) 
(light grey) and pooled human urine (dark grey) after 24 h (Panel A) and 48 h (Panel B). 
Significant differences to the biomass in LB broth are shown using *P<0.05 **P<0.001; 
significant differences P<0.05 between AUM and pooled urine are denoted with a solid line 
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Figure 4.3 Per capita biofilm biomass for 15 clinical P. aeruginosa clinical isolates in LB broth 
(LB) and artificial urine media (AUM) relative to OD600 after 24 h. Significant differences are 
shown using **P<0.001 
The data shows that under AUM conditions, bacteria had a greater ability to form 
biofilms compared LB media. This suggested that relatively more bacteria (of the total 
bacteria) were adhered to the surface of the plastic in AUM than in LB and that AUM 
conditions may promote biofilm formation. To investigate this observation further, a 
selected number of clinical isolates were studied using confocal microscopy to study 
the structure and architecture of the biofilms (Figure 4.4). Isolates grown in AUM 
appear to form denser and tighter biofilms than those grown in the richer nutrient 
medium LB. Figure 4.4 displays PAO1 biofilms formed in A) LB and B) AUM. The 
biofilms formed in AUM are more densely packed with bacteria and are thicker 
(minimum 25 μm). The trend for more dense biofilms in AUM can also be observed 
for two clinical isolates (Figure 4.4 C-F). This provides further evidence that AUM 
promotes enhanced biofilm formation on plastic surfaces. 
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Figure 4.4 Biofilm microscopy of P. aeruginosa grown in LB and AUM for 24h. Each panel 
contains an image of a 3D biofilm, an image of P. aeruginosa attached to the bottom of the 
chamber slide at the base of the biofilm and a cross section to display the profile of the 
biofilm. A) PAO1 grown in LB, B) PAO1 grown in AUM C) 133117 grown in LB, D) 133117 
grown in AUM, E) 133043 in LB and F) 133043 in AUM. The white bar denotes 10 µm 
4.8.3 Isolate-dependent pyocyanin production in LB & AUM  
This assay was conducted on three reference strains and three UTI isolates 
(133043,133065 and 133098) to compare pyocyanin production in AUM compared 
to LB (Figure 4.7). Production of pyocyanin produced in AUM was reduced 
significantly in LESB58 (P<0.001) and PA14 (P=0.009). In contrast, only isolate 
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133065 showed significant reduction in LB compared to AUM (P=0.009). The 
differences in growth were not accounted for in this assay. The response seems to 
be isolate dependent. 
 
Figure 4.5 Mean pyocyanin production in LB (black) and AUM (Light grey) calculated after 
measuring absorption at A=695 OD. Significant differences are shown using *P<0.05 
**P<0.001 
4.8.4 Gene expression is isolate dependent in LB and AUM 
In order to determine the relative gene expression between LB and AUM, a small 
panel of clinical isolates (133043,133065, 133098) and the two reference isolates 
PAO1 and PA14 were investigated using qPCR. Total RNA was extracted from isolates 
grown in LB and AUM, gene expression of a panel of genes was determined. 
4.8.4.1 Planktonic growth conditions 
RNA extraction was performed from LB and AUM cultures. Gene expression was 
determined for isolates PAO1, PA14, 133043,133065 and 133098. Reference genes 
rpoD and proC were used for normalisation purposes since they have previously been 
used as housekeeping genes in P. aeruginosa [416]. Overall, similar trends in gene 
expression were observed with each housekeeping gene (Figure 4.6 A-B). Genes 
associated with initial biofilm formation were studied in the five isolates. pelB was 
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expressed >1.5 fold increase in AUM in all isolates excluding 133098. However, the 
other genes tested (flgD, algD and pslA) either showed no change or were 
downregulated. For flgD, PA14 showed a downregulation of five-fold.  One of the 
genes involved in alginate production (algD) showed a >1.5-fold downregulation for 
4/5 isolates with PA14 and 133098 showing over a four-fold downregulation in 
expression (Figure 4.7). For pslA, the response is mixed with some isolates showing a 
slight increase in expression and other showing a decrease. However, only isolates 
PA14 and 133065 show a greater the 1.5-fold change (downregulated) (Figure 4.7). A 
similar isolate-dependent response could also be seen in QS-related genes (Figure 
4.7). In AUM, lasR expression did not change in PAO1, however, three isolates 
displayed a strong reduction in lasR expression of between -six and -14 -fold. For phzF 
and rhlR, all isolates apart from PAO1 showed a reduction in expression of the gene. 
Expression of pqsR did not follow a particular pattern and was isolate dependent 
(Figure 4.8). For genes mexX and mexB, the response was again isolate-dependent 
with some isolates displaying upregulation and others downregulation. The gene 
encoding the virulence factor, Cif was also studied. For two isolates, there was no 
change in expression in AUM, however, for the remaining three isolates a 
downregulation in expression was observed, particularly in PA14 (-six-fold change) 
(Figure 4.9).  Overall, the changes in gene expression were largely isolate dependent. 
Some trends were observed, such as the upregulation of pelB and the down 
regulation of algD.  
Figure 4 6 Relative gene expression for A). PAO1 growing in planktonic AUM culture and B) 
UTI isolate 133043, compared to growth in LB, normalised to rpoD and proC genes. Similar 
trends in gene expression can be seen using both housekeeping genes 
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Figure 4.7 Fold change of genes expressed in relation to biofilm formation. Two red lines 
denote the fold change deemed significant; upregulation 1.5, downregulation, -1.5 
 
Figure 4.8 Fold change of genes expressed in QS mechanisms. Two red lines denote the fold 
change deemed significant; upregulation 1.5, downregulation, -1.5 
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Figure 4.9 Fold change of genes expressed in antimicrobial resistance and virulence. Two red 
lines denote the fold change deemed significant; upregulation 1.5, downregulation, -1.5 
4.8.5 Mapping the proteome of UTI clinical isolate 133098  
To address whether the proteomic profile of UTI P. aeruginosa is altered in LB, AUM 
and urine, 5 biological replicates of isolate 133098 were grown in each medium until 
growth reached the optical density of 0.25 OD (+/- 0.005). This was due to the 
inability of the bacterium to grow to 0.5 OD in the urine medium in larger culture 
volumes. Rapid growth in LB was observed in comparison to AUM and urine. 
However, growth in urine was much slower than AUM. Proteomic studies were 
performed by Stuart Armstrong and the Centre for Proteomics, University of 
Liverpool. This was followed by in silico proteomic analysis. 
  
PCA was conducted to demonstrate the level of variance and clustering of replicates 
(Figure 4.10). Furthermore, proteins with significant abundance difference were 
identified and a heat map was constructed (Figure 4.11) to assess the distribution of 
the protein abundance profile. The heat maps revealed large areas of differentially 
produced protein. Protein abundance was compared between AUM and urine in 
comparison to LB as the control growth media. The criterion by which a protein is 
deemed significantly abundant is set at > 1.5-fold change and a significant P value 
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(P<0.05). Each condition gave rise to a distinct subset of replicates that are tightly 
clustered.
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Figure 4.10 PCA of 5 biological replicates in each of LB, AUM and urine present no outliers in the variation of protein abundance in each medium. X axis and Y 
axis demonstrate principal component 1 and principal component 2 that explain 16.3 and 73.9% of the total variance, respectively
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Figure 4.11 Heat map of the distribution of the profile of abundant proteins across all three 
conditions; LB, AUM and Urine. Red colour demonstrates highest upregulation while dark 
blue lowest downregulation.  Each condition contains 5 biological replicates
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4.8.6 P. aeruginosa proteome in urine  
4.8.6.1 Proteins higher in abundance in urine compared to LB  
In silico analysis revealed 1970 proteins which displayed significantly higher 
abundance in urine compared to LB (Figure 4.14). 30 proteins showed a large 
upregulation in urine by over 100-fold. Of these, 43% were categorised as either 
uncharacterised/hypothetical proteins such as PA0543 (infinity fold change, 
undetectable in LB) and PA2161 (70,022-fold change). Ortholog matches are found in 
the Pseudomonas database to LESB58 (PALES_05411-putative depolymerase) [839] 
and to Pseudomonas dentrificans (ATCC13867 lpqC) [840]. PA2161 is regulated by 
AlgU, which is the transcription factor that also activates alginate overproduction 
[841]. Another protein, ExaB is a soluble cytochrome C550 which grows on ethanol 
with a quinoprotein ethanol dehydrogenase [842], and was found to be higher in 
urine by 467 fold. Two component systems consists of sensor kinases and response 
regulators, which sense the surrounding environment and adapt accordingly [162]  
such as the orphan chemotaxis sensor regulator which increases virulence and 
antimicrobial tolerance [843]. Proteins PA2572 (regulator) and PA2573 (sensor) were 
higher in urine by five and 16 folds in comparison to LB, respectively.  
 
Figure 4.12 A: Upregulated proteins in urine and AUM compared to LB. B: Downregulated 
proteins in Urine and AUM compared to LB 
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4.8.6.2 Proteins lower in abundance in urine compared to LB 
There are 1888 proteins which are downregulated > 1.5-fold and above, including 6 
proteins that were down by over 100-fold. 50% of these proteins are hypothetical, 
one of the notable proteins is ExoS, an effector of the T3SS. When the proteins were 
compared further to AUM, a trend was observed in which T3SS proteins were more 
suppressed in urine than AUM as well as LB (Urine<AUM<LB). However, the global 
downregulation in both conditions may suggest that AUM is a suitable model to study 
P. aeruginosa in UTIs.  
Two-component systems such as the PhoP-PhoQ system respond to environmental 
cues, this system is present in P. aeruginosa, Yersinia pestis, and Salmonella enterica 
[844]–[846]. Upregulation of the PhoP-PhoQ increases virulence and resistance to 
anticatatonic peptides [846]. Our results show upregulation in LB. Both of proteins of 
PhoP and PhoQ were more abundant by 10-fold in LB in comparison to urine.   
 
4.8.6.3 Proteins higher in abundance in AUM compared to LB  
As for the results obtained in AUM in comparison to LB, 1293 proteins displayed a 
significantly higher abundance by >1.5-fold change. The analysis identified that three 
proteins show over 100-fold increase in AUM in comparison to LB, the proteins were 
all hypothetical (PA0543, PA2384 and PA2161). These proteins were upregulated by 
“infinity”, 356 and 209- fold change, respectively. PA2384 protein has been studied 
and is involved in responses to iron limitation, it acts as a global activator of several 
important genes involved in iron acquisition and uptake [847]. PA2161 is another 
uncharacterised protein that has been shown to be AlgU regulated. Elastase showed 
a 50-fold upregulation in AUM. Elastase is a potent virulence factor and has been 
shown to promote virulence in the CF lung by degrading mucin and targeting the 
epithelial tissue [848]. Lactate dehydrogenase (LldA) was also upregulated by 48-fold. 
Lactate is thought to serve as an important energy source for bacteria, particularly 
during chronic infection [849]. Increased abundance of this protein may indicate the 
altered metabolism of P. aeruginosa in AUM compared to LB. Other pathways 
displaying increased protein abundance are phenazine biosynthesis (Table 4.8), 
pyoverdine production (Table 4.6) and other pathways for which the function is not 
entirely clear (PA3327-PA3335). This cluster of proteins encoded by the putative 
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operon PA3327-PA3335 show upregulation of a total of eight proteins believed to 
control the synthesis of a secreted secondary metabolites which include a gene 
cluster with a putative efflux transporter [850]. 
4.8.6.4 Proteins lower in abundance in AUM compared to LB 
Many proteins associated with the cell surface and the modification of cell surface 
properties were down in abundance in AUM compared to LB. These included          
ArnA, ArnB and Arnc (-20, -21 and -39- fold respectively) and proteins involved is 
spermidine utilisation (SpeE2 and SpeH at -26 and -16-fold respectively). 
Downregulation of the Pmr system was observed in AUM in comparison to LB as 
proteins PmrA and PmrB were found to be upregulated in LB by seven and 14-fold, 
respectively. A large number of pili-related proteins were also down in abundance in 
AUM. These included PilW, PilQ and PilU all down by 3-fold and PilM, PilB, PilV and 
PilN (all down by two-fold). 
4.8.6.5 Similarities between AUM and urine compared to LB 
418 proteins were upregulated in both of urine and AUM growth media. Notably, 
proteins involved in the production of the siderophore pyoverdine were all 
upregulated (Table 4.5). These were similarly upregulated in both AUM and urine. 
246 proteins were downregulated in both of AUM and urine. Strikingly, the T3SS 
system was downregulated in both AUM and urine compared to LB (Table 4.6). 
Interestingly, the extent to which the proteins were downregulated in urine were 
higher, as demonstrated by the protein PcvR 35-fold downregulation compared to 
AUM’s 2.7-fold change
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Table 4.5 Proteins in pyoverdine pathway upregulated (black) and (red) downregulated 
Protein Urine Q value AUM Q value 
PvdO 31.3 2.35E-09 5.5 0.01076928 
PvdP 14.5 8.62E-07 3.7 0.08180011 
PvdA 1.6 0.00073368 8.8 0.01398713 
PvdD 3.1 1.48E-07 7.9 0.01990013 
PvdE 2.1 0.00542378 17.8 0.00213072 
PvdF 1.8 0.0026495 4.6 0.01477302 
PvdJ 1.4 0.00135028 2.9 0.07056501 
PvdR 1.3 0.06260262 16.0 0.00158822 
PvdQ 2.8 0.00017731 2.8 0.07068926 
PvdN 35.8 2.35E-08 35.8 2.35E-08 
FpvA 15.4 1.66E-08 3.7 0.00023054 
PvdL 1.6 0.00017863 4.6 0.02659835 
PvdH -1.5 9.65E-06 5.5 0.02930295 
FpvB 35.9 2.45E-10 1.7 0.00699365 
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Table 4.6 Proteins involved in T3SS pathway downregulated in Urine and AUM annotated 
in red 
Protein Urine Q value AUM Q value 
ExsA -8.4 3.91E-05 
  
-1.7 0.09261383 
  
ExsC -1672.7 4.18E-05 
  
-3.9 0.00461173 
  
ExsD -6.2 4.36E-07 
  
-2.4 0.00036314 
  
PopB -7.6 2.94E-07 
  
-6.3 7.29E-06 
  
PopD -5.9 0.00033522 
  
-3.4 2.22E-05 
  
PopN -12.9 6.71E-07 
  
-9.0 4.73E-05 
  
PcrV -35.2 1.29E-06 
  
-2.7 0.0011945 
  
ExoT -18.0 6.45E-09 
  
-3.9 3.84E-06 
  
ExoY -7.8 6.69E-07 
  
-2.8 0.00595532 
  
PscF -1.9 0.00302357 
  
-3.8 0.00010479 
  
PscC -4.3 1.04E-06 
  
-3.2 0.00070171 
  
PscJ -11.9 4.89E-08 
  
-3.9 3.64E-05 
  
PcrH -11.7 4.79E-06 
  
-4.0 6.91E-05 
  
PscQ -11.0 1.00E-06 
  
-2.6 5.35E-05 
  
PscH -7.6 4.79E-06 
  
-5.3 0.00137482 
  
PscL -75.4 4.87E-07 
  
-16.8 6.30E-06 
  
PscE -23.5 2.12E-08 
  
-2.7 6.83E-05 
  
PscD -20.1 4.33E-05 
  
-13.7 0.01620284 
  
PscB -17.7 2.74E-08 
  
-5.5 3.31E-05 
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4.8.6.6 Differences between AUM and urine compared to LB 
Overall, 465 different proteins were upregulated in urine in comparison to 187 in 
AUM. More proteins were downregulated in urine (611 proteins), while only 118 
were downregulated in AUM. One of the main differences observed in protein 
abundance was of proteins involved in phenazine biosynthesis (Table 4.7). Some 
proteins involved in phenazine biosynthesis were both down in abundance in urine 
and AUM. However, there was very little similarity in PhzD, PhzE, PhzF, PhzG and PhzS 
abundance. In addition, proteins contributing to the PQS system were downregulated 
in urine versus up in AUM, particularly PqsH with a reduction of 28-fold change 
(compared to LB) as opposed to a 1.5-fold increase in AUM. 
Table 4.7 Fold change of phenazines and pqs pathway protein abundance in urine and AUM 
media. Grey= upregulation. Red= downregulation   
Protein Urine Q value AUM Q value 
PhzM 3.0 0.00118385 15.7 3.97E-05 
PhzB 4.2 3.06E-07 5.6 0.00018109 
PhzC 1.5 0.08236075 14.8 9.87E-05 
PhzD 1.1 0.08526314 21.1 6.57E-05 
PhzE -1.8 0.0004553 8.9 0.00016609 
PhzF 1.5 0.00116558 20.8 3.67E-05 
PhzG 1 0.06703159 12.7 0.00054675 
PhzS 1.8 9.53E-05 11.3 7.29E-05 
PqsA -4.9 2.68E-06 2.5 0.00048118 
PqsB -4.6 6.16E-06 4.2 0.00012162 
PqsC -5.1 2.36E-06 4.0 8.61E-05 
PqsE -1.2 0.05692529 4.1 0.00025938 
PhnA -3.3 0.00017614 4.5 0.00013111 
PhnB -4.0 0.000583 5.4 0.00080591 
PqsD -2.3 0.00027679 4.2 7.62E-05 
PqsH -28.7 8.03E-09 1.5 0.01074726 
PqsL -4.6 6.61E-05 2.1 0.0071457 
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4.9 The use of AUM as a platform to test therapeutics  
To assess the difference between the therapeutic ability of phages in LB and AUM 
medium, the UK panel of isolates were first treated with 4 phages; PELP20, 42/1, PT6 
and PNM to determine sensitivity in LB. PELP20 was the most effective phage and 
showed activity against 86.6 % of the UTI isolates followed by PNM (53.3%), PT6 
(40%) and 42/1 (33.3%) (Table 4.8). 
Table 4.8 The panel of UK UTI isolates grown and results of treatment with 4 phages PELP20 
,42/1, PT6, and PNM. +=clear lysis, +/-=lysis with cloudy plaques, -=no lysis  
 
For the isolates from Kuwait, PELP20 was only effective against 25% of the total number of 
isolates. Phage 42/1 was active against the isolate 902, while PT6 was active against 1083 
only. PNM failed to produce any plaques (Table 4.9). 
UTI isolates PELP20 42/1 PT6 PNM 
133042 + - - - 
133043 + + + + 
133044 +/- +/- +/- +/- 
133065 + - +/- +/- 
133075 + +/- +/- +/- 
133082 + +/- +/- +/- 
133083 + +/- +/- +/- 
133090 + - - + 
133098 + - - - 
133099 + - - - 
133104 - - - +/- 
133105 - - - - 
133106 + - - - 
133117 + - - - 
133126 + - - - 
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Table 4.9 The panel of Kuwait UTI isolates grown and results of treatment with four phages 
PELP20, 42/1 PT6, and PNM 
 
To initially test AUM as a platform to study phage infection to P. aeruginosa isolates 
were pre-grown in AUM. Phage testing was conducted by growing five isolates 
(133043,133065,13398,133105 and 133117) overnight and then incorporation into a 
standard plaque assay. In comparison to the phages activity in isolates grown in LB 
media, only one phage (PELP20) displayed inhibitory activity against some of the 
isolates grown in AUM, namely 133043, 133065 and 133098 (Table 4.10). 
Furthermore, isolate 133098 appeared sensitive to phage PELP20 in LB, however, it 
was resistant in AUM. This small preliminary study suggests that AUM may be useful 
as a controlled medium to test phage activity.  
Table 4.9 A panel of UTI Isolates grown in AUM prior to treatment with phages 
UTI Isolate PELP20 42/1 PT6 PNM 
133043 + - - - 
133065 + - - - 
133098 - - - - 
133105 - - - - 
133117 +/- - - - 
Isolate PELP20 42/1 PT6 PNM 
758 - - - - 
783 -  - - - 
786 -  -  - - 
864 - - - - 
888 - - - - 
902 + +/_ - - 
925 + - - - 
1083 -  -  +/- -  
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4.10 Discussion  
The urinary tract is a harsh environment for bacterial growth and survival [743]. To 
assess whether AUM mimics urine, in vitro comparisons using AUM formulation of 
Brooks et al, (1997) [800], urine and nutrient rich LB were conducted. Urine 
components vary between healthy and ill individuals and even amongst samples 
taken from the same individuals in different time points [727]. Thus, we aimed to 
determine whether this formulation of AUM accurately recapitulates the host-
environment encountered by P. aeruginosa during UTI pathogenesis. This could then 
subsequently be used to study other host factors in isolation. 
Analysis of growth rates of uropathogenic P. aeruginosa suggest that their kinetics 
are similar in AUM compared to urine, as such, suggesting that AUM may provide a 
better model to study the in vitro growth of uropathogenic P. aeruginosa than LB 
media. UPEC is the most widely studied uropathogen. Though no studies have been 
conducted to test the growth rate of UPEC using AUM media and the formulation of 
Brooks et al, (1997) [800], studies have been performed in human urine which 
showed that ABU E.coli outcompetes UPEC  [748]. Biofilm formation is a virulence 
factor utilised by uropathogens to aid persistence in the host and is involved in CAUTI 
colonisation [280], [462]. Despite the higher biomass identified in LB compared to 
AUM and urine, when per capita biofilm formation was studied, which corrects for 
cell number, the data suggests that biofilm formation is favoured in AUM. This was 
reinforced further by the microscopy data which showed densely packed, thick 
biofilms formed in AUM. According to the results, biomass formed in urine tend to 
be significantly less than AUM in the majority of the isolates. This could be due to 
host factors not present in AUM such as THP, which is the most abundant protein in 
urine and exhibits protective effects against uropathogens such as E. coli by 
interfering with epithelium adhesion [765]. Conversely, studies conducted in vitro 
and in vivo of CAUTI P. aeruginosa indicated that this glycoprotein promotes biofilm 
formation on catheters [484]. As mentioned previously, antimicrobial peptides may 
play a role against invading bacteria. Human cathelicidin LL-37 is present in human 
urine [851]. This antimicrobial peptide may downregulate the transcription of QS 
mechanism of las and rhl by affecting more than 50 genes that are involved                         
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in the development and maintenance of biofilms such as rhlA, rhlB, the 
rhamnosyltransferase genes [684]. These events could impact biofilm formation by 
decreasing the attachment of bacterial cells [684].  Antimicrobial peptides can also 
affect biofilm formation by promoting twitching motility via the stimulation of genes 
involved in Type VI pili synthesis [852], [853]. Thus, inclusion of molecules involved in 
UTI defences in AUM media may lead to better resemblance of biofilm formation in 
UTI pathophysiology.   
Upon conducting pyocyanin assays to a selection of three clinical isolates in LB and 
AUM, I observed that production of pyocyanin is isolate-dependent, with only one 
UTI clinical isolate (133065) producing significantly more pyocyanin in AUM. This 
could be attributed to the specific characteristics of each isolate. Pyocyanin is a type 
II zwitterion, redox-active, blue pigmented toxin released by P. aeruginosa which 
promote inflammation and impair urothelial cells ability to repair [269]. The 
abundance of proteins involved in the synthesis of pyocyanin was shown to be more 
abundant in AUM compared to urine. In AUM, the pyocyanin production pathway 
was upregulated along with the pqs QS system, which appeared to be inhibited in 
urine. The underlying mechanisms of such inhibition requires further investigation. 
Another potential role of pyocyanin in UTIs is in biofilm formation. Pyocyanin is 
thought to interact with eDNA on urothelium or on the catheters [134].  
In order to investigate the profile of proteins (including virulence factors) produced 
in response to the urinary environment, the abundance of proteins was measured in 
the three mediums; LB, AUM and urine. Iron acquisition mechanisms are 
indispensable for uropathogens and bacterial survival in general [26], [753]. Our 
results support using AUM as a model to test iron uptake strategies comparatively to 
urine since both mediums appeared to be similarly regulated in terms of abundance 
of proteins associated with iron uptake pathways. However, urine showed greater 
abundance of these proteins compared to AUM, particularly FpvB, PvdN, PvdO,    
which were downregulated by 35.9, 35.8, 31.3-fold, respectively in urine. Thus, 
upregulation of such molecules may increase bacterial ability to scavenge for iron 
compounds such as those in lactoferrin in urine [854] and allow the bacteria to 
survive, invade and colonise the urinary tract. The importance of iron chelating and 
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acquisition mechanisms in uropathogenesis has been shown in several studies on 
UPEC. Transcriptomic analysis of an in vivo mouse model showed dramatic 
upregulation of iron acquisition genes such as the outer membrane receptor hemin 
chuA (13-fold) and the putative heme/haemoglobin transport protein chuS (8-fold) 
[463]. In comparison to intestinal E. coli isolates, UPEC strains from the same patients 
expressed deferentially higher production of siderophores yersiniabactin and 
salmochelin [464]. 
Several proteins were more abundant in AUM in comparison to LB. PA2384 protein 
function has been elucidated and is involved in responses to iron limitation as a global 
activator. Zheng et al, (2007) performed mutagenesis knockout studies on PA2384 in 
iron-limited medium and observed the downregulation 71 genes involved in iron 
acquisition including those of the pyoverdine pathway, pyochelin pathway and Haem 
uptake mechanism [847]. In addition, upregulation of elastase in AUM is observed in 
these results. This is consistent with the upregulation of lasB in anaerobically grown 
P. aeruginosa PAO1 biofilms [753]. Elastase is a potent virulence factor and has been 
shown to promote virulence by degrading extracellular matrix components by 
hydrolysis. The toxin can also disrupt tight junctions of epithelial cells and neutralise 
several cytokines such as TNF-α and IFN-γ [855], [856]. Thus, a possible role in the 
urinary tract would be targeting the tight junction within the urothelium.                             
P. aeruginosa produces lactate dehydrogenases (LldA), which has been shown to be 
induced by the L-enantiomer of lactate, a component in the mucin of both the CF 
lung and in AUM. Lin et al, (2018) demonstrated that LldA can contribute to cross-
feeding of biofilm formation by catalysing the production of L-lactate in the anaerobic 
zones within biofilms and transported to aerobic zones in conditions mimicking 
chronic infections [849].    
PmrAB is a two component system which consists of PmrB and is regulated by the 
other component PmrA [857].  PmrB is a sensor kinase that is activated in response 
to low Mg+2 levels or cationic peptides by modifying the PA3552-PA3559 LPS locus 
leading to resistance of cationic antimicrobial peptides and cationic polymyxins B 
[546], [547]. Our results show that the two-component system of PmrAB is down in 
abundance in AUM. This is in agreement with the earlier phases of CF lung infection 
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where loss of pmrB function is associated with increased antibiotic susceptibility to 
trade-off for early colonisation of the host [858]. In addition, proteins which 
contribute to the biosynthesis of L-Ara4N such as ArnA, ArnB and Arnc were all 
downregulated by 20, 21 and 39-fold, respectively. The aim of the addition of L-Ara4N 
to the lipid A moiety of LPS in P. aeruginosa, is to evade cationic antimicrobial 
peptides [859]. Thus, the inability of P. aeruginosa to resist this process may result in 
its clearance from the bladder by cationic peptides in the urinary tract setting. 
Polyamines such as spermidine (has a 3+ charge) are important molecules for                  
P. aeruginosa for LPS stabilisation and protection against antimicrobial peptides 
[860]. SpeH and SpeE2 were also downregulated, which may also increase 
susceptibility and cationic peptides , antibiotics and oxidative stress in a natural UTI 
setting [860].  
Comparisons between urine and LB were conducted. Some of the notable 
upregulated proteins were cytochrome C550, which appears to be important in urine 
given the substantially higher expression of this protein. Cytochrome C550 is as 
essential molecule in the oxidation of the ethanol system [842]. Ethanol and its 
derivatives exist in urine and are utilised as a carbon source by P. aeruginosa [861]–
[864]. Thus, altered ethanol metabolism maybe a route by which this bacterium 
adapts in the urinary tract. 
Another stark difference in the proteomic profile between AUM and urine is the 
expression of the two-component system containing the putative response regulator 
PA2572 and the probable chemotaxis transducer PA2573 [865]. Both proteins are co-
expressed in response to environmental cues such as aerobic respiration containing 
nitrate and to bacterial inoculation into human lung epithelial cells [866]–[868]. This 
two-component system  is involved in regulating a set of 49 genes involved in motility 
and increased tolerance to antibiotics [865]. These results show that human urine 
may trigger this two-component system in P. aeruginosa to enhance and promote 
invasion and colonisation in the urinary tract. The PhoQ-PhoP is another two-
component system  that is involved in resistance to cationic peptides and polymyxins 
[869]. Transcription of the sensor kinase system occurs in response to low Mg+2 or 
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Ca+2  and to cationic peptides [846]. This two-component system was downregulated 
significantly in urine. 
One of the main aims of conducting proteomic analysis was to investigate how 
different the abundance protein profile of UTI P. aeruginosa in AUM and urine. In 
urine, there was a significant downregulation of the T3SS in urine compared to LB. 
This effect was also seen in AUM. The T3SS is associated with acute infections rather 
than chronic infections [870]. Expression of T3SS is triggered by either low 
concentrations of calcium or contact to the host cell. No host cells were present in 
any of the models. These results show that both NuoL and ShaC are downregulated 
in urine, these are involved in the metabolism of nucleotides, amino acids, and are 
required for T3SS [871]. This is consistent with other findings that metabolic stresses 
inhibit the T3SS [221], [871], [872].  Urine and AUM conditions may therefore, favour 
switching to chronic infections where biofilm formation is paramount.  
In summary, AUM appears to mimic urine more than LB. 418 proteins were 
upregulated and particularly in the similar response mounted by the upregulation of 
iron acquisition mechanisms which was largely similar with a few exceptions such as 
downregulation of PvdH (1.5- fold change). The other notable similarity is the 
downregulation T3SS, which is consistent with several studies conducted with other 
uropathogens such as E. coli and P. mirabilis [207], [208], [210]. Thus, the T3SS may 
be universally dispensable amongst uropathogens. However, in vivo studies would be 
needed to study this further. 
Based on these proteomic results, AUM is the more suitable laboratory medium to 
study pathogenesis of P. aeruginosa in UTIs (compared to LB). However, some 
differences in the abundance of proteins reveal the need for optimisation of this 
medium. One crucial difference is the expression of the PQS system which was up in 
AUM compared to urine. Functional PQS system is associated with severe 
inflammation and tissue destruction in an acute pyelonephritis mouse model [129], 
which further highlights the need for a model that gives more similar responses to 
urine. Recent attempts have been made to optimise artificial urine composition by 
adding 0.2% yeast and casamino acids, these results showed optimal growth of Gram-
positive and Gram-negative urinary pathogens [745]. None of the formulations, 
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however, take into account the inclusion of host factors such as cationic peptides and 
THP which could bridge the gap and yield a closer bacterial response.  
In addition to the proteomic analysis presented here, gene expression was 
investigated in LB and AUM for genes involved in quorum sensing, biofilm formation, 
virulence, antimicrobial resistance. Gene expression was generally lower in AUM 
compared to LB in the strains and clinical isolates of P. aeruginosa cells in planktonic 
There was little consistency between the qPCR results and the proteomic analysis, 
however, the growth conditions differed. The most notable upregulation of a gene in 
AUM was pelB as it was upregulated in PAO1, PA14, 133043 and 133065. PelB is 
involved in exopolysaccharide production that leads to biofilm formation. In vitro 
expression of either psl or pel genes is involved in biofilm formation. Little is known 
about the contribution of Pel exopolysaccharides in UTIs. However, the interactions 
of pyocyanin and eDNA is thought to be the driving force behind biofilm formation 
by UTI P. aeruginosa in agreement with the published literature [753], alginate 
production (using algD expression as a proxy for this) was downregulated in PA14 
and the uroisolate 133098, indicating that alginate is not expressed in AUM. QS genes 
were not universally upregulated. However, lasR was upregulated in 133065 and 
pqsR in 133098. PqsR was higher in abundance in the proteomics experiment too. A 
functional PQS system is associated with severe inflammation and tissue destruction 
in an acute pyelonephritis mouse model. There was evidence of mexB upregulation 
in AUM, suggesting a possible increased level of resistance by the utilisation of efflux 
pumps.  
Lytic phages were utilised to determine whether phages have the same impact on 
UTI P. aeruginosa upon pre-treatment in LB and AUM. Four phages displayed variable 
activity, with PELP20 showing the highest rate of bacterial inhibition in LB. 
Interestingly, this phage lost its effectiveness against one clinical isolate 133098 when 
pre-grown in AUM. The other phages, however, were totally ineffective when 
introduced to AUM containing P. aeruginosa. These results indicate that the 
behaviour of P. aeruginosa in AUM may alter the ability of phages to infect their 
bacterial target. Through proteomic data analysis, it was evident that many pili 
proteins were significantly down in abundance in AUM compared to LB. These 
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included PilW, PilQ, and PilU (-3-fold) along with PilM, PilB, PilV and PilN (2-fold). Pili 
can often act as a receptor for phage infection and therefore depending on the 
phage, this may alter the ability to infect and kill the bacteria. In addition, the porin 
OprH, which serves as another receptor, was downregulated by 11-fold. The 
receptors for phages used in this study are unknown. Thus, studying phage resistance 
mechanism in AUM warrants more research. This provides further evidence that 
AUM may provide a more suitable environment for therapeutic testing with phages 
than other laboratory media. Furthermore, investigation using a cocktail of phages or 
phage-antibiotic treatment may lead to better outcome [834]–[837].
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Chapter 5 
5.The Impact of Sex Hormones on UTI P. aeruginosa  
5.1 Introduction  
5.1.1 The impact of sex hormones on bacterial infections 
Several bacterial infections are known to affect men more than women, for instance, 
gender preference for gastrointestinal tract infections with Salmonella typhi, 
Helicobacter pylori, and Clostridium difficile is biased towards men [873].                                      
In contrast, bacterial infections such as UTIs caused by UPEC, sexually transmitted                           
infections (Chlamydia trachomatis, Neisseria gonorrhea) and listeriosis by Listeria                                                                                                                                                                       
monocytogenes affect women more than men. The pathogenicity of these organisms 
is extensively reviewed elsewhere [873], [874].  
5.1.1.1 Sex hormones and their role in sepsis 
Sepsis is defined as a systemic illness involving microbial invasion in sterile locations 
in the body such as the bloodstream [875]. Physiologically, overproduction of 
cytokines such as TNF-α, IL-1β and IL-6 by macrophages is stimulated in sepsis upon 
the introduction of bacterial LPS. In vitro, Moxley et al, (2002) examined isolated 
human peripheral blood where the inflammatory cytokine TNF-α was found to be 
higher in males than females [876], [877]. This is attributed to the protective effects 
of oestrogen in relation to immune responses, which have been known since the 
1960s [878]. In a series of experiments conducted by Nolan and O'Connell, isolated 
livers from rats were perfused with female blood, resulting in alteration of the normal 
vasoconstrictive responses to E. coli LPS [878]. In a subsequent study Nolan 
administrated conjugated oestrogen 1 h prior to LPS exposure and observed a 
protective effect against the lethality of the endotoxin [879]. In a report by Christeff 
et al, (1994) it was revealed that dose-dependent administration of oestradiol 
minimised the percentage of deaths due to the presence of LPS among male rats 
[880]. Post-administration of synthetic oestrogen (ethynyloestradiol) to rats 
challenged with E. coli LPS restored cardiac output and led to the attenuation of 
hemodynamic changes [881]. These protective effects were observed pre and post 
challenge with LPS and do not address whether circulating oestrogens in females 
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provide the same protective effects [881]. Thus, Merkel et al, (2001) conducted an 
experiment using male and female rats with three treatment groups; rats challenged 
with LPS (extracted from Vibrio vulnificus), rats challenged with LPS following 
gonadectomy, and a third group of rats receiving LPS, gonadectomy and oestrogen 
supplementation (2 μg/day). In the first treatment group, the fatality rate was 82% in 
males in comparison to females at 21% during the estrus cycle after the preovulatory 
oestrogen surge. In the second group, ovariectomised females died in a significantly 
higher rate to normal females (75% to 21%) and very similar to males (75% to 80%), 
no oestrogen was detected in ovariectomized females. To determine whether 
oestrogen was indeed protective, ovariectomized females were administered 
oestradiol-17β for 5 days (2 μg/day) then injected with LPS (30 to 50 mg/kg of body 
weight) at the end of supplementation period. As a result, mortality rate dropped to 
38% in ovariectomised female rats, a similar rate to the normal rats [882]. This section 
highlights the first example of sexual dimorphism in bacterial infection in which males 
appear to be more susceptible to sepsis than females. In the next section, I will 
highlight the role of hormones in dimorphic responses to Mycobacterium infections. 
5.1.1.2 Sex hormones in Mycobacterium infections 
Mycobacterium infections are one of the most studied respiratory infections in 
relation to gender-dependent dimorphism [883]. The global prevalence of men 
affected by Mycobacterium tuberculosis is higher than females [884]. Although 
tuberculosis infections are more common in middle to low-income countries, the 
general trend of greater prevalence in men compared to women is thought to be 
approximately a 2:1 ratio, with men also being at higher risk of developing severe 
outcomes, including mortality [885], [886]. Large epidemiological studies in Asia and 
Africa, reported that being  male is an independent risk factor [887], [888]. The overall 
higher risk in men, is attributed to the complex interplay between genetic elements, 
the immune system, sex hormones and environmental factors. However, the link 
between sex hormones and the immune system appears to play the largest part in 
the disparity observed between males and females [889].  A study on unvaccinated 
males by the Bacillus Calmette-Guerin (BCG) vaccine revealed that males mount a 
stronger immune response through IFN-γ to purified tuberculin derivative, which 
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could be associated with a dysregulated pro-inflammatory response, and therefore, 
a worse disease prognosis in males [890]. In addition, further studies indicated that 
males mount a stronger innate immune response. For example, males showed higher 
levels of serum C-reactive protein (CRP), than females [891]. A study conducted in 
Italy, which involved 10,260 patients 0 to 18 years revealed that there was no 
difference in cases recorded between male and females in the paediatric population 
[892]. Interestingly, women with oestrogen deficiency due to medical castration 
(oophorectomy) between the age of 15-30, suffered from an increased risk to 
tuberculosis mortality [363]. Chan et al, (2010) demonstrated that post-menopausal 
women suffered from a higher risk of developing nontuberculous mycobacteria due 
to oestrogen deficiency, abnormal expression of adipokines and/or TGF-β [364].  
To investigate the pathophysiology of sex hormones on mycobacterium infections, 
several studies have been conducted in animal models. Male mice were found to be 
more susceptible than female mice and exhibited less resistance to Mycobacterium 
marinum. Upon the castration of mice, male mice became more resistant to 
infection, this was reversed by continuous administration of testosterone treatment 
(5 mg/day) [893]. To assess whether 17β-oestradiol provide protective effects against 
Mycobacterium avium complex (MAC) pulmonary disease, female mice were 
ovariectomised and were given 17β-oestradiol subcutaneously (10ng/ml). 
Ovariectomised mice were more susceptible to MAC infection than the controls, 
however, susceptibility was reduced, suggesting that oestradiol plays a protective 
role [894]. Progesterone can also influence bacterial infections [873]. A study 
administered a contraceptive called depot medroxyprogesterone acetate (DMPA), 
which contains progestin as the active compound, observed that it increases 
susceptibility of female mice to M. tuberculosis by reducing the activity of cytokines 
[895].  
These studies clearly suggest that there is differential susceptibility between males 
and females. Furthermore, sex hormones appear to influence infection susceptibility 
in in vivo models of infection. 
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5.1.1.3 The role of hormones in UTIs 
Current evidence suggests that women are more susceptible to UTI than men, and 
when infected, suffer from increased disease severity [11], [896], [897]. The higher 
prevalence of UTIs in women is primarily attributed to anatomical differences such 
as the shorter urethra [898]. Indeed, the distance between the urethra meatus and 
the anus is longer in men than their female counterparts [899]. Furthermore, the 
peri-meatal environment in men is drier and the release of prostatic secretions 
provides antimicrobial activity against infections [899]. Differences in the prevalence 
and severity of UTIs are also attributed to variable levels of sex hormones such as 
oestrogen and testosterone throughout life [900]. Adult UTI prevalence may not 
reflect the rate of UTIs in children. The prevalence of infected male infants to female 
infants is almost twice as much, however, this ratio changes in children up to 2 years 
old with females accounting for 60% of UTIs [901], [902]. In geriatric populations (>65 
years), the rate of UTI prevalence recorded is almost identical 11% to 14% in men to 
women [903]. Thus, sexual dimorphism between men and women is apparent during 
the reproductive years, thereby suggesting that sex hormones play a role in host 
susceptibility to UTIs. 
Current studies examining the role of oestrogen-based therapeutics in the prevention 
of UTI is contradictory and inconclusive in menopausal women [904]. A double-blind 
randomised controlled trial involving 93 post-menopausal women for a follow-up 
period of eight months, investigated the impact of administering intravaginal oestriol 
cream on their susceptibility to UTI. The treatment was deemed successful due to the 
substantial reduction of the recurrent UTIs  (0.5 vs. 5.9 episodes per patient-year) 
[905]. In a randomised, parallel, controlled trial in Norway using an oestradiol 
releasing silicon-vaginal ring, the impact of the ring was assessed for 36 weeks and 
was found to be preventing UTI in the treatment group [906]. Contrary to these 
findings, a study conducted on postmenopausal women who received an oestriol 
vaginal pessary and other group which was treated with nitrofurantoin microcrystal 
antimicrobial agent, found that treatment with the pessary was less effective [907]. 
Brown et al, (2001) used data obtained from randomised trials on the influence of 
oral hormone therapy (conjugated oestrogens/medroxyprogesterone acetate) on 
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coronary heart disease, and found that hormone treated patients had a higher rate 
(although this was not significant) of UTIs in comparison to the placebo group over a 
mean period of 4.1 years [908]. Another study of a prospective cohort of 1017 
postmenopausal women, aged 55 to 75 years, revealed that neither vaginal nor oral 
oestrogen was protective against cystitis [909]. The Cochrane collaboration, in 2008, 
reviewed two studies comparing vaginal oestrogen creams to placebo and found that 
oestradiol had a positive impact on recurrent UTIs depending on the type of the 
oestrogen and the duration of the study [910].    
To study the impact of sex hormones on UTI pathogenesis, several studies have been 
conducted. Some strains of UPEC possess Dr adhesins which enable the bacteria to 
adhere to the urothelium by binding to the host receptor CD55 [911]. Such adherence 
is followed by internalisation into the bladder and kidney cells to form bacterial 
reservoirs that contribute to recurrent infections. Oestrogen also influences Dr-
expressing E. coli and its binding to the endometrium and regulates the expression of 
CD55 in mouse tissues and humans [912]–[914]. As previously discussed in this 
section, post-menopausal women suffer recurrent infections in the urinary tract and 
supplementation of oestrogen reduces the risk of recurrent UTIs [915], [916]. 
Paradoxically, oestradiol is linked to increasing susceptibility to UTIs in reproductive 
age women [917], [918].  Lüthje et al, (2013) sought to investigate the mechanism 
behind this observation in both mouse models and human samples. Using the serum 
of healthy menstruating and post-menopausal women, it was observed that tissues 
from the former had a higher concentration of the antimicrobial peptide cathelicidin 
LL-37/hCAP-18 (median serum oestradiol levels, 245 to 40 pM) suggesting that 
oestradiol enhanced the production of this peptide. Lüthje and colleagues 
administered oestradiol to exfoliating cells extracted from the urine of healthy post-
menopausal women and administered oestradiol led to increased detection of 
mRNAs from antimicrobial peptides (hBD1, hBD2, hBD3, psoriasin ,and RNase 7) in 
75% of the women [919]. Oestradiol promotes epithelial barrier function [920], [921], 
and enhances the function of tight junction proteins such as ZO-1, occludin and E-
cadherin [919]. To test whether UPEC CFT073 invades and colonises oestradiol-
lacking epithelial tissue, ovariectomised mice were utilised to mimic the post-
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menopausal environment within the urinary tract. Increased cellular invasion and 
higher bacterial load was observed in comparison to sham-treated controls [919]. 
However, the question remains as to why oestrogen might increase susceptibility to 
UTIs in young women? The Lüthje et al study reported that oestrogen increased the 
expression of infection-promoting receptors uroplakin Ia (UPIa) and β1 integrin in the 
earlier phases of the infection [919]. UPIa are located on the umbrella cells on the 
inner surface of the bladder and are presumed to be important mediators of UPEC 
entry into the cells, while  β1 integrin subunits mediate entry into epithelial cells by 
interacting with UPEC’s FimH [922]. Wang et al, (2013) further utilised an 
ovariectomised murine model to test whether alterations of oestradiol play a role in 
modulating the passage of UTI in the bladder. Mice lacking ovaries suffered from 
severe and persistent infection by UPEC strain UTI89 with higher rates of bacteriuria, 
aggressive inflammatory immune response, and a higher number of intracellular 
bacterial reservoirs [923]. Administration of 17β-oestradiol ( 0.01 mg per neck pellet) 
to a cohort of ovariectomised mice prior to infection resulted in reduced 
inflammation as levels of serum IL-6, which is associated with a strong inflammatory 
response, were less abundant than ovariectomised mice than those that were not 
supplemented by oestradiol [923]. Hormones have receptors such as ERα, ERβ and 
GRBP30 in various human and mice tissues throughout the body, which adds another 
layer of complexity to pathogen-host interactions [924]–[926]. ERs induce or repress 
the transcription of multiple genes involved in immune responses such as cytokines, 
which suggests that they play major roles in regulating innate immune response 
infections [927], [928]. Immune modulation of ERs has been studied in multiple viral 
and bacterial infections including herpes simplex viruses, hantaviruses, C. difficile and 
P. aeruginosa [874], [929], [930]. Evidence suggests that ERα is expressed in the 
kidneys more than ERβ, the variation and expression of these receptors differs 
around the body and accordingly, the impact of oestradiol differs [369]. In a recent 
report, Sen et al, (2013) sought to identify whether the presence of ERα had any 
influence on the expression of TNF-α and the modulation of host receptor C55 
(targeted by Dr-expressing E. coli). This was conducted by administrating of propyl-
pyrazole-triol (PPT) which is an agonist that activates the expression of ERα [931]. 
This was administered to ovariectomised mice and methyl-piperidino-pyrazole 
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(MPP), an antagonist which blocks the activity of ERα [932], to sham-controlled mice. 
The severity of UTI was assessed by determining the bacterial load and the expression 
of CD55 and TNF-α in both the bladder and the kidneys. The drugs were delivered 
subcutaneously for seven days, followed by transurethral infection by Dr expressing 
E. coli and subsequent sacrifice of the mice two- and six-days post-infection. PPT 
treatment of ovariectomised mice reduced the bacterial load in the kidneys but 
increased the load in the bladder with minimal effects on TNF-α and CD55, suggesting 
that ERα is mediating protection against UPEC. In contrast, MPP treatment impaired 
the ability of mice to clear the infection in the kidneys but reduced infection in the 
bladder (lower production TNF-α and CD55), leading the authors to conclude that 
ERα is indeed involved in the protective action in the kidneys [933]. 
5.1.1.4 Sexual dimorphism and the role of P. aeruginosa in respiratory infections 
Several inflammatory lung diseases are known to exhibit greater severity in females 
more than males [873]. Females suffer from greater severity of conditions such as 
asthma, especially post-puberty with more physician visits, hospital visits and an 
overall 30% higher rate of mortality than affected males [934]–[936]. A similar 
outcome is seen in chronic obstructive pulmonary disease (COPD), from 1998-2009 
the prevalence of this disorder was higher in women than men in all age groups 
except those from 75–84 and 85+ years in the USA. Overall mortality was also found 
to be higher in women [937]. Female bronchiectasis patients are hospitalised more 
often than males with increased risk to bacterial infections such as nontuberculous 
Mycobacteria due to impaired immunity [938]. In CF, the prevalence of the disease is 
equal. However, females tend to die younger than their male counterparts by an 
average of three years [939], [940]. CF mortality is linked to P. aeruginosa chronic 
persistent infection leading to lung failure. Females tend to acquire the pathogen at 
an earlier age and suffer worse outcomes than males [941]. These differences are 
sex-based since multiple confounding factors such as morphometric and nutritional 
factors, were found to be independent from worse CF outcome in females [940]. 
Major female sex hormones are variable during the menstrual cycle, ovulatory cycle, 
pregnancy and menopause [942], [943]. The circulating serum levels of oestradiol 
(17β-oestradiol) range between 20 to 400 pg/ml. However, the expression is 
178 
 
dependent on the main receptors ER-α and ER-β, both of which possess high affinity 
for oestradiol [944]. In contrast, progesterone ranges in concentration from 300 to 
10,000 pg/ml, and acts on two receptors; progesterone receptors A & B (PR-A), PR-
B). Interestingly, receptors for both sex hormones are expressed in the lungs [945], 
[946]. As discussed previously in the context of oestrogen impact on the urothelium 
and the regulation of innate immune responses, oestrogen can act on ERs in 
neutrophils and help clear P. aeruginosa [947]–[949]. The impact of sex hormones on 
neutrophils has been reported in several studies. In vitro pharmacological doses of 
oestradiol and progesterone inhibited the activity of neutrophils [950]. A study by 
Chiang et al, (2004) observed that physiological concentrations of oestradiol 
enhanced degranulation of neutrophils and oxidative stress markers [951]. Female 
sex hormones have also been found to mediate neutrophil cell apoptosis by delaying 
cell death and also increase production of ROS [952]. A landmark study investigated 
the role of sex hormones (oestradiol, oestrone and testosterone) and their perceived 
contribution to worse outcomes in female CF patients in Ireland [953]. In vitro testing 
of the impact of oestradiol on PAO1 and CF clinical isolates was observed by the 
induction mucoidy in non-mucoid P. aeruginosa compared to testosterone and 
vehicle control ethanol. Oestradiol also upregulated genes involved in mucoid 
conversion such as mucA, algD, and algT. In addition, the study assessed the 
relationship between oestradiol serum levels and exacerbations in women suffering 
from CF with regular menstrual cycles. The highest spike of oestradiol during the 
follicular phase was associated with exacerbations [953].  To elucidate the role of 
17β-oestradiol in sexual dimorphism in inflammatory lung disease such as CF,            
Abid et al, (2017) conducted a series of experiments [930]. Firstly, oestradiol was 
administered to wild-type female and male mice then challenged by P. aeruginosa 
PAO1 and a CF-clinical isolate capable of mucoid conversion. Female mice succumbed 
to death quicker (at least 30 h earlier) with higher bacterial load in lungs than male 
mice. In a subsequent experiment, oestradiol, progesterone, and a vehicle control 
were administered to female ovariectomised mice before inoculation with P. 
aeruginosa. Treatment with oestradiol was associated with faster death than the 
groups receiving the vehicle control or progesterone. In addition, male mice treated 
with oestrogen died quicker than males administered with vehicle control. To assess 
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whether the significant differences in death rate in the treated groups with oestradiol 
were specific to ER, a group of ovariectomised mice received oestradiol with 
antagonist blocker ICI 182,780 (500 μg/day). This led to a longer survival time, which 
suggests that blocking nuclear and non-nuclear ERs attenuates poorer survival 
outcomes than group treated with oestradiol only. To determine whether ER-α and 
ER-β are involved with oestradiol in worse survival outcome, a group of mice were 
administered with PPT (ER-α agonist) and Diarylpropionitrile (DPN; ER-β agonist) and 
compared with the control vehicle group. This resulted in significantly worse survival 
time after P. aeruginosa challenge, leading the authors to conclude that both 
receptors are indeed involved with oestrogen in mediating worse disease 
pathophysiology in mice. Furthermore, intact-female mice receiving ICI 182,780 
exhibited improved survival upon infection with P. aeruginosa, cementing the finding 
that both ER-α and ER-β are involved with oestradiol in worse response. The 
researchers also found no direct impact from oestradiol or progesterone on                      
P. aeruginosa growth rates or mucoidy, thus, they speculated that it may due to pro-
inflammatory responses associated with cytokines, chemokines and neutrophils. 
Indeed, upon harvesting oestradiol-treated murine lungs 9h after P. aeruginosa 
infection, increases in inflammatory cytokines TNF-α, neutrophil granular proteins 
myeloperoxidase and neutrophil elastase, were observed in lung tissue in the 
oestradiol-treated mice. Treatment of neutrophils with oestradiol enhanced 
oxidative burst but compromised P. aeruginosa neutralisation [930]. So, there is clear 
evidence of a role for sex hormones in modulating the pathogenicity of P. aeruginosa 
infections in vivo. 
Other studies which investigated the interaction between sex hormones did not 
account for the possible role of testosterone. Rowland et al, (1992) identified 
oestrogen binding proteins in the cytosol of 14 strains of P. aeruginosa [954]. Upon 
analysis of gene expression of PAO1 P. aeruginosa, efflux pumps such as mexD and 
mexF were found to be induced by oestrogenic endocrine disruptor 17α-
ethynyloestradiol, nonylphenol, and bisphenol-A and leading to the expulsion from 
such contaminates from the cell. Oestradiol, oestrone and oestrione were found to 
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be QS inhibitors at high physiological concentrations of 2 mM (0.5 mg/ml), which is 
higher than normal physiological levels [955].  
5.1.2 Iron acquisition mechanisms in P. aeruginosa   
Bacterial pathogens require iron which is an essential factor, due to its importance to 
cellular respiration [956]. The host limits iron availability as a strategy to counter 
colonisation by the bacteria [957], [958]. In mammalian hosts, iron is found in heme 
proteins (cytochromes and haemoglobin) and attached to extracellular proteins such 
as transferrin and lactoferrin [959]. Insoluble iron compounds constitute the vast 
majority of iron in the host, thus, P. aeruginosa amongst other pathogens must devise 
various mechanisms to acquire iron (Table 5.1) [460], [960], [961]. P. aeruginosa  
utilises different strategies to chelate iron in different environments including the 
type of infection (acute V chronic).The siderophore pyoverdine is utilised in acute 
infections such as that shown in burn mouse models, while pyochelin has been 
identified in chronic CF infections [474], [962][275]. 
Table 5.1 Iron acquisition mechanisms utilised by P. aeruginosa and their function during 
infection 
Iron uptake systems Function Example Reference 
Siderophores Synthesis of 
extracellular 
Fe3+chelating 
molecules 
Pyoverdine 
and pyochelin 
[960], [963] 
Heme proteins Take-up of heme from 
host hemeproteins 
PhuS [279] 
Xenosiderophores Hijacking 
siderophores made by 
other 
microorganisms. 
Enterobactin [964] 
Feo system Acquisition of Fe2+ via 
the FeOABC system 
Phenazines 
utilisation 
[965] 
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5.1.2.1 Siderophores; Iron chelating molecules 
Siderophores are soluble, organic ligands excreted as low-molecular compounds to 
chelate Fe3+ with high specificity and affinity. Two major siderophores known to be 
highly involved in the virulence of P. aeruginosa are pyoverdine and pyochelin [275], 
[966]. Pyoverdine is yellow-green, fluorescent siderophore that is produced in low-
iron environments and consists of a chromophore which contains a conserved region 
and highly variable peptide chain [460], [967]. The chromophore is also shared 
amongst multiple fluorescent Pseudomonas species such as P. aeruginosa,                       
P. fluorescens, P. syringae and participates in the chelation of the Fe3+ [968]. The 
variable peptide chain consists of 6-12 amino acids and is involved in the production 
of at least three different pyoverdines (I-III) based on amino acid composition [275], 
[460], [967]. The production of pyoverdine is a complex process which involves 20 
proteins contributing to regulation, maturation, transportation and iron uptake, 
which spans across the bacterial membrane (Figure 5.1) [969]. 
Pyoverdine binds to iron, for example host transferrin, with a very high affinity and is 
transferred via a TonB-dependent receptor (TBDR) mechanism into the bacterial 
cytoplasm (Figure 5.2) [275]. TBDRs play a major role in acquiring ferric substances 
and ensuring their transportation into the cytoplasm of the cell [35], [36].                           
P. aeruginosa has more than 30 genes that control TBDRs, the majority of which are 
involved in acquisition of (siderophore-ferric) complexes known as ferrisiderophores 
[9], [37]. TBDRs are categorised into simple TBDR and TonB-receptor transducers 
(TBDT) [36]. TBDRs do not possess the cell signalling N-terminal domain [36]. In 
contrast, TBTDs contain a signalling domain upstream of the tonB box, which enables 
it to interact with a sigma regulator in the inner membrane [38]. The sigma regulator 
in P. aeruginosa is FpvR [970]. 
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Figure 5.1 Illustration of the steps involved in pyoverdine production and export. Initiation 
of pyoverdine production occurs once a low concentration of iron is detected. This results in 
dissociation of the binding of Fur-PvdS promoter complex. The release of the Sigma-factor 
PvdS helps it bind to the promoter IS boxes of pyoverdine genes, resulting in transcription 
and then translation of pyoverdine proteins. The peptide synthases are PvdL, PvdI, PvdJ, and 
PvdF assemble the precursor PVDIq, which begins with a C14 fatty acid’s (FA) to L-Glu and is 
finalised upon the release of PVDIq from the PvdD protein by the thioesterase module (TE). 
As for the role of PvdH, PvdA, PvdF, these enzymes produce amino L-diaminobutyrate (L-Dab) 
and L-formyl-OH-ornithine which are merged into PVDIq by the four peptide synthases. PvdE 
is tasked with transporting PVDIq into the periplasm, followed by the removal of myristoleic 
acid by the acylase PvdQ. This leads to the maturation of the chromophore and the catalysis 
of the precursor ferribactin. The role of the periplasmic PvdM, PvdN and PvdO in the 
maturation of the ferribactin is unknown. However, it is possible that one of the proteins 
transform L-glutamate into one of the of three residues in pyoverdine. The siderophore is 
transported outside the cell via PvdRT-OpmQ into the environment. Adapted from  [969]  
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Figure 5.2 The left panel displays an apo pyoverdine (beige dot) prior to engaging FpvA, a 
TBDR associated with the FpvR anti-σ factor. The role of FpvR is to prevent involvement of 
both ECF σ PvdS and Fpvl by its cytoplasmic domain. Thus, the possibility of sigma factors 
association with the core RNA polymerase is small, resulting in non-transcription of the PvdS 
and FpvI. The right panel displays the event of activation of pyoverdine synthesis; the 
ferripyoverdine (red dot) binds to the FpvA receptor, which leads to conformational change 
that induces proteolysis of FpvR. The sigma factors PvdS and FpvI establish the needed 
association with the core RNA polymerase resulting in the transcription of pyoverdine genes 
and virulence actors ToxA and prpl [275] 
TBDTs can regulate their own synthesis along with cognate siderophores. FpvA is 
another example of a TBDT and this protein can sense cognate ferrisiderophores by 
recognising anti-sigma factor proteins at the membrane resulting in proteolytic 
cleavage and releasing extracytoplasmic sigma factor (ECF σ) [15], [18], [36]. The 
expression of ECF sigma factors, which are also known as starvation sigma factors, is 
controlled by iron via the ferric-uptake regulator (Fur) [39]. Three types of TBDRs are 
present in P. aeruginosa, which correspond to the pyoverdine types; (FpvAI, FpvAII, 
and FpvAIII).  It is estimated that more than 95% of P. aeruginosa possess an FpvB 
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receptor, which allows them to utilise type I ferripyoverdine produced by other 
isolates [37], [41]. Dingemans et al, (2014) analysed P. aeruginosa isolates from CF 
clones from a patient population admitted to the Universitair Ziekenhuis Brussel. It 
was reported that the FpvB gene was deleted during CF adaptation in 17 of the 
collected 54 isolates, and seven other TBDRs in various isolates were observed upon 
comparison to DK2 strain [971].    
Evidence suggests that pyoverdine is critical for virulence in a murine burn infection 
model, where TBDR mutants are deemed avirulent [275], [972]. Pyoverdine not only 
acts as an iron chelator, it also acts as a signal molecule for two other extracellular 
virulence factors; exotoxin A and protease PrpL [460], [973]. In addition, availability 
of iron, or lack thereof, is detrimental to the formation of biofilms and its architecture 
[974]. P. aeruginosa on glass surfaces form thin biofilms in presence of lactoferrin 
with planktonic cells performing twitching motility [975]. In the absence of 
lactoferrin, thicker biofilms with mushroom-like structures are produced, correlating 
with pyoverdine production. Mutant strains lacking pyoverdine are not capable or 
forming mushroom-like structures[974]. A study by Patriquin et al, (2008) found that 
biofilms are in need of iron supplementation more than planktonic cells. Iron 
deficiency leads to the stimulation of twitching motility via the Rhl QS system  [976].  
Pyochelin is another siderophore produced by P. aeruginosa. Dumas et al, (2013) 
demonstrated that pyochelin is produced first followed by pyoverdine as iron 
concentrations start to plummet [977]. Production of pyochelin correlates with 
higher levels of availability of iron in the environment. Pyochelin requires the iron-
regulated pchDCBA operon to be produced [977], [978]. Pyochelin-iron causes 
oxidative cell damage and inflammation to the host, this activity is compounded in 
the presence of pyocyanin  [979]–[981]. In CF lungs, sustainability of inflammation 
could be one of the roles attributed to pyochelin [474]. Increasing levels of pyochelin 
have also been observed in artificial sputum medium (ASM), which may indicate that 
it plays a role in CF infections by chelating iron [982].  
5.1.2.2 Xenosiderophores: siderophore piracy     
P. aeruginosa is capable of hijacking siderophores released by other Gram-negative 
bacteria such as E. coli (Table 5.2). This is exemplified by the capture of the 
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siderophore enterobactin via two receptors; PfeA and PirA [983], [984]. The 
importance of these xenosiderophores has not been fully elucidated yet in real-time 
infections with all related studies conducted in vitro. Siderophore piracy may help        
P. aeruginosa fend off competition in polymicrobial infections [985]. 
Table 5.2 Types of xenosiderophores obtained by P. aeruginosa from different bacterial 
species 
 
5.1.2.3 The FeoABC transport system and the role of phenazines  
Fe3+ is not the only form of iron scavenged by P. aeruginosa.                                                                 
In anaerobic/microaerobic, low pH environments, Fe2+ is present in a soluble form 
[961]. The FeoABC system, which is present in Gram negative bacteria is utilised to 
transport ferrous iron to the cell cytoplasm following the diffusion of Fe2+ through 
the outer membrane [965], [990]. P. aeruginosa employs the Feo system comprising 
of the permease FeoB with the proteins FeoA and FeoC [965]. Wang et al, (2011) 
demonstrated that deletion of FeoB attenuates P. aeruginosa virulence and reduces 
the ability to form biofilms [278]. This transport mechanism of iron could be utilised 
in microaerobic or anaerobic environment such as the lungs of CF patients [991]. 
Phenazines such as phenazine-1-carboxylic acid (PCA) and pyocyanin can reduce the 
Fe3+ bound in host proteins to Fe2+, which in turn enables the Feo transport system 
to acquire these soluble iron molecules (Figure 5.3) [992]. This mechanism is plausible 
in the CF lungs where P. aeruginosa biofilms are formed and high levels of PCA and 
Receptor Xenosiderophores Reference 
FoxB, FiuA ferrioxamine and 
ferrichrome 
[986] 
FemA mycobactin and 
carboxymycobactin 
[987] 
FecA Fe-citrate [988] 
ChtA rhizobactin, aerobactin, 
and schizokinen 
[964] 
FvbA Vibriobactin [989] 
186 
 
pyocyanin present in the latter stages of infection accompanied with progressive 
health deterioration for CF patient [993], [994]. Pyocyanin has been linked to biofilm 
formation in UTIs and therefore this mechanism of iron acquisition may also play a 
role in the urinary tract. 
  
Figure 5.3  (A) Structures of two P. aeruginosa phenazines, Phenazines-1-carboxylyic acid and 
pyocyanin. (B) The white circles represent reduced PCA which is excreted out of the cell then 
becomes oxidised (red circle), leading to the reduction of Fe3+ to Fe2+. Phenazines undergoing 
oxidation via this pathway are further recycled inside the cell and reduced again by 
simultaneous oxidation of NADH to NAD [275] 
5.1.2.4 Extraction of heme from the host by P. aeruginosa  
Heme proteins in the host are also targeted directly by P. aeruginosa. This occurs via 
two systems known as Has and Phu [995]. Heme is not freely available since it is 
hydrophilically bound to the host membranes. Therefore, heme extraction occurs 
from host haemoglobin or hemopexin, both are heme proteins [996], [997]. The Has 
system acquires heme from the host and extracts Fe2+ in a multi-step process               
(Figure 5.4). This is initiated by the heme protein hemophore and a TBDR known as 
HasR which deposits the heme into the periplasm [996]. Heme is then transported 
into the cytoplasm by an ABC transporter and subsequently bound to the heme 
chaperone PhuS, where heme is oxygenised by HemO and degraded to carbon 
monoxide (CO), biliverdin and  Fe2+ [275], [997]. 
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Figure 5.4 P. aeruginosa possess two heme uptake system; PhuR and HasR. The TBDR is 
associated with PhuR and binds directly to hemeproteins to extract heme. The HasR receptor 
differs, as it binds heme merged to a secreted hemphore protein HasA. Upon introduction 
into the bacterial periplasm, heme is attached to a periplasmic protein that is driven to an 
ABC transporter. Once it enters the cytoplasm, heme is chaperoned by PhuS to direct the 
heme to the heme oxygenase enzyme HemO. Which in turn, cleaves the tetrapyrrole ring, 
leading to the emergence of biliverdin, CO, and Fe2+ [275] 
5.1.2.5 Iron acquisition in the urinary tract by UPEC  
Iron is in limited supply in the urinary tract [743]. Thus, uropathogens must devise 
ways to chelate and extract iron from the host for successful invasion and 
colonisation. Iron acquisition in UTIs is best studied in UPEC [998]. UPEC acquires iron 
via three mechanisms; import of free iron metals, import of metal-ion complexes in 
the host, and siderophores [999].  
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UPEC model strains such as UTI89 and CFT073 contain a system known as Sit, which 
is similar to the aforementioned FeoABC system In P. aeruginosa. In a murine 
infection model of cystitis, transcriptomic analysis revealed upregulation of the iron 
transporter SitA upon CFT073 growth in mouse urine [1000]. The sitA gene which 
encodes an ABC type-ferric iron transporter, was found to be upregulated in UTI89 
strain to facilitate ferric iron transport [1001], [1002].  
UPEC also targets metal ion complexes such as heme by the Chu and Hma systems 
which are found more in UPEC in comparison to commensal strains of E. coli [683], 
[1003]. A study by Hagan et al compared eight UPEC isolates with the CFT073 strain 
by measuring global gene expression utilising microarrays. seven of the eight isolates 
expressed the heme-receptor encoded by the gene chuA [1004]. In a murine co-
infection model, wildtype CFT073 outcompeted an isogenic hma mutant by infecting 
the spleen and the kidney, suggesting that the novel receptor hma is required by 
UPEC for infection [1003].   
As explained in P. aeruginosa iron mechanism systems, UPEC also utilises 
siderophores to capture ferric iron to form ferric iron complexes and transport them 
via receptors into the cell. Enterobactin, which is the prototypical siderophore 
produced in all intestinal E. coli [464], has been implicated in UTI pathogenesis in 
humans [1005]. Enterobactin gains access to the bacterial cells via two outer 
membrane receptors Fiu and CirA, transcription of corresponding mRNAs were found 
to increase in urine in response to iron limitation [1006]. Chen et al conducted 
comparative genomic analysis of UPEC strain UTI89 to identify genes which undergo 
positive selection amongst conserved genes, upregulation of entrobactin 
biosynthesis genes entD, entF and uptake fepE was observed [1007]. These findings 
indicate that enterobactin plays a role in UPEC uropathogens.  
Salmochelin is a major siderophore in Salmonella enterica and UPEC strains [1008]. 
This siderophore is characterised by a C-glucosylated catechols with an enterobactin 
analogue as the key component [1009]. Reigstad et al compared gene expression 
between UTI89 intracellular bacterial communities (IBC) isolated from the distal gut 
and the bladder of mice by laser microdissection. The iroA gene which involved in the 
glycosylation of salmochelin siderophore, was upregulated by 45 ± 3-fold, while iroN, 
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a gene which encodes the salmochelin siderophore receptors was upregulated by 234 
± 28-fold increase in the UTI89 voided from the bladder, in comparison to cecal 
isolates [1002]. Similar findings were reported in different settings, concurrent E. coli 
isolated from urine and rectum from female outpatients were collected and analysed 
for salmochelin production and UPECs produced more salmochelin [464]. Johnson et 
al, (2005) collected 65 concurrent urinary and rectal isolates from the same male 
hosts with febrile UTIs and conducted phylotyping and virulence genotyping. The 
UPEC isolates contained more virulence genes than rectal isolates, including the 
salmochelin receptor gene ironN  [1010].  
The third characterised siderophore is aerobactin, which is a citrate-derived 
siderophore identified first in the Gram-negative bacterial species Aerobacter 
aerogenes [1011].  Aerobactin is a hydroxamate-type siderophore encoded by the 
operon iucABCD and includes the outer membrane encoding gene iutA [1012], 
[1013]. In addition, the conserved E. coli fhuBCD genes are involved in aerobactin-
associated ferric hydroxmate uptake [1014]. The involvement of aerobactin in UPEC 
pathogenesis is currently unclear. The Hagan et al, (2010) study detected the 
expression of the outer membrane receptor gene iutA in voided UPEC strains isolated 
from female UTI patients [1004]. Detection of this gene does not signify the 
involvement of aerobactin in pathogenesis, since some iutA carrying isolates do not 
produce a functional siderophore system [464]. The role of aerobactin in UTI 
pathogenesis has been disputed, epidemiolocal studies often show contradictory 
results but a trend can be established in which aerobactin carriers are found more in 
isolates from the bladder, kidneys and blood [1015]. 
The fourth siderophore is yersiniabactin, which was identified in Yersinia Pestis, the 
causative bacteria of the plaque known as the black death that swept Europe in the 
14th century [1016]. Yersiniabactin is a siderophore and metallophore and genes 
encoding this iron uptake system are located on a multi-operon pathogenicity island 
called the high pathogenicity island. It is comprised of four operons expressed by the 
activation of the transcription factor YbtA [1017]. The yersinia high pathogenicity 
island exerts a direct impact on the host in UPEC uropathogenesis [999]. Mass 
spectrometry analysis of yersiniabactin producing UPEC revealed the presence of 
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copper(II)-yersiniabactin complexes to protect UPEC from copper toxicity [1018]. The 
Hagan et al, (2010) study has also detected the expression of the outer membrane 
ferric yersiniabactin importer fyuA as result of clinical UPEC infection [1004]. Isolation 
of IBCs containing UPEC by laser microdissection from a mouse infection model of 
UTI, detected the first expressed enzyme YbtS in the biosynthetic pathway of 
yersiniabactin and revealed the upregulation of 2000-fold increase in comparison to 
an intestinal E. coli isolate [1002]. The Henderson et al, (2009) study which collected 
concurrent UPEC and rectal isolates from female patients of uncomplicated UTIs, 
observed production of more yersiniabactin in UTI isolates compared to the rectal 
isolates upon conducting metabolomic analysis [464]. A similar outcome was 
observed in males with febrile UTI, as UPEC were found to be carrying the 
yersiniabactin gene fyuA more often than rectal isolates [1010]. Soto et al, (2006) 
conducted a study involving 43 outpatients, in which 27 UPEC isolates caused relapse 
(same strain) and 53 caused recurrent UPEC infections (different strains).  Detection 
by PCR In vitro revealed that strains causing relapse to have the capacity to form 
biofilms and carry the yersiniabactin gene [1019]. All these findings suggest that 
yersiniabactin may have a prominent role to play in UPEC pathogenesis.  
5.1.2.6 The role of iron acquisition mechanisms in P. aeruginosa uropathogenesis  
The vast majority of uropathogenic P. aeruginosa produce pyochelin and pyoverdine 
as observed by Visca et al, (1992) as only 2.4% were pyochelin-deficient and 7.4% 
were pyoverdine-deficient amongst 121 UTI isolates [461]. Yadav et al, (2000) utilised 
a P. aeruginosa pyochelin and haemolysin producing UTI isolate to infect mice in an 
acute ascending pyelonephritis model, the infection produced renal lesions 
(abscesses) in mice. The exact role of both iron uptake systems in infection was not 
elucidated [57]. This was followed by another study which sought to find association 
between P. aeruginosa virulence factors in vitro and their contribution to virulence 
In vivo. 18 UTI isolates which produced pyoverdine, pyochelin and haemolysin were 
selected to be tested on an ascending mice model of pyelonephritis. An association 
was found between haemolysin and high bacterial renal counts in mice [58]. 
Pyochelin and haemolysin were significantly reduced when treated with cranberry 
juice in a static in vitro biofilm model [1020]. Production of pyoverdine in vitro was 
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also reported in 30 P. aeruginosa urinary tract isolates, suggesting it has a crucial role 
in UTI pathogenesis [90]. Different bacterial species also compete one another for 
iron resources in certain settings [1021]. As a result, enterobacteria such as E. coli 
secrete an inhibitor called escherichelin which acts as a bacterial antagonist to 
pyochelin synthesis in P. aeruginosa [1022], [1023]. 
Given the lack of understanding about the direct role that hormones play in the 
pathogenicity of Gram-negative uropathogens, in this chapter I aim to understand 
the impact of sex hormones on UTI pathogenesis. More specifically, these studies 
have assessed the effects of testosterone, oestradiol and progesterone on the 
expression and production of several key virulence factors known to be important      
in UTI. Proteomic analysis was also conducted using a UTI clinical isolate of                              
P. aeruginosa to determine whether sex hormones cause shifts in the proteome that 
may affect pathogenicity.  
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5.2 Aims  
-   To determine global changes in the bacterial proteome in response to sex 
hormones and identify key pathways. 
-    To investigate the impact of oestradiol, testosterone and progesterone on                    
P. aeruginosa protein abundance.  
-       To investigate the impact of hormones on virulence factors and biofilm formation.     
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5.3 The influence of hormones on P. aeruginosa  
5.3.1 Proteomic analysis of the influence of sex hormone in AUM   
In order to assess the abundance of proteins following exposure to oestradiol, 
testosterone and progesterone, isolate 133098 was chosen to be inoculated in AUM 
as a model of infection. The isolate was treated with 20 nM concentration with each 
of oestradiol, testosterone and progesterone. The cultures were grown under static 
conditions to an OD of 0.25 +/- 0.045.   
Initially, a comparison between AUM and AUM-V was performed. AUM-V consisted 
of AUM plus the vehicle/ carrier that the sex hormones were prepared in (ethanol). 
19 proteins displayed a significant increased abundance of >1.5 fold in AUM 
compared to AUM-V. These included PhzF (56-fold) and PhzM (26-fold), both part of 
the phenazine biosynthesis pathway. PqsE, which was higher in abundance by 6-fold, 
is involved in the production of alkyl-quinolones and PA4131, which is a probable 
iron-sulphur protein. Only 2 proteins were significantly decreased in AUM. These 
were PA3009 (uncharacterised protein, 2-fold down) and DapE (Succinyl-
diaminopimelate desuccinylase, 1.78-fold down). Overall, very few proteins 
displayed a significant difference between AUM and AUM-V. Despite this, the 
samples were clearly separated on the PCA plot (Figure 5.5). AUM-V was the more 
appropriate control for studying the impact of the sex hormones alone and therefore 
this was used in all subsequent analysis. In addition, observation of protein 
abundance in all conditions revealed that most proteins were upregulated in the 
controls, AUM and AUM-V (Figure 5.6).  
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Figure 5.5 PCA of 5 biological replicates in each of AUM, (AUM-V= vehicle control, AUM-
E=oestradiol, AUM-T=testosterone and AUM-P=progesterone) displays the clustering of 
conditions and their related samples 
195 
 
 
Figure 5.6 Heat map of the distribution of the profile of abundant proteins across all non-
treated samples (AUM) and treated samples AUM-V, AUM-E, AUM-T, AUM-P (AUM-V= 
vehicle control, AUM-E=oestradiol, AUM-T=testosterone and AUM-P=progesterone) 
5.3.1.1 Proteins increased under all hormone treatment conditions 
In silico analysis revealed 52 proteins which displayed significantly higher abundance 
in all hormones in comparison to AUM-V. There was also a subset of proteins that 
were unique to each treatment type with 42, 43 and 82 proteins significantly higher 
in oestradiol, testosterone and progesterone, respectively (Figure 5.7).  
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Figure 5.7 Venn diagram of upregulated proteins AUM containing hormone in comparison to 
AUM- V 
Proteins which contribute to denitrification pathways were upregulated in response 
to the presence of hormones. NirS for instance, is a nitrate involved in haem binding 
in addition to NirF and NirL, both of which contribute to the biosynthesis of heme d1. 
These Nir pathway proteins were upregulated across all hormone treatments from 
1.8-fold to 8-fold change. KatA is a catalase which protects P. aeruginosa against 
hydrogen peroxide released by the invaded host and self-produced nitric-oxide, and 
also involved with haem binding [1024]. The protein is upregulated by 2.69, 1.85 and 
2.25-fold in oestradiol, testosterone and progesterone, respectively. leuC is a gene 
which encodes a 3-isopropylmalate dehydratase large subunit with a 4 iron, 4 sulphur 
cluster binding subunit, the protein was upregulated from 1.7 to 2.5 fold-change 
[655].   
5.3.1.2 Proteins decreased under all hormone conditions 
67 proteins displayed significantly decreased abundance of more than 1.5-fold in all 
three hormone conditions. Only seven proteins were uniquely reduced in oestradiol 
with 45 and 46 proteins decreased in progesterone and testosterone conditions only 
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(Figure 5.8). Of the 67 shared proteins, a large proportion were identified as being 
involved in iron acquisition pathways.  
 
Figure 5.8 Venn diagram of proteins downregulated upon treatment with oestradiol, 
testosterone and progesterone 
Iron acquisition mechanisms are indispensable in P. aeruginosa infections or other 
types of bacterial infections. Thus, we analysed the impact of sex hormones on these 
mechanisms. Pyochelin is a siderophore produced to counteract iron scarcity in the 
host. All expressed proteins participating in pyochelin biosynthesis were less 
abundant across all hormones compared to the AUM-V, as the decrease in 
abundance ranged from -two to -eight fold less than in AUM-V.  (Figure 5.9). A similar 
result is observed for the pyoverdine synthesis pathway, the synthases enzymes and 
the receptor proteins were less abundant in the presence of hormones.  In addition, 
heme uptake and proteins associated in iron acquisition in both of the PhuR and HasR 
systems were also less abundant than AUM-V. 
The most marked effect on proteins involved in pyochelin synthesis was found in 
progesterone since five proteins were down-regulated by eight-fold or more (Figure 
5.9). These proteins are PchG, PchF, PchE, PchR and PchE and PchB, all of which are 
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involved in pyochelin synthesis and regulation. Similar decreased abundance was 
observed with oestradiol and to a lesser extent testosterone, similarly to the 
pyochelin pathway, the pyoverdine pathway proteins participate in iron uptake such 
as PvdJ (pyoverdine biosynthesis), PvdD (pyoverdine synthetase), and PvdR 
(pyoverdine biosynthesis) were found to be significantly less abundant in oestradiol. 
Interestingly, oestradiol also had the strongest impact on heme uptake associated 
mechanisms although inhibition of the system could be seen with all hormones.  
P. aeruginosa can also hijack siderophores made by other bacteria. Proteins such as 
ChtA and FecA contribute to the capture of xenosiderophores and were found to be 
less abundant in all hormone treated AUM ranging from 11-fold and to two-fold 
reductions [275]. PfeR is a member of a two-component response regulator pair with 
the sensor PfeS [1025], the regulator pfeR was downregulated by 78-fold in the 
oestradiol samples. In addition, PfeR was less abundant by three-fold in testosterone 
samples and five-fold in the progesterone samples.  
Other proteins were also lower such as fumarate hydratase FumC, which is produced 
in response to iron starvation and is also linked to pyochelin and pyoverdine 
production [1026]. In addition, SodA is a superoxide dismutase that is reduced in 
response to iron starvation and intracellular redox increase in P. aeruginosa [1027], 
was reduced by at least two-fold in the presence of oestradiol, testosterone and 
progesterone. PA2033 is hypothetical protein linked to a novel iron-acquisition 
mechanism [1028], was found to be downregulated in oestradiol, testosterone and 
progesterone by > six-fold,>two-fold and > four-fold, respectively. There is a clear 
impact caused by all three hormones leading to a decreased abundance of proteins 
associated with iron acquisition. 
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Figure 5.9 Abundance of P. aeruginosa proteins involved in iron acquisition across three 
hormone treatment conditions. The figures display 43 proteins that were either 
downregulated or failed to increase in the presence of oestradiol, testosterone and 
progesterone. (A displays protein involved in pyochelin and pyoverdine siderophore 
synthesis and uptake. B) The panel of proteins participates in heme chelation and uptake. 
Fold-change of > 1.5 is deemed significant [275], [655]
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5.4 The Impact of oestradiol on P. aeruginosa 
5.4.1 The Influence of varying oestradiol on bacterial growth 
The impact of oestradiol was assessed on growth over 24 h in a small representative 
panel of isolates; PAO1, PA14 and 133098. No statistical significance was observed 
by the treatment of oestradiol on each isolate with 20nM of hormone (Figure 5.10 A-
C). This suggests that oestradiol has no direct impact on bacterial growth in vitro.  
  
Figure 5.10 Growth of 2 reference strains and a clinical isolate was measured between a 
control strain and isolate treated with 20 nM oestradiol over 24h. Optical density was 
measured at A600nm. (A: No statistically significant difference was observed in the growth 
pattern in PAO1 following testing by equal variance test (Brown-Forsythe) on Ranks at all the 
examined time points (0, 6, 12, 18h) (P = 0.572) at 24h and for B) and PA14 (P=0.700) at 24h 
and  C) 133098 (P=0.664) 
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5.4.2 The impact of oestradiol on the P. aeruginosa proteome  
5.4.2.1 Upregulated proteins in comparison to AUM-V 
127 proteins were over 1.5-fold up in AUM-E. Of these, 110 had a significant P value 
(P<0.05). 33 proteins (shaded in grey) were only upregulated in oestradiol and not 
the other two hormone conditions (Table 5.3).  
Table 5.3 Proteins upregulated in response to oestradiol, unique proteins are shaded in grey 
Gene names Max FC Description Gene names Max FC Description 
PA4131 50.21 Probable iron-sulfur protein PA2771 2.48 Uncharacterized protein O 
PA1503 21.46 Uncharacterized protein  PA3419 2.47 UPF0162 protein  
PA4129 19.01 Uncharacterized protein  phzS 2.45 
Flavin-containing 
monooxygenase  
gcl 8.99 Glyoxylate carboligase lasD 2.44 Chitin-binding protein CbpD  
ccpA 6.73 Cytochrome c551 peroxidase  PA3483 2.38 Uncharacterized protein 
lasB 6.06 Elastase  PA2116 2.38 UPF0317 protein PA2116  
PA5446 5.62 Uncharacterized protein  PA1260 2.36 
Amino acid ABC transporter 
periplasmic binding protein  
PA4130 4.94 Probable sulfite or nitrite reductase  phzM 2.36 
Probable phenazine-specific 
methyltransferase  
PA4139 4.76 Uncharacterized protein  PA1518 2.35 5-hydroxyisourate hydrolase  
PA4928 4.76 UPF0313 protein PA4928  PA0553 2.34 Uncharacterized protein  
ilvA2 4.64 L-threonine dehydratase  pqsA 2.34 Anthranilate--CoA ligase  
phnB 4.61 
Anthranilate synthase component 2, 
pyocyanine specific  pqsB 2.34 PqsB  
PA4880 4.39 Probable bacterioferritin  PA3187 2.32 
Probable ATP-binding 
component of ABC 
transporter 
bdhA 4.12 3-hydroxybutyrate dehydrogenase  nosZ 2.29 Nitrous-oxide reductase 
PA0122 3.95 Uncharacterized protein  gtdA 2.29 Gentisate 1,2-dioxygenase  
hcnC 3.72 
Hydrogen cyanide synthase subunit 
HcnC 4129 PA0586 2.28 Uncharacterized protein  
PA0510 3.67 
Probable uroporphyrin-III c-
methyltransferase  PA1516 2.27 Uncharacterized protein 
PA5359 3.66 Uncharacterized protein  PA3922 2.23 Uncharacterized protein 
PA1500 3.57 Probable oxidoreductase  PA3332 2.23 
Uncharacterized PhzA/B-like 
protein  
PA2266 3.45 Probable cytochrome c  pfpI 2.21 Protease PfpI  
hcnB 3.39 
Hydrogen cyanide synthase subunit 
HcnB  PA5188 2.20 
Probable 3-hydroxyacyl-CoA 
dehydrogenase  
PA4571 3.27 Probable cytochrome c  PA1662 2.20 
Probable ClpA/B-type 
protease 
PA1254 3.24 
Probable dihydrodipicolinate 
synthetase PA2291 2.20 Porin 
phnA 3.22 
Anthranilate synthase component 1, 
pyocyanine specific  PA4739 2.19 Uncharacterized protein  
pqsE 3.17 Uncharacterized protein  PA2433 2.18 Uncharacterized protein  
allA 3.12 Ureidoglycolate lyase  PA0537 2.17 Uncharacterized protein  
PA3924 3.03 
Probable medium-chain acyl-CoA 
ligase pcaF 2.16 Beta-ketoadipyl-CoA thiolase  
PA3119 2.99 Uncharacterized protein phaC1 2.16 
Poly (3-hydroxyalkanoic acid) 
synthase 1 
PA1112 2.98 Uncharacterized protein  PA3699 2.15 
Probable transcriptional 
regulator  
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nirF 2.97 Protein NirF  PA3461 2.15 Uncharacterized protein  
gbuA 2.96 Guanidinobutyrase  PA5546 2.12 Uncharacterized protein  
PA1517 2.91 Uncharacterized protein  PA5178 2.12 Uncharacterized protein  
PA1667 2.83 Uncharacterized protein phzD 2.12 
Phenazine biosynthesis 
protein PhzD  
PA5220 2.82 Uncharacterized protein PA2567 2.11 Uncharacterized protein  
PA2544 2.77 Uncharacterized protein  PA0794 2.10 Probable aconitate hydratase  
PA3880 2.74 Uncharacterized protein  PA2169 2.10 Uncharacterized protein  
PA4505 2.71 
Probable ATP-binding component of 
ABC transporter  acsA1 2.09 
Acetyl-coenzyme A 
synthetase 1  
PA0144 2.70 Uncharacterized protein  ccoP2 2.09 
Cbb3-type cytochrome c 
oxidase subunit 
katA 2.69 Catalase  PA5535 2.09 Uncharacterized protein  
pqsC 2.67 PqsC  PA4608 2.08 
Cyclic diguanosine 
monophosphate-binding 
protein  
PA1140 2.67 Uncharacterized protein  sdaA 2.08 L-serine dehydratase 
opdO 2.65 Pyroglutatmate porin OpdO  PA3602 2.07 Uncharacterized protein  
PA1881 2.65 Probable oxidoreductase  PA2633 2.06 Uncharacterized protein  
PA2330 2.63 Uncharacterized protein  acnA 2.06 Aconitate hydratase A  
PA2481 2.62 Uncharacterized protein  PA2021 2.05 Uncharacterized protein  
htpX 2.61 Protease HtpX  chiC 2.04 Chitinase 
leuC 2.58 
3-isopropylmalate dehydratase large 
subunit  PA2572 2.04 
Probable two-component 
response regulator  
PA4792 2.58 Uncharacterized protein narH 2.03 
Respiratory nitrate reductase 
beta chain  
pqsD 2.57 
2-heptyl-4(1H)-quinolone synthase 
PqsD  fusB 2.03 Elongation factor G 2  
mmsA 2.55 
Methylmalonate-semialdehyde 
dehydrogenase [acylating]  PA1880 2.03 Probable oxidoreductase  
PA4738 2.53 UPF0337 protein PA4738  PA3712 2.03 Uncharacterized protein  
PA5481 2.52 Uncharacterized protein PA1921 2.02 Uncharacterized protein  
nirS 2.52 Nitrite reductase PA4520 2.01 
Probable chemotaxis 
transducer  
amiE 2.48 Aliphatic amidase  phzB2 2.01 
Phenazine biosynthesis 
protein PhzB 2  
panE 2.48 
Probable 2-dehydropantoate 2-
reductase  PA2176 2.01 Uncharacterized protein 
 
Notably, the activation of QS sensing mechanism is linked to an increase of the 
virulence factors pyocyanin and HCN (Figure 5.11). Production of PQS-associated 
proteins was upregulated in oestradiol treatments. A two-fold increase in comparison 
to AUM-V is PqsA-E was observed. The PQS system is implicated in the control of the 
production of phenazines and HCN. The increase in PQS proteins correlated with an 
increase in nine proteins linked to phenazines biosynthesis and hydrogen cyanide 
(HcnB and HcnC). Notably, PA4129 was upregulated in oestradiol, this recently 
discovered novel protein protects P. aeruginosa from the self-produced cyanide 
[1029]. Overall, oestradiol seems to have a direct impact on P. aeruginosa leading to 
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the increased abundance of proteins associated with the PQS QS system, phenazine 
biosynthesis and HCN (Figure 5.11). This effect was not observed in the presence of 
the other two hormones.  
 
Figure 5.11 Abundance of P. aeruginosa proteins associated with the PQS system, phenazine 
biosynthesis and the production of hydrogen cyanide. A fold-change of > 1.5 and a significant 
P value (P<0.05) is significant. Increased abundance is shown in green and decreased 
abundance is in red 
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5.4.2.2 Proteins reduced in response to oestradiol  
93 proteins were less abundant over 1.5-fold. 82 of these has a significant P value of 
<0.05. 5 proteins were only down in oestradiol (shaded in grey) (Table 5.4). Some of 
the proteins displaying a reduced response with oestradiol treatment include PopN, 
a protein involved in the T3SS (reduced by 2.35-fold change). PriA is a helicase which 
could be essential in cell division and may have a role in response to antibiotics [655], 
[1030]. The PriA protein was downregulated by six-fold. FpvA, an outer membrane 
protein which acts a receptor to ferric-pyoverdine receptor also showed decreased 
abundance (-2.06-fold).    
Table 5.4 Proteins downregulated in response to oestradiol, unique proteins are shaded in 
grey 
Gene 
names Max FC Description Gene names Max FC Description 
PA5487 -122.21 Uncharacterised protein PA2393 -4.24 Probable dipeptidase  
PA2034 -87.73 Uncharacterized protein phuT -4.22 Heme-transport protein, PhuT  
pfeR -78.25 Transcriptional activator protein PfeR  PA3734 -4.20 Uncharacterized protein  
PA2412 -64.54 Uncharacterized protein  PA1490 -4.05 Probable transcriptional regulator  
pchR -46.13 Regulatory protein PchR  pirA -3.86 Ferric enterobactin receptor PirA  
PA2384 -39.19 Uncharacterized protein  PA4705 -3.62 Uncharacterized protein  
pvdA -34.62 L-ornithine N(5)-monooxygenase PA5149 -3.59 Uncharacterized protein  
pvdR -33.61 PvdR fumC2 -3.41 Fumarate hydratase class II 1  
PA2452 -31.98 Uncharacterized protein  PA4675 -3.32 Probable TonB-dependent receptor  
pvdH -28.78 
L-2,4-diaminobutyrate:2-ketoglutarate 
4-aminotransferase, PvdH  PA2550 -3.27 Probable acyl-CoA dehydrogenase  
hemO -28.36 Heme oxygenase  pscL- -3.26 Type III export protein PscL  
PA2411 -27.96 Probable thioesterase  PA1365 -3.20 Probable siderophore receptor 
pvdE -21.04 Pyoverdine biosynthesis protein PvdE  tonB- -3.19 Protein TonB  
PA2451 -17.32 Uncharacterized protein PA0047 -3.12 Uncharacterized protein  
pvdF -16.96 Pyoverdine synthetase F  PA2204 -2.96 
Probable binding protein component 
of ABC transporter  
pvdD -16.69 Pyoverdine synthetase D  PA3866 -2.94 Pyocin protein  
PA2402 -14.69 
Probable non-ribosomal peptide 
synthetase ampDh2- -2.89 AmpDh2  
pvdL -14.60 PvdL  sodA- -2.80 Superoxide dismutase [Mn]  
pvdJ -14.08 PvdJ  exoT- -2.71 Exoenzyme T 
fecA -11.66 Fe(III) dicitrate transport protein FecA  hasR- -2.68 
Heme uptake outer membrane 
receptor HasR  
 phuV -11.33 
Hemin import ATP-binding protein 
HmuV  PA0046 -2.66 Uncharacterized protein  
PA4709 -10.72 Probable hemin degrading factor  PA2381 -2.63 Uncharacterized protein  
nrdD -8.70 
Class III (Anaerobic) ribonucleoside-
triphosphate reductase subunit, NrdD  PA2196 -2.61 Probable transcriptional regulator  
pvdQ -8.04 Acyl-homoserine lactone acylase PvdQ  PA4373 -2.57 Uncharacterized protein  
PA2033 -7.91 Uncharacterized protein PA1699 -2.55 Uncharacterized protein  
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pchF -7.23 Pyochelin synthetase  tadA- -2.42 tRNA-specific adenosine deaminase  
pvdN -7.12 PvdN  rrmA- -2.39 rRNA methyltransferase  
pvdP -6.85 PvdP  PA0821 -2.38 Uncharacterized protein 
pvdO -6.81 PvdO  PA2528 -2.37 
Probable Resistance-Nodulation-Cell 
Division (RND) efflux membrane 
fusion protein 
phuR -6.49 
Heme/hemoglobin uptake outer 
membrane receptor PhuR popN- -2.35 
Type III secretion outer membrane 
protein PopN 
PA3268 -6.44 Probable TonB-dependent receptor  PA1302 -2.34 Probable heme utilization protein  
PA4358 -6.21 Ferrous iron transport protein B glpD- -2.33 Glycerol-3-phosphate dehydrogenase  
pchB -6.11 Isochorismate pyruvate lyase icmP- -2.29 
Insulin-cleaving metalloproteinase 
outer membrane protein  
priA -6.07 Primosomal protein N'  PA3768 -2.27 Probable metallo-oxidoreductase 
PA5445 -5.22 Probable coenzyme A transferase PA3310 -2.20 Uncharacterized protein  
PA4514 -5.11 
Probable outer membrane receptor for 
iron transport  rpmE2 -2.18 50S ribosomal protein L31 type B  
pchG -4.71 Pyochelin biosynthetic protein PchG fpvA -2.06 Ferripyoverdine receptor  
opdP -4.51 Glycine-glutamate dipeptide porin OpdP  PA3054 -2.04 Uncharacterized protein  
PA4357 -4.30 Uncharacterized protein  popD -2.03 
Translocator outer membrane protein 
PopD  
piuC -4.27 PKHD-type hydroxylase PiuC PA5022 -2.02 Uncharacterized protein  
pchE -4.25 Dihydroaeruginoic acid synthetase  PA5508 2.00 Probable glutamine synthetase  
 
5.4.3 Biofilm assay to asses oestradiol’s impact on biofilms  
To determine whether oestradiol had a direct impact on biofilm formation, varying 
concentrations of oestradiol at 10, 40 and 100m applied to all panel of clinical 
isolates. A selection of the three isolates PAO1, PA14 and 133098. No statistical 
significance was observed between oestradiol treatment and the control (Figure 5.12 
A-C).  
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Figure 5.12 The total biomass produced post CV staining in the control (0) and treatment 
groups of 10 nM,40 nM and 100 nM of oestradiol.  A) treatment of PAO1 with oestradiol did 
not produce any significant differences P = 0.229. B) treatment of PA14 strain resulted in no 
significant differences P = 0.618. C) No significant differences observed in clinical isolate 
133098, P = 0.927.  Statistical analysis was conducted with equal variance test (Brown-
Forsythe) 
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5.4.4 Minimal impact of oestradiol on pyocyanin production  
A pyocyanin assay was conducted to assess the impact of oestradiol on P. aeruginosa 
in LB media. Only three strains and isolates were reduced in the treatment group of 
oestradiol, namely, PA14 (P=0.014), 133099 (P=0.028), 133106 (P=0.011). In contrast, 
isolate 133065 (P=0.039) treatment with oestradiol increased the production                            
of pyocyanin (Figure 5.13). Isolate 133098, the isolate used in the proteomics 
experiment, did show an increase in pyocyanin in the presence of oestradiol, 
however, this increase was not significant. It is clear from these results that this 
response is not universal.   
Figure 5.13 Mean pyocyanin calculated of three biological isolates in the C= control group 
(black) and E=10 nM oestradiol (light grey) of UTI P. aeruginosa.  Significant differences 
observed in three isolates. * denotes P<0.050 
5.5 The Impact of testosterone on P. aeruginosa 
5.5.1 Investigation of 20nM testosterone influence on growth rates  
To determine whether testosterone had a direct impact on bacterial growth, growth 
rates in the presence and absence of the hormone were investigated in PAO1, PA14 
and 133098. There was some evidence that testosterone increased growth in one 
isolate. Over the first 12 hours, PAO1 was significantly increased by the presence of 
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testosterone at 20 nM. However, no statistical significance was observed for the 
other isolates, PA14 (P = 0.700) (Figure 5.14) and the UTI isolate 133098 P= 0.664 
(Figure 5.14 A-C).   
 
Figure 5.14 Growth pattern of three strains with control lacking hormones and 20 nM 
testosterone over 24h. A) PAO1 growth higher in the oestradiol treated group at 6h with **P 
= <0.001 using the methods of Holm-Sidak of pairwise comparison, no statistical significance 
was observed at the end of the growth rates at 24h with (P = 0.400). B) No statistically 
significant relationship observed between the control and the strain PA14 P = 0.572. C) 
Clinical isolate 133098 produced no significant relationship P = 0.898. Equal variance test 
(Brown-Forsythe) was conducted for all statistical tests 
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5.5.2 Proteomics of testosterone  
5.5.2.1 Upregulated proteins in testosterone treatment  
Overall, 64 proteins were significantly upregulated with testosterone treatment, of 
which 13 were uniquely upregulated in this condition (Table 5.5). One of the notable 
upregulated proteins is the outer membrane OprM efflux pump [1031], which                     
was upregulated by a 1.78-fold change. SpeH gene is an S-adenosylmethionine 
decarboxylase proenzyme that is part of spermidine biosynthesis and is linked to 
resisting oxidative stress in the host, the protein was upregulated by 1.84-fold.  
Table 5.5 Proteins upregulated in response to testosterone, unique proteins are shaded in 
grey 
Gene 
names Max FC Description 
Gene 
names 
 
Max FC 
                                                                      
Description 
PA4928 5.32 UPF0313 protein PA4928  PA1517 1.83 Uncharacterized protein  
ccpA  4.14 Cytochrome c551 peroxidase  PA1500 1.82 Probable oxidoreductase  
PA5103 3.90 Uncharacterized protein  PA3924 1.82 Probable medium-chain acyl-CoA ligase  
PA0510 3.15 
Probable uroporphyrin-III c-
methyltransferase  
ccoP2  1.81 Cbb3-type cytochrome c oxidase subunit  
PA2330 3.08 Uncharacterized protein  
PA2572 1.81 Probable two-component response 
regulator  
gtdA  2.87 Gentisate 1,2-dioxygenase  PA2169 1.81 Uncharacterized protein  
PA0122 2.57 Uncharacterized protein  coxB  1.80 Cytochrome c oxidase subunit 2  
gbuA  2.57 Guanidinobutyrase  PA1516 1.79 Uncharacterized protein  
katE  2.44 Catalase HPII  PA1140 1.78 Uncharacterized protein  
PA1733 2.42 Uncharacterized  oprM   1.78 Outer membrane protein OprM  
PA1260 2.35 
Amino acid ABC transporter periplasmic 
binding protein  
PA0794 1.75 Probable aconitate hydratase  
htpX  2.34 Protease HtpX  leuC  1.72 3-isopropylmalate dehydratase large subunit  
PA5359 2.34 Uncharacterized protein  chiC  1.71 Chitinase OS=Pseudomonas aeruginosa  
PA1921 2.24 Uncharacterized protein  gcl  1.70 Glyoxylate carboligase  
ccoN2  2.17 
Cytochrome c oxidase, cbb3-type, CcoN 
subunit  
glgP  1.70 Alpha-1,4 glucan phosphorylase  
nirF  2.15 Protein NirF  PA3922 1.67 Uncharacterized protein PA3922  
PA3416 2.10 
Probable pyruvate dehydrogenase E1 
component, beta chain  
PA4066 1.65 Uncharacterized protein  
PA2266 2.10 Probable cytochrome c  PA1817 1.61 Uncharacterized protein  
allA  2.05 Ureidoglycolate lyase  rpsT  1.60 30S ribosomal protein S20 5231 
PA4792 2.05 Uncharacterized protein  PA2419 1.59 Probable hydrolase  
PA4880 2.04 Probable bacterioferritin  PA2567 1.59 Uncharacterized protein  
PA5535 2.04 Uncharacterized protein  
PA5231 1.59 Probable ATP-binding/permease fusion ABC 
transporter  
PA5534 2.02 Uncharacterized protein  lecA  1.58 PA-I galactophilic lectin  
PA0536 2.02 Uncharacterized protein  narG  1.58 Respiratory nitrate reductase alpha chain  
mmsA  1.97 
Methylmalonate-semialdehyde 
dehydrogenase [acylating]  
PA0915 1.58 Uncharacterized protein  
PA3880 1.95 Uncharacterized protein  PA3757 1.57 Probable transcriptional regulator  
PA3187 1.95 
Probable ATP-binding component of 
ABC transporter  
PA1166 1.56 Uncharacterized protein  
nosZ  1.94 Nitrous-oxide reductase  PA1048 1.56 Probable outer membrane  
PA4571 1.93 Probable cytochrome c  
PA3417 1.90 
Probable pyruvate dehydrogenase E1 
component, alpha subunit  
PA2291 1.88 Porin  
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PA1880 1.87 Probable oxidoreductase  
nirS  1.87 Nitrite reductase  
PA2024 1.87 Uncharacterized protein PA2024  
katA  1.85 Catalase  
 
5.5.2.2 Downregulated proteins in testosterone treatment  
AmpC, a chromosomally encoded protein involved in intrinsic resistance in                       
P. aeruginosa [312], was downregulated by 1.94-fold change (Table 5.6). Again, there 
was evidence of down-regulated T3SS proteins including PscH and PscB which were 
downregulated by two and 1.5-fold, respectively. Both proteins are type III export 
apparatus proteins [1032]. 
 
211 
 
Gene 
names Max FC Description Gene names Max FC Description 
priA  -105.36 Primosomal protein N' PA3866 -2.23 Pyocin protein  
PA5487 -9.45 Uncharacterized protein  PA5149 -2.22 Uncharacterized protein  
PA2550 -7.06 Probable acyl-CoA dehydrogenase PA2393 -2.19 Probable dipeptidase  
fecA  -6.61 
Fe (III) dicitrate transport protein 
FecA  phzC1  -2.19 
Phospho-2-dehydro-3-deoxyheptonate 
aldolase  
PA2452 -4.84 Uncharacterized protein phuT  -2.14 Heme-transport protein, PhuT  
PA2451 -4.26 Uncharacterized protein  PA1699 -2.14 Uncharacterized protein  
PA1490 -4.19 Probable transcriptional regulator  PA3310 -2.06 Uncharacterized protein  
pchR  -3.93 Regulatory protein PchR  tyrS1  -2.06 Tyrosine--tRNA ligase 1  
hemO  -3.90 Heme oxygenase  tonB  -2.05 Protein TonB  
PA2412 -3.82 Uncharacterized protein  PA2381 -2.04 Uncharacterized protein  
pvdR  -3.72 PvdR  pscH  -2.03 Type III export protein PscH  
PA3268 -3.56 
Probable TonB-dependent 
receptor PA0704 -2.03 Probable amidase  
pvdL  -3.55 PvdL  PA4675 -2.03 Probable TonB-dependent receptor 
pvdH  -3.48 
L-2,4-diaminobutyrate:2-
ketoglutarate 4-aminotransferase, 
PvdH  argA  -1.95 Amino-acid acetyltransferase  
pvdD  -3.48 Pyoverdine synthetase D  ampC  -1.94 Beta-lactamase  
pvdE  -3.47 
Pyoverdine biosynthesis protein 
PvdE  PA0046 -1.94 Uncharacterized protein  
PA4643 -3.46 Uncharacterized protein  PA1302 -1.90 Probable heme utilization protein  
PA4514 -3.45 
Probable outer membrane 
receptor for iron transport  PA4373 -1.90 Uncharacterized protein  
phuV  -3.41 
Hemin import ATP-binding protein 
HmuV  PA5445 -1.87 Probable coenzyme A transferase  
pvdA  -3.34 L-ornithine N(5)-monooxygenase  PA3317 -1.86 Uncharacterized protein  
PA2034 -3.31 Uncharacterized protein  PA3889 -1.82 
Probable binding protein component of ABC 
transporter 
pvdJ  -3.29 PvdJ  PA4615 -1.78 Probable oxidoreductase  
PA2402 -3.29 
Probable non-ribosomal peptide 
synthetase  PA1377 -1.76 Uncharacterized protein 
PA2033 -3.26 Uncharacterized protein  PA3783 -1.76 Uncharacterized protein  
PA1365 -3.20 Probable siderophore receptor  anmK  -1.74 Anhydro-N-acetylmuramic acid kinase  
pvdF  -3.19 Pyoverdine synthetase F  PA1068 -1.74 Probable heat shock protein (Hsp90 family)  
pchG  -3.12 
Pyochelin biosynthetic protein 
PchG  PA0938 -1.73 Uncharacterized protein 
phuR  -3.09 
Heme/hemoglobin uptake outer 
membrane receptor PhuR PA4317 -1.72 Uncharacterized protein 
PA2411 -3.09 Probable thioesterase  PA1315 -1.68 Probable transcriptional regulator  
pchF  -3.07 Pyochelin synthetase  prpD  -1.66 Propionate catabolic protein PrpD  
hscB -3.03 
Co-chaperone protein HscB 
homolog  icmP  -1.65 
Insulin-cleaving metalloproteinase outer 
membrane protein  
pvdP  -2.82 PvdP  tadA  -1.64 tRNA-specific adenosine deaminase  
pchE  -2.77 Dihydroaeruginoic acid synthetase  PA4372 -1.63 Uncharacterized protein  
pvdQ  -2.77 
Acyl-homoserine lactone acylase 
PvdQ  PA0086 -1.63 Uncharacterized protein  
pchB  -2.68 Isochorismate pyruvate lyase  ppgL  -1.63 Periplasmic gluconolactonase, PpgL  
PA2204 -2.66 
Probable binding protein 
component of ABC transporter  PA0663 -1.61 Uncharacterized protein  
PA4709 -2.66 Probable hemin degrading factor  PA1494 -1.61 Uncharacterized protein  
Table 5.6 Proteins downregulated in response to testosterone, unique proteins are shaded in 
grey 
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5.5.3 Biofilm assay to investigate the impact of on P. aeruginosa 
Testosterone appears to have significant impact on the reduction of reference strain 
PAO1 at 40 nM treatment (P=0.049). This is in contrast to the increased growth that 
testosterone exerted on PAO1 previously. No other statistically significant 
relationship observed between testosterone and control groups. However, all 
concentrations showed a reduction compared to the control (Figure 5.15-A).  This 
reduction was also observed for PA14 (Figure 5.15-B) and 133098 (Figure 5.15-C). 
rcpC  -2.66 RcpC  popD  -1.60 Translocator outer membrane protein PopD  
ampDh2  -2.59 AmpDh2  PA1062 -1.59 Uncharacterized protein  
pvdO  -2.57 PvdO  PA1832 -1.57 Probable protease 
PA0079 -2.53 Uncharacterized protein  PA5022 -1.57 Uncharacterized protein 
piuC  -2.53 PKHD-type hydroxylase PiuC  PA4491 -1.57 Uncharacterized protein  
pirA  -2.49 Ferric enterobactin receptor PirA PA4440 -1.56 Uncharacterized protein  
pvdN  -2.49 PvdN  fpvB  -1.56 Second ferric pyoverdine receptor FpvB 
PA4705 -2.45 Uncharacterized protein  pscL  -1.55 Type III export protein PscL  
fumC2  -2.42 Fumarate hydratase class II 1 PA0460 -1.55 Uncharacterized protein  
PA4200 -2.40 Uncharacterized protein  PA0840 -1.52 Probable oxidoreductase  
sodA  -2.29 Superoxide dismutase [Mn]  exoT  -1.52 Exoenzyme T  
hasR  -2.29 
Heme uptake outer membrane 
receptor HasR  pscB  -1.50 Type III export apparatus protein  
rrmA  -2.29 rRNA methyltransferase  PA4390 -1.50 Uncharacterized protein  
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Figure 5.15 The total biomass produced post CV staining in the control (0) and treatment 
groups of 10 nM,40 nM and 100 nM of testosterone. A) treatment of PAO1 with testosterone 
resulted in a statistically significant reduction between the control (C) and 40nM treatment, 
* <P=0.050. B) treatment of PA14 strain resulted in no significant differences, P = 0.474 C) No 
significant differences observed in clinical isolate 133098, P= 0.888. Statistical analysis was 
conducted with equal variance test (Brown-Forsythe) 
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5.5.4 Isolate-dependent reduction of pyocyanin by testosterone  
Testosterone showed the highest reduction of pyocyanin amongst all hormones as 
five isolates were significantly reduced <P=0.05 in comparison to the control (Figure 
5.16). Strains and isolates PA14,133099, 133106 all registered P=0.002 while isolates 
133117 (P= 0.020) and 13317 (P=0.028).    
 
Figure 5.16 Mean pyocyanin calculated of three biological isolates in the control group (black) 
and 10 nM testosterone (dark grey) of UTI P. aeruginosa.  Significant differences observed in 
6 isolates. * denotes P<0.050 
5.6 The Impact of progesterone on P. aeruginosa 
5.6.1 The Influence of 20nM progesterone on growth rate 
The impact of progesterone was also investigated on growth rates of the three 
representative isolates PAO1, PA14 and 133098 (Figures 5.17 A-C).  
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Figure 5.17 Growth pattern of three strains with control lacking hormones and 20nM of 
progesterone treatment, measured at A600nM optical density. A) The mean of the three 
biological replicates was calculated and showed no statistical significance P = 0.400 at 24 h. 
B) Treatment of progesterone resulted in significant differences at the 6th and 12th time 
points as the growth increased for the strain PA14 at ** P<0.001 but reached P=0.400 at 24h. 
C) Treatment with progesterone to isolate 133098 yielded no statistical significance at P= 
0.230. Statistical tests performed by the Holm-Sidak method and Brown-Forsyth test 
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5.6.2 Proteomics of progesterone  
5.6.2.1 Upregulated proteins in response to progesterone treatment  
180 proteins displayed higher abundance in progesterone, 143 of these had a 
significant P value. Of these 69 were uniquely up in progesterone (Table 5.7). SodB is 
superoxide dismutase that has been linked to antibiotic tolerance [1033] and is 
downregulated by 1.6-fold change. NarL which is a two component regulator 
associated with nitrate sending and has been linked to increased virulence [1034], 
SigX  is an ECF sigma factor involved in regulating responses to the environment 
[1035]. 
Table 5.7 Proteins upregulated in response to progesterone, unique proteins are shaded in 
grey 
Gene names Max FC Description Gene names Max FC Description 
PA0880 Infinity Probable ring-cleaving dioxygenase PA1518 1.78 
5-hydroxyisourate 
hydrolase 
amiE 14.04 Aliphatic amidase PA4880 1.78 Probable bacterioferritin 
nirL 8.27 Protein NirL lap 1.78 Aminopeptidase 
katE 6.47 Catalase HPII PA1517 1.77 Uncharacterized protein 
ccpA 6.39 Cytochrome c551 peroxidase PA4200 1.77 Uncharacterized protein 
PA4928 5.10 UPF0313 protein PA4928 PA4520 1.77 
Probable chemotaxis 
transducer 
PA4131 4.05 Probable iron-sulfur protein PA3602 1.77 Uncharacterized protein 
PA1254 3.93 Probable dihydrodipicolinate synthetase PA4571 1.77 Probable cytochrome c 
PA0510 3.85 
Probable uroporphyrin-III c-
methyltransferase PA3347 1.76 Uncharacterized protein 
PA0144 3.42 Uncharacterized protein PA1922 1.74 
Probable TonB-dependent 
receptor 
PA3119 3.25 Uncharacterized protein PA1673 1.73 Bacteriohemerythrin 2920 
PA2169 3.04 Uncharacterized protein azu 1.73 Azurin 
PA3880 3.03 Uncharacterized protein PA4349 1.72 Uncharacterized protein 
nosZ 3.02 Nitrous-oxide reductase PA0743 1.72 
NAD-dependent L-serine 
dehydrogenase 
PA5359 3.01 Uncharacterized protein PA1140 1.71 Uncharacterized protein 
PA5532 2.97 Uncharacterized protein PA1500 1.71 Probable oxidoreductase 
PA0122 2.93 Uncharacterized protein PA1041 1.71 
Probable outer 
membrane protein 
PA3416 2.91 
Probable pyruvate dehydrogenase E1 
component, beta chain ldh 1.70 Leucine dehydrogenase 
PA5535 2.87 Uncharacterized protein tesA 1.70 Esterase TesA 
PA3417 2.86 
Probable pyruvate dehydrogenase E1 
component, alpha subunit PA3628 1.69 
S-formylglutathione 
hydrolase 
PA2481 2.74 Uncharacterized protein PA2633 1.69 Uncharacterized protein 
chiC 2.62 Chitinase hmp 1.69 Flavohemoprotein 
nirS 2.56 Nitrite reductase acsA2 1.69 
Acetyl-coenzyme A 
synthetase 2 
PA4913 2.52 
Probable binding protein component of 
ABC transporter PA0269 1.69 
Alkyl hydroperoxide 
reductase AhpD 
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PA5534 2.47 Uncharacterized protein lecA 1.68 PA-I galactophilic lectin 
gbuA 2.46 Guanidinobutyrase PA2567 1.68 Uncharacterized protein 
PA1665 2.39 Uncharacterized protein pscB PA3190 1.67 
Probable binding protein 
component of ABC sugar 
transporter 
PA1921 2.39 Uncharacterized protein PA1880 1.67 Probable oxidoreductase 
mmsA 2.39 
Methylmalonate-semialdehyde 
dehydrogenase [acylating] PA4328 1.67 Uncharacterized protein 
ccoP2 2.38 Cbb3-type cytochrome c oxidase subunit PA4139 1.65 Uncharacterized protein 
napA 2.38 Periplasmic nitrate reductase PA1516 1.64 Uncharacterized protein 
PA1881 2.30 Probable oxidoreductase narL 1.64 
Two-component response 
regulator NarL 
PA3922 2.30 Uncharacterized protein PA3922 PA3187 1.64 
Probable ATP-binding 
component of ABC 
transporter 
PA2266 2.26 Probable cytochrome c acsA1 1.64 
Acetyl-coenzyme A 
synthetase 1 
katA 2.25 Catalase PA3458 1.64 
Probable transcriptional 
regulator 
fusB 2.23 Elongation factor G 2 PA1789 1.64 Uncharacterized protein 
allA 2.20 Ureidoglycolate lyase dctP 1.63 
C4-dicarboxylate-binding 
periplasmic protein DctP 
nirF 2.18 Protein NirF PA3858 1.62 
Probable amino acid-
binding protein 
gcvP2 2.15 
Glycine dehydrogenase (decarboxylating) 
2 rbsB 1.62 
Binding protein 
component of ABC ribose 
transporter 
PA1551 2.15 Probable ferredoxin PA3723 1.61 
Probable FMN 
oxidoreductase 
pcaF 2.14 Beta-ketoadipyl-CoA thiolase sdaA 1.60 L-serine dehydratase 
PA3924 2.11 Probable medium-chain acyl-CoA ligase sodB 1.60 Superoxide dismutase [Fe] 
PA1760 2.06 Probable transcriptional regulator PA2841 1.59 
Probable enoyl-CoA 
hydratase/isomerase 
PA4792 2.02 Uncharacterized protein PA4333 1.59 Fumarate hydratase class I 
phzF 2.02 
Trans-2,3-dihydro-3-hydroxyanthranilate 
isomerase PA5027 1.58 Uncharacterized protein 
ccoN2 2.02 
Cytochrome c oxidase, cbb3-type, CcoN 
subunit PA4063 1.58 Uncharacterized protein 
PA0747 2.01 Probable aldehyde dehydrogenase arcC 1.58 Carbamate kinase 
dksA 1.99 
RNA polymerase-binding transcription 
factor DksA PA0959 1.57 Uncharacterized protein 
PA0586 1.99 Uncharacterized protein zwf 1.57 
Glucose-6-phosphate 1-
dehydrogenase 
leuC 1.98 
3-isopropylmalate dehydratase large 
subunit PA1202 1.56 Probable hydrolase 
coxB 1.97 Cytochrome c oxidase subunit 2 arcA 1.56 Arginine deiminase 
PA2920 1.95 Probable chemotaxis transducer PA4352 1.55 Uncharacterized protein 
PA0794 1.93 Probable aconitate hydratase PA0459 1.55 
Probable ClpA/B protease 
ATP binding subunit 
nirQ 1.92 Denitrification regulatory protein NirQ PA1287 1.54 Glutathione peroxidase 
PA2024 1.92 Uncharacterized protein PA2024 glgB 1.54 
1,4-alpha-glucan 
branching enzyme GlgB 
pyrQ 1.92 Dihydroorotase PA3972 1.54 
Probable acyl-CoA 
dehydrogenase 
sbp 1.91 Sulfate-binding protein PA0915 1.53 Uncharacterized protein 
PA0250 1.91 Uncharacterized protein sigX 1.53 ECF sigma factor SigX 
phzG1 1.89 
Probable pyridoxamine 5'-phosphate 
oxidase PA4787 1.53 
Probable transcriptional 
regulator 
PA4611 1.89 Uncharacterized protein PA5540 1.52 Uncharacterized protein 
PA3923 1.88 Uncharacterized protein PA3712 1.52 Uncharacterized protein 
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PA5475 1.87 Acetyltransferase PA5475 acnA 1.52 Aconitate hydratase A 
PA2433 1.86 Uncharacterized protein ackA 1.51 Acetate kinase 
leuD 1.85 
3-isopropylmalate dehydratase small 
subunit fdhE 1.51 Protein FdhE homolog 
PA1746 1.84 Uncharacterized protein fdnH 1.51 
Nitrate-inducible formate 
dehydrogenase, beta 
subunit 
PA4502 1.83 
Probable binding protein component of 
ABC transporter PA5047 1.51 Uncharacterized protein 
ccoO2 1.83 
Cytochrome c oxidase, cbb3-type, CcoO 
subunit rimO 1.51 
Ribosomal protein S12 
methylthiotransferase 
RimO 
phaC1 1.82 Poly(3-hydroxyalkanoic acid) synthase 1 PA4463 1.51 Uncharacterized protein 
PA3415 1.82 
Dihydrolipoamide acetyltransferase 
component of pyruvate dehydrogenase 
complex chpB 1.50 
Protein-glutamate 
methylesterase 
PA5545 1.81 Uncharacterized protein bfrB 1.50 Bacterioferritin 
PA2504 1.79 Uncharacterized protein PA3618 1.50 Uncharacterized protein 
PA1470 1.79 Probable short-chain dehydrogenase  
 
5.6.2.2 Downregulated proteins in response to progesterone treatment  
155 proteins were down in abundance to progesterone and of these 104 had a 
significant P value (Table 5.8). 20 of these proteins are significantly reduced in 
progesterone only. These include AmbE which is lowered by 1.62-fold-change. Amb 
is L-2-Amino-4-methoxy-trans-3-butenoic acid that is a potent P. aeruginosa toxin 
involved in the inhibition of Bacillus spp and E. coli growth [1036]. OpmQ contributes 
to pyoverdine transport and was reduced by 1.7-fold change [275]. Ohr is an organic 
hydroperoxide resistance protein [655], [1037], which is downregulated by 1.7-fold.   
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Table 5.8 Proteins downregulated in response to progesterone, unique proteins are shaded 
in grey 
Gene names Max FC Description Gene names Max FC Description 
pchG -14.01 Pyochelin biosynthetic protein PchG PA1791 -2.31 Uncharacterized protein  
pchF -12.22 Pyochelin synthetase  PA5445 -2.28 
Probable coenzyme A 
transferase 
pchE -10.47 Dihydroaeruginoic acid synthetase  sodA -2.27 
Superoxide dismutase 
[Mn]  
pchB -10.42 Isochorismate pyruvate lyase  PA0277 -2.21 Uncharacterized protein 
fecA -9.98 Fe(III) dicitrate transport protein FecA  PA2196 -2.20 
Probable transcriptional 
regulator  
pchR -7.96 Regulatory protein PchR  phuT -2.17 
Heme-transport protein, 
PhuT  
pvdE -7.21 Pyoverdine biosynthesis protein PvdE  clpV1 -2.16 Protein ClpV1  
PA2452 -6.36 Uncharacterized protein  PA3850 -2.12 Uncharacterized protein  
fabH -6.09 3-oxoacyl-[acyl-carrier-protein] synthase 3  PA4675 -2.11 
Probable TonB-
dependent receptor 
pvdH -5.51 
L-2,4-diaminobutyrate:2-ketoglutarate 4-
aminotransferase, PvdH  PA3054 -2.09 Uncharacterized protein  
pvdL -5.48 PvdL  piuC -2.08 
PKHD-type hydroxylase 
PiuC  
pfeR -5.45 Transcriptional activator protein PfeR  fptA -2.02 
Fe (3+)-pyochelin 
receptor  
pvdD -5.36 Pyoverdine synthetase D tonB -2.00 Protein TonB  
PA2034 -5.24 Uncharacterized protein  PA1832 -1.99 Probable protease  
PA2402 -5.04 
Probable non-ribosomal peptide 
synthetase  PA0938 -1.94 Uncharacterized protein 
pvdR -4.88 PvdR  PA0046 -1.94 Uncharacterized protein 
PA4514 -4.67 
Probable outer membrane receptor for 
iron transport  PA3889 -1.90 
Probable binding protein 
component of ABC 
transporter  
pvdA -4.65 L-ornithine N(5)-monooxygenase  fpvB -1.87 
Second ferric pyoverdine 
receptor FpvB 
PA2033 -4.40 Uncharacterized protein  PA2212 -1.86 
4-hydroxythreonine-4-
phosphate 
dehydrogenase 2 
PA2411 -4.36 Probable thioesterase  PA5149 -1.85 Uncharacterized protein  
PA3330 -4.34 Probable short chain dehydrogenase  nrdD -1.84 
Class III (Anaerobic) 
ribonucleoside-
triphosphate reductase 
subunit, NrdD  
pvdJ -4.24 PvdJ  PA1377 -1.84 Uncharacterized protein  
pvdP -4.23 PvdP  PA5022 -1.81 Uncharacterized protein  
PA2451 -4.19 Uncharacterized protein  tadA -1.81 
tRNA-specific adenosine 
deaminase 
hemO -4.17 Heme oxygenase  PA1601 -1.77 
Probable aldehyde 
dehydrogenase  
PA2384 -4.10 Uncharacterized protein  PA0704 -1.75 Probable amidase  
PA1365 -4.09 Probable siderophore receptor  PA0045 -1.74 Uncharacterized protein 
PA3268 -3.78 Probable TonB-dependent receptor  ohr -1.73 
Organic hydroperoxide 
resistance protein  
pvdQ -3.64 Acyl-homoserine lactone acylase PvdQ  PA4373 -1.73 Uncharacterized protein  
pvdF -3.61 Pyoverdine synthetase F  PA1068 -1.73 
Probable heat shock 
protein (Hsp90 family)  
phuR -3.57 
Heme/hemoglobin uptake outer 
membrane receptor PhuR  PA4615 -1.71 Probable oxidoreductase  
pirA -3.47 Ferric enterobactin receptor PirA  opmQ -1.70 
Probable outer 
membrane protein  
220 
 
fumC2 -3.11 Fumarate hydratase class II 1  PA3768 -1.70 
Probable metallo-
oxidoreductase  
PA2109 -3.10 Uncharacterized protein  PA5113 -1.68 Uncharacterized protein  
PA2412 -3.09 Uncharacterized protein PA0086 -1.68 Uncharacterized protein  
PA3866 -3.07 Pyocin protein  exsC -1.67 
Exoenzyme S synthesis 
protein C  
pvdN -3.00 PvdN icmP -1.66 
Insulin-cleaving 
metalloproteinase outer 
membrane protein  
phuV  -2.95 Hemin import ATP-binding protein HmuV  PA1494 -1.63 Uncharacterized protein  
PA4705 -2.94 Uncharacterized protein  ambE -1.62 AmbE  
ampDh2 -2.88 AmpDh2  PA0851 -1.61 Uncharacterized protein  
pvdO -2.79 PvdO  PA0660 -1.61 Uncharacterized protein  
fiuA -2.79 Ferrichrome receptor FiuA  PA4491 -1.60 Uncharacterized protein  
PA4709 -2.77 Probable hemin degrading factor  PA1132 -1.60 Uncharacterized protein  
PA0047 -2.69 Uncharacterized protein  PA3891 -1.59 
Probable ATP-binding 
component of ABC 
transporter  
PA2204 -2.67 
Probable binding protein component of 
ABC transporter  PA4317 -1.59 Uncharacterized protein  
PA3318 -2.66 Uncharacterized protein  PA4390 -1.58 Uncharacterized protein  
PA0079 -2.64 Uncharacterized protein  ansA -1.56 L-asparaginase I  
PA2550 -2.60 Probable acyl-CoA dehydrogenase  hutH -1.56 Histidine ammonia-lyase  
PA2393 -2.56 Probable dipeptidase popD -1.54 
Translocator outer 
membrane protein PopD 
hasR -2.50 
Heme uptake outer membrane receptor 
HasR  gbt -1.53 
Glycine betaine 
transmethylase  
PA1302 -2.50 Probable heme utilization protein  PA3729 -1.52 Uncharacterized protein  
PA2528 -2.41 
Probable Resistance-Nodulation-Cell 
Division (RND) efflux membrane fusion 
protein  ubiG -1.52 
Ubiquinone biosynthesis 
O-methyltransferase  
 
5.6.3 Biofilm assay assessment of the effects of progesterone on biofilm formation 
A reduction in biofilm biomass was observed in the presence of progesterone in all 
three isolates shown (Figure 5.18 A-C). However, no statistical significance was 
determined. 
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Figure 5.18 The total biomass produced post CV staining in the control (C) and treatment 
groups of 10 nM,40 nM and 100 nM of progesterone. A) treatment of PAO1 with 
progesterone produced no significant differences P = 0.582. B) treatment of PA14 strain 
resulted in no significant differences P = 0.774 C) No significant differences observed in 
clinical isolate 133098, P = 0.928. Statistical analysis was conducted with equal variance test 
(Brown-Forsythe) 
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5.6.4 Minimal impact of progesterone on pyocyanin production 
Treatment with progesterone reduced the amount of pyocyanin significantly in the 
three strains and isolates (Figure 5.19). The reduction of pyocyanin was the most 
significantly observed in LESB58 strain and clinical isolate 133083 with a P value of < 
0.001. However, in isolate 133098, there was no change in pyocyanin production, and 
this was consistent the proteomics results.   
 
Figure 5.19 Mean pyocyanin calculated of 3 biological isolates of UTI P. aeruginosa compared 
between the controls (black) and treatment group of 10 nM progesterone (Dark grey). 
Significant differences observed in comparison in 3 strains and isolates. * denotes P<0.050 
and ** denotes P≤ 0.001 
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5.7 Discussion 
Sexual dimorphism exists in relation to susceptibility to viral, parasitic and microbial 
infections [929], [1038], [1039]. There is growing evidence that sex hormones play a 
prominent role in affecting such infections in animal infection models and humans 
[904], [905], [919], [930]. The impact of hormones on bacterial infections has been 
largely attributed to immune modulation effects. However, evidence of direct 
impacts on the P. aeruginosa PAO1 reference strain has been reported as oestradiol 
induced mucoidy and upregulated genes involved in its conversion pathway [953]. 
UTI prevalence is higher in reproductive-age women than men, in part, due to 
anatomical differences. However, sex hormones have been shown to play a role in 
modulating infections involving UPEC. As such, diminishing hormone levels in males 
and particularly, females, may have a negative impact as age progresses past the 
reproductive stages of life. In this chapter, we sought to assess the direct impact of 
sex hormones oestradiol, testosterone and progesterone on P. aeruginosa in LB and 
an artificial urine model by conducting several in vitro experiments including growth 
rates, proteomic analysis, biofilm and pyocyanin production.  
Our results suggest that hormones do not reproducibly affect growth rates. Although 
significant differences were determined in the impact of testosterone on the 
reference strain PAO1 and progesterone on the reference strain PA14 at certain time 
points, these differences are minimal and do not affect the overall growth rates.  
Treatments with sex hormones in AUM inoculated with P. aeruginosa revealed 
common responses of the bacteria in the presence of all three hormones. The 
proteins involved in iron-uptake were universally down in abundance, with few 
exceptions. Iron acquisition mechanisms are essential for survival of bacterial 
pathogens and to invade and colonise the host [1040]. In this chapter, the proteomics 
data demonstrated that iron chelating systems produced by the opportunistic 
pathogen are reduced in the presence of the sex hormones oestradiol, testosterone 
and progesterone. One of those systems involves the production of siderophore 
pyoverdine, which is produced in response to severe iron starvation in the 
environment [275]. Urine and the urinary tract are scarce in iron [743], [1041], thus, 
we used the AUM model to identify whether sex hormones alter the proteomic 
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profile of UTI P. aeruginosa clinical isolate 133098. Approximately 20 proteins are 
involved in pyoverdine synthesis and these span the inner bacterial membrane, the 
periplasm and the outer membrane. Examples of these proteins include PvdE, PvdH, 
PvdL, PvdR, PvdJ, PvdP PvdN, PvdO and opmQ [969]. Upon conducting proteomic 
analysis, it was observed that the sex hormones used in this study, in particular, 
oestradiol reduced pyoverdine synthesis. Proteins initiating the process of 
pyoverdine production such as PvdA, PvdJ and PvdD were all down in abundance. In 
addition, PvdQ, PvdO and PvdN, which participate in the production and maturation 
of pyoverdine, were all less abundant in all hormone conditions, particularly, 
oestradiol treated AUM. The transport complex which includes PvdR was 
downregulated by 33-fold, 3.7-fold, 4.8-fold in each of oestradiol, testosterone and 
progesterone, respectively. These findings, together, suggest that oestradiol, and to 
a lesser degree progesterone and testosterone, play a substantial role in reducing the 
production of pyoverdine-associated proteins.   
Pyochelin synthesis is produced when more iron is available in the surrounding 
environment relative to the state of which pyoverdine is produced [977]. Reduction 
of proteins associated with pyochelin production was observed in AUM treated with 
sex hormones. In order for pyochelin to be produced, it requires PchABCD and the 
cytoplasmic transcriptional regulator PchR. The levels of these proteins were reduced 
in the presence of, particularly, oestradiol and progesterone. Haem uptake from the 
host is conducted via two different pathways, the Phu and HasR systems [995]. In the 
former, the TBDR PhuR extracts heme directly from haemoproteins, while in the 
latter, a hemophore with the protein Has extracts haem from haemoproteins to form 
a complex, which is received by the HasR receptor [996], [997]. Our results show that 
treatment with all hormones reduced the abundance of all proteins involved in haem 
uptake. In addition, further reduction of intracellular proteins involved in processing 
haem such as PhuS and the heme oxygenase are reduced. Furthermore, all sex 
hormones in this study reduced fumarase C, a protein that is part of the tricarboxylic 
acid cycle, this protein is produced in response to iron starvation and is involved in 
alginate biosynthesis and conversion to mucoidy [1026]. This may indicate that, 
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unlike in CF, the presence of oestradiol in menstruating women may supress                   
P. aeruginosa mucoidy [953].  
P. aeruginosa can hijack siderophores made by another microorganism to colonise 
and expand in different ecological niches [275]. chtA gene encodes a TDBR to acquire 
cognate xenosiderophores aerobactin, rhizobactin, and schizokinen, potentially in 
setting of polymicrobial infection such as CAUTI. [964] All sex hormones in this study 
reduced the expression of ChtA protein. PfeR is a part of a two component sensor 
kinase system with PfeS which uptakes enterobactin and imports to the cellular 
receptor PfeA [1025]. PfeR was reduced significantly in oestradiol treated cultures, 
thus, this may affect the ability of P. aeruginosa to acquire any of these 
xenosiderophores in UTI-related conditions in polymicrobial infection, potentially 
providing other UTI pathogens such as UPEC to outcompete P. aeruginosa for the 
hosts limited iron substances.      
To the best of our knowledge, our findings are the first to report in-depth proteomic 
profile of iron acquisition mechanisms of a P. aeruginosa clinical isolate in an in vitro 
model mimicking UTI environment in the presence of hormones. The first report of 
the existence of pyochelin and pyoverdine in UTI P. aeruginosa was discussed in a 
study by Visca et al, both were reported to be present in 97.6% and 92.6% 
respectively in all of the 121 tested UTI isolates in poor iron medium [461]. While the 
previous study shows that UTI isolates are capable of producing iron-chelating 
proteins, our study also shows that under urine and urine-like conditions, these 
mechanisms are upregulated (as shown in chapter 4). However, there is a reduction 
in iron acquisition mechanisms upon treatment with sex hormones. Previous studies 
which utilised UTI P. aeruginosa producing pyochelin, pyoverdine and haemolysin in 
vivo mouse model demonstrated that haemolysin was involved with higher severity 
of infection, while the exact contribution of pyochelin and pyoverdine remained 
elusive [57], [58]. A study by Tielen et al, (2011) which examined 30 P. aeruginosa UTI 
isolates provided further evidence of the importance of pyoverdine as all isolates 
produced it [90]. In a study which utilised proteomics to assess the response strain 
PAO1 to iron starvation, all classical iron upregulation proteins of haem, pyochelin 
and pyoverdine were upregulated [1042]. This is in contrast to our results which show 
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that iron acquisition mechanisms are downregulated, which may suggest that the 
bioavailability of iron in AUM containing hormones is increased. This is an unusual 
finding and the exact method is unclear. What is also unclear is how this may affect 
infection in vivo. Our data could suggest that iron bioavailability is good and therefore 
the bacteria do not need to upregulate the energy intensive production of multiple 
iron acquisition methods. However, it could be that the hormones may play a 
protective role in directly reducing iron uptake mechanisms by which P. aeruginosa 
establish colonisation and invasion. This could be further investigated in the future 
studies by adding different levels of hormone and iron concentrations into AUM or 
minimal media to determine the impact on bacterial survival and growth. 
Furthermore, siderophore production assays or qPCR gene expression experiments 
under relevant conditions could also be performed.   
QS mechanisms control the production of virulence factors such as phenazines, 
elastases and HCN. PQS is the third QS system identified in P. aeruginosa and can 
promote the synthesis of phenazines and HCN [131]. In this study, the abundance 
profile of PQS proteins is higher in oestradiol-treated samples. Expression of PQS 
molecules is associated with higher virulence as shown in an acute UTI mouse model 
[129].  P. aeruginosa with a fully functional PQS biosynthetic pathway resulted in 
higher virulence, tissue destruction and in severe inflammatory responses in mice. 
Isolates lacking PqsA and PqsH failed to produce PQS in mice and resulted in mild 
damage and lower bacterial load [129]. In contrast to the reduced proteome 
abundance of iron acquisition mechanisms, phenazines were upregulated by 
oestradiol. As previously discussed in chapter 3, phenazines are redox active 
secondary metabolites that are involved in biofilm formation and act as electron 
acceptors [1043], [1044]. Oestradiol appeared to increase the expression of all 
phenazine proteins in the PCA and pyocyanin pathways. PCA biosynthesis in 
dependent on enzymes encoded by highly similar operons, phzA1 to phzG1 (phz1) 
and phzA2 to G2 (phz2) [155]. Pyocyanin, along with other phenazines, are produced 
by proteins involved in the modification of PCA by PhzM and PhzS [1042], both of 
which were upregulated by oestradiol. In the phenotypic pyocyanin assay, however, 
the response was isolate dependent. The conditions of the experiments were not 
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identical and further study into the link between oestradiol and pyocyanin could be 
performed. Additionally, proteins encoding HCN were promoted by oestradiol. HCN 
is toxic and produced and degraded by a number of bacterial species and it is 
synthesised via enzymatic decarboxylation of glycine and catalysed by a protein 
complex called HCN synthase [1045], [1046]. HCN synthase is encoded by the hcnABC 
operon. The expression of HCN synthase is regulated in a tight manner at both the 
transcriptional and post-transcriptional level [206], [1047], [1048]. The QS systems 
las and rhl positively regulate HCN in response to high cell density, low oxygen, 
glycine and iron starvation [202], [1048]. The ANR transcriptional regulator also 
positively regulates the hcnABC promoter in anaerobic conditions [1048]. HCN 
inhibits ciliary beating function in CF lungs [1049]. In this study, both the las and rhl 
QS systems were less active in AUM compared to LB and this was not altered in the 
presence of hormones. Therefore, these systems do not appear to be involved in HCN 
production in this model.  It is possible that both HcnB and HcnC were increased           
by the female hormone oestradiol via a PQS-induced mechanism. Current 
understanding of the PQS mechanism is poor, however, it appears that PQS acts both 
dependently and independently of its cognate PqsR and can possibly target hundreds 
of unknown protein partners within the cell [122], [1050]. HCN optimal production 
levels are reached upon transition from the exponential phase into the stationary 
phase [1051]. HCN has been detected in paediatric CF patients and has been 
suggested to be identified as biomarker of early P. aeruginosa infection [1052], 
[1053]. Further experimentation in vitro and in vivo models are required to establish 
the role of HCN in the pathogenesis of P. aeruginosa UTIs.  As for the role of oestradiol 
in promoting mucoidy [953], there is no evidence in this study that oestradiol alters 
alginate production in the UTI P. aeruginosa clinical isolate 133098. This could 
suggest that the conditions in CF lung and the urinary tract play a different role in the 
control/production of certain virulence factors.  However, it may be that the impact 
on alginate, like many other features, is isolate dependent and although oestradiol 
does increase alginate in PAO1, it may not in other isolates. Based on these 
experiments, oestradiol may increase virulence of P. aeruginosa in females (at 
reproductive age) more than males during UTI infection.    
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Testosterone is present in men at 10 times higher than in women in the reproductive 
stages of life [1054]. One of the interesting findings in the proteomic profile is related 
to antimicrobial resistance in the upregulation and downregulation of OprM and 
AmpC, respectively. OprM is a porin protein and is a part of the efflux pump MexAB-
OprM [532], [1055]. In addition to the involvement of OprM in antimicrobial 
resistance, the porin is also involved in QS systems (through efflux of products) and 
response to environmental stresses [1056], [1057]. The MexAB-OprM has been 
shown to be induced by oxidative stress, such as during triclosan and 
pentachlorophenol treatment [1058], [1059]. Based on these results, it appears that 
testosterone can increase OprD and thus, potentially promotes transient 
antimicrobial resistance. This finding is similar to a study by Li et al, (2015) which 
reported the that synthetic oestradiol promotes the expression of efflux pumps in                             
P. aeruginosa [1060].  Many proteins linked to antimicrobial resistance were altered 
under testosterone treatment. Further studies could determine whether these 
protein changes result in phenotypic changes in resistance. This could then help to 
inform treatment choices. 
Proteins involved in the T3SS export apparatus proteins PscH and PscB were 
decreased in abundance in the presence of testosterone, suggesting that 
testosterone may have a further inhibitory effect on the T3SS.  
Progesterone is released in the second half of the menstruation cycle to line the 
endometrium and prepare reproductive age women for pregnancy [1061]. Very little 
is known about the interaction of progesterone and its role in bacterial infectious 
diseases. In addition to the reduction reported to iron acquisition mechanisms, AmbE 
also showed decreased abundance. This protein is a product of one of the genes in 
the ambABCDE cluster, which encodes AMB, a L-2-Amino-4-methoxy-trans-3-
butenoic acid that is a potent P. aeruginosa toxin capable of inhibiting Bacillus Spp 
and E. coli growth [1036]. The decrease of AmbE could potentially be beneficial to       
P. aeruginosa establishing infection in a polymicrobial host settings such as CAUTI 
and could help to compete with UPEC. Another notable reduction is the decreased 
abundance of Ohr, which is an organic hydroperoxide resistance protein. The protein 
is regulated by the ohrR gene and its deletion leads to a peroxide sensitive phenotype 
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[1037]. Based on this, progesterone may perform a protective role against                        
P. aeruginosa UTI infection. On the other hand, proteins involved in denitrification 
and survival in anaerobic conditions such NarL, were increased in abundance. This 
protein is part of classical two-component regulatory system NarX/NarL which senses 
nitrate. A ΔnarL mutant has been shown to lead to a hyper-swarming motile 
phenotype, promoting biofilm formation [1034]. Thus, the impact of progesterone 
on biofilm formation could be further investigated in P. aeruginosa mutants lacking 
narL to assess its potential role in virulence. SigX is another important protein that 
was increased in response to progesterone. The protein is an ECF sigma factor which 
contributes to regulating responses to the environment. SigX mutants exhibit 
reduced motility, surface attachment and biofilm formation [1035]. Therefore, the 
role of progesterone on P. aeruginosa biofilm formation is unclear and this was 
consistent with the biofilm microscopy results.   
Biofilm formation plays a vital role in virulence of P. aeruginosa [129], [462], [683]. 
Again, variable results were obtained in terms of the isolate type or the sex hormone 
in use. Upon conducting hormone treatments on biofilms with variable 
concentrations of hormone (10nM, 40nM and 100 nM), only one significant reduction 
was observed across the isolates used (PA14 treated with 40nM of testosterone). 
Thus, this was investigated further with confocal microscopy with the same method 
utilised in chapter three.  No significant reductions in the biomass formed, maximum 
thickness, surface area, roughness coefficient and surface to biofilm ratio was 
observed.  in the future, a study of castrated male mice and ovariectomised female 
mice supplemented with hormones of interest could provide more insight into CAUTI. 
New analytic techniques such as BiofilmX could be used to quantify and characterise 
biofilms measured using microscopy [1062].  
In chapter four\, the proteomic profile of P. aeruginosa grown in either LB medium, 
AUM, or urine was analysed. By adding the sex hormones, the aim was to study the 
direct impact of hormones in AUM as a model to study P. aeruginosa UTI 
pathogenesis. This enabled the study of a specific effect and determine the role in 
UTIs, which, otherwise, would not be possible in urine due to endogenous variations 
in hormones.  However, there are some limitations to this study, and these must be 
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considered. Although the proteomics was conducted in AUM, many of the other 
assays required LB and had not been optimised in AUM. Thus, for optimal 
comparisons, these should be conducted in AUM-containing oestradiol, testosterone 
and progesterone.  
While this study shows that there is a direct impact of these hormones on                           
P. aeruginosa, the exact mechanism should be investigated further. In particular, it 
would be interesting to determine whether there are certain receptors on the                  
P. aeruginosa outer membrane that can facilitate cell-hormones interactions. 
Additionally, since the proteomics assay was conducted in vitro, this study does not 
consider potential interactions between hormone receptors in the bladder and the 
kidney to P. aeruginosa UTI infections. For instance, ERα, an oestradiol receptor has 
been shown to be present in kidney and affects immunes responses to UPEC if 
supplemented by the agonist (activator) PPT or the antagonist (suppressor) MPP in a 
mouse UTI model [932]. A similar finding was observed in CF mice where worse 
outcomes were evident in the presence of oestradiol. Oestradiol induced pro-
inflammatory immune responses to P. aeruginosa challenge [930]. Thus, more in vitro 
and in vivo experiments are warranted. 
The levels of these hormones are not consistent throughout life. Testosterone 
steadily declines in men as they progress into middle-age [1063] and the levels of 
oestradiol and progesterone fluctuate in reproductive-age women [333], [387]. In 
addition, the use of oral contraceptives containing estrogen-progestin to prevent 
pregnancy in premenopausal women affect these levels and therefore, may affect 
bacterial pathogenesis in infections [953], [1064]. Indeed, the use of oral 
contraceptive in Ireland has been associated with decreased severity of P. aeruginosa 
infections in CF patients and less treatment with antibiotics, suggesting that 
oestradiol has a protective effect [1065][953]. During pregnancy, oestrogen and 
progesterone levels rise constantly to reach their peak in the third  trimester and drop 
shortly after child birth [1066]. Several studies reported the increased frequency of 
UTIs during pregnancy, in part due to the dilation of the urinary ureters, which could 
be attributed to be caused by mechanical, hormonal and physical interplay in 
pregnancy [1067], [1068]. The detection of P. aeruginosa MDR isolates have been 
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reported in developing countries such as Nigeria, where asymptomatic women 
carrying significant bacteriuria have been reported [1069]. Thus, the higher levels of 
oestradiol and progesterone may play a protective role.  The dual impact of oestradiol 
and progesterone on P. aeruginosa could be further examined in AUM in levels 
resembling hormone levels in the second and third trimesters. Evidence in the 
literature suggests that the three hormones studied play an active role in altering the 
gut microbiome. The relationship between urinary sex hormone levels, UTI P. 
aeruginosa and the urinary microbiome, therefore, may provide more insight on the 
influence of sex hormones during infections if investigated further.     
Overall, this study shows that sex hormones can have a universal influence on some 
systems such as iron acquisition. However, other systems may be specifically affected 
by only one of the three hormones. These changes may have implications for 
bacterial pathogenesis in UTIs. Further studies ought to be conducted in vivo with 
subsequent robust clinical trials. Sex hormones can induce virulence factors in some 
instances. Production of sex hormones is reduced in both male and female patients 
as age progresses. Thus, a greater understanding of gender-dependent host-
pathogen interactions is needed and may lead to a personalized medical approach. 
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Chapter 6 
 6 General discussion and future research 
P. aeruginosa is an important opportunistic pathogen that causes a wide spectrum of 
nosocomial infections [90], [438], [690], [707]. This opportunist bacterium is capable 
of forming biofilms on urinary catheters and can be highly resistant to antibiotics [58], 
[485], [659], [753]. One of the infections that P. aeruginosa can cause is UTIs, 
particularly CAUTIs, both of which are generally understudied in the literature and 
there is a paucity of information and less interest in this field in comparison to                 
P. aeruginosa respiratory CF infections [90], [269], [280]. 
 
In chapter 3, I sought to develop further understanding of the genotypic and 
phenotypic characteristics of UTI P. aeruginosa, given the limited and sporadic 
reporting in the literature of such traits [58], [90]. The diverse genomic profile of UTI 
P. aeruginosa has been reported in a few studies either as part of a major sequencing 
project of P. aeruginosa isolates obtained from multiple type of infections or in 
studies solely focused on UTI isolates [659], [660], [664]. In the former, it was difficult 
to ascertain to which strain these isolates grouped in the P. aeruginosa population 
structure. While, in the latter, the limited number of studies indicated that                       
P. aeruginosa isolates are diverse and from different environmental resources in the 
same country [90], [662], [664]. Thus, we obtained isolates sourced from the UK and 
the state of Kuwait. Our findings suggest that these UTI isolates are obtained mostly 
from different environmental sources. However, a few XDR isolates clustered closely 
together from Kuwait which could indicate that it may have been a clone isolated 
from the same patient, spread between patients or from a common environmental 
source such as the same hospital. These isolates were highly resistant to antibiotics 
and analysis of the sequence data revealed that many of the genes had previously 
been identified on plasmids. In this study, it was unclear whether the isolates carried 
plasmids, however, this could be analysed further. Certainly, the possibility of 
plasmids contributing to the spread of such resistant isolates requires further 
investigation.  Unfortunately, epidemiologic data for these isolates from Kuwait is 
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severely lacking.  To establish whether common or shared clones UTI patients occur, 
sequencing of more isolates would be required. This would be important especially 
given the rise of AMR in the region and the throughout the world [559], [629].  
AMR is a major threat worldwide, carbapenem resistant P. aeruginosa has been 
classified as requiring an urgent need for intervention by the WHO in 2017 [36]. These 
results show a worrying level of extremely resistant UTI P. aeruginosa isolates from 
Kuwait and also MDR isolates from the UK. Fears of antibiotic misuse have been 
reported in the literature over the past few decades. In Kuwait, the seemingly 
generous prescription of antibiotics has dismayed healthcare providers due to             
the government healthcare policies [633]. Kuwait’s government has recently 
implemented strict guidelines to combat the spread of AMR, however, the impact of 
these guidelines has not been reported yet [609]. Therefore, I propose a long-term 
surveillance study to monitor the spread of potential AMR P. aeruginosa UTI clones 
within Kuwaiti hospitals.  
 
In terms of phenotypic studies, I have established that the majority of urinary                 
P. aeruginosa isolates are motile and can perform swimming, twitching and/or 
swarming motility [90], [706]. Other studies have reported that isolates derived from 
midstream urine were more likely to be able to swim than isolates from CAUTI [90]. 
One of the limitations of our study is the unknown method by which our isolates were 
obtained, thus, it’s not possible to link whether each isolate with certain motility 
characteristic such as swimming, was derived from midstream urine or urinary 
catheters. CAUTI P. aeruginosa isolates show reduced motility as reported by Tielen 
et al (2011) [90]. To establish whether each type of motility has a role to play infection 
and progression in acute and chronic UTIs, knock-out mutations of genes involved in 
flagella and pili genes, followed by infection of murine UTI model are required. 
Alternatively, a transcriptomic and/or proteomic analysis from isolates derived from 
each of midstream urine and catheters may provide insights into the utilisation of 
swimming, twitching and swarming motility. Further studies on isolates from UTIs 
could also use assays assessing multiple virulence factors such as rhamnolipid assays, 
cytotoxicity assays, quorum sensing assays, and LPS O-serogroup testing. 
234 
 
Furthermore, it may be more suitable to conduct these assays in AUM (or potentially 
urine) given the differences in the proteome established in Chapter four between 
laboratory rich media, urine and AUM. 
 
P. aeruginosa is a model organism for biofilm studies. The ability to form biofilms on 
catheters contributes to virulence in CAUTIs [280], [706]. The biofilm CV assays in 
vitro in LB rich medium presented in this study showed variation between isolates in 
terms of biofilm formation ability. Consequently, further investigations sought to 
further identify differences in the biofilm architecture, however, no differences 
amongst all the isolates tested were found using confocal laser microscopy. The 
variation between replicates was high and therefore this brings into question the 
reliability of this method used for this purpose. This was followed by comparison of 
biofilms grown in LB rich medium, AUM and urine to establish how closely AUM 
reflects urine. Biofilms in AUM form flat and densely packed biofilms and therefore it 
was evident that biofilms in AUM were different to LB and that AUM is a more 
suitable medium to study urinary isolates of P. aeruginosa than LB. However, there 
were differences in the proteome of P. aeruginosa grown in AUM and urine. AUM 
could be improved and future experiments could involve the addition of components 
such as THP, a highly abundant glycoprotein found in urine. This has been linked to 
promoting P. aeruginosa biofilm formation [484]. 
 
Pyocyanin is a potent exotoxin released by P. aeruginosa and is thought to intercalate 
with eDNA to promote P. aeruginosa biofilm formation in the urinary tract [56], [669]. 
Based on these results, most of the isolates produced pyocyanin to varying levels. In 
chapter four, a simple pyocyanin assay revealed that clinical isolates produce more 
pyocyanin in AUM. When proteomic analysis was further conducted, we observed 
increased abundance of proteins in the phenazine synthesis pathway in AUM 
compared to urine, which throws into question how important this system is in the 
host urinary tract. Cole et al, (2018) reported that mouse urine inhibited QS and as a 
result, pyocyanin and rhamnolipid production were decreased [485]. To further 
elucidate the role of pyocyanin production in UTI pathogenesis, knockout mutations 
in genes such as phzS and phzM could be used to assess the ability of relevant UTI                             
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P. aeruginosa isolates in acute CAUTI mouse models or progression on catheters. 
Currently, the exact mechanisms by which P. aeruginosa invade and colonize the 
urinary tract and the degree of the involvement of phenazines, is unknown and 
therefore, requires more research.  
 
AUM has not been widely used to assess the phenotypes of UTI P. aeruginosa  [753]. 
One of the main objectives of chapter 4 was to observe the similarities and 
differences of P. aeruginosa grown in AUM media in comparison to human urine. In 
this study only one clinical isolate was used to study the proteomic profile. This was 
due to both time and cost. However, the possibility of different responses 
corresponding to different clinical isolates exists based on the genotypic and 
phenotypic assays conducted in chapter three, thus, future studies could select more 
isolates to study. These could be based on the relatedness to PAO1 and/or PA14, or 
phenotypes of interest. Nonetheless, interesting patterns of increased and decreased 
protein abundance, particularly related to important virulence factors, was observed.  
AUM mimics urine on its impact on the P. aeruginosa proteome with regards to 
certain systems. For instance, TS33 proteins are heavily decreased in AUM and urine. 
This finding supports multiple studies on other Gram-negative uropathogens, in 
which no evidence of T3SS contribution to UTI pathogenesis is found [207], [208], 
[210]. This suggests that certain components in urine can alter bacterial 
pathogenesis. Identification of such components could identify targets or avenues for 
therapeutics. These results also show the increase in proteins associated with iron 
acquisition mechanisms in AUM and urine are similar, though the extent of the 
increase differs between the two. This similar trend may indicate that the there is a 
scarcity of iron in urine and AUM [743]. While I conclude that AUM may be a more 
adequate medium to study the uropathogensis of P. aeruginosa, I also acknowledge 
the media is limited, largely due to its basic biochemical components [800]. These do 
not the address the complexity of urine and the existence of diverse immune and 
metabolic compounds [717], [1070]. The inclusion of the most abundant protein in 
urine, THP [462], in future AUM in vitro experiments may aid to close the gap 
reflected in the differences between AUM and urine.  Furthermore, developing a 
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new-AUM formulation which contains antimicrobial peptides such as cathelicidin-37, 
could lead to a more accurate representation of the UTI P. aeruginosa proteome.  
As part of this wider project, a number of colleagues (Dr. Christina Bronowski and 
John Newman) conducted multiple experiments utilising AUM to assess the efficacy 
of antibiotics (data not shown) and found that, when grown in AUM, P. aeruginosa 
tolerance increases to antibiotics including piperacillin/tazobactam and ciprofloxacin. 
This indicates that diagnostic testing using LB (or other rich media such as Muller-
Hinton) may not be accurate and potentially overestimates the action of those 
antibiotics. This in line with several studies which have questioned diagnostic testing 
and the relevance to clinical application related to P. aeruginosa CF infections [795], 
[797], [1071], [1072]. Additionally, phages used in this study were less effective 
towards UTI isolates pre-grown in AUM, which may be linked to decreased 
abundance of pili and porin proteins that are utilised by phages as receptors [1073].  
 
Finally, I used AUM to further investigate the role of sex hormones on P. aeruginosa. 
Sexual dimorphism is known to play a role in bacterial infection severity and sex 
hormones have been shown to be contributing factors in animal models and 
epidemiological studies in humans [873], [930], [953]. As such, evidence of UPEC 
infection modulation by oestradiol in a mouse model and humans has been 
demonstrated and shown to lead to a reduction of recurrent UTIs [919]. Furthermore, 
oestradiol appears to exacerbate P. aeruginosa infections in the CF lungs of female 
patients and modulates a severe immune response in mice, contributing to higher 
morbidity and lower life expectancy than their male counterparts [930], [953]. In 
chapter five, I conducted several phenotypic experiments to assess the influence of 
the sex hormones oestradiol, testosterone and progesterone on growth and 
virulence of P. aeruginosa.  Phenotypic assays used to investigate growth and biofilm 
formation showed no significant difference in traits of all the selected isolates in the 
study. However, future studies could include the investigation of the impact of 
hormones on antibiotic susceptibility. MIC assays in the presence of hormones could 
be performed with antibiotics such as tobramycin. The impact of these hormones on 
the P. aeruginosa proteome resulted in two types of responses; either a universal 
effect (common to all 3 hormones) in the increase or decrease of proteins from 
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certain pathways, or hormone-specific responses. Alterations in Iron acquisition 
proteins was one of the main observations as a significant reduction of associated 
proteins was observed across all mechanisms involved in sequestering, transport and 
uptake of iron in the presence with either of the three hormones. This is interesting 
since iron levels are scarce in this medium, which could mean that sex hormones 
either increases the bioavailability of iron or directly suppresses these proteins 
resulting in further restriction of access to the available iron. To test these 
hypotheses, transposon mutagenesis of major genes in these pathways could be 
tested in iron scarce medium with the presence of hormones in increasing 
concentrations. This may provide more insight. Alternatively, gene knockout 
experiments of iron acquisition genes in P. aeruginosa followed by infection with 
mutant strains in ovariectomised female mice and castrated male supplemented with 
sex hormones could be performed to elucidate the role further. In animal models, 
the roles of sex hormone receptors can be further addressed by the utilisation of 
agonists (PPT) and antagonists (MPP), which act as promoters or blockers of ERα, 
based on the evidence that the activity of those chemical agonists and antagonists 
modulate the severity of infection to UPEC pathogenesis [933].  
 
For the hormone-specific impacts on the P. aeruginosa proteome, a direct impact on 
the QS mechanisms was observed for oestradiol since multiple proteins were 
increased in the PQS pathway, along with increased proteins involved in the 
production of pyocyanin and HCN. The PQS QS system is linked to increased virulence 
in an acute mouse model [129]. In samples treated with testosterone, one of the 
notable findings is the increase of OprM, which acts in concert with MexA and MexB 
proteins as part of the efflux pump MexAB-OprM. The decrease of AmpC may 
contribute to changes in P. aeruginosa intrinsic resistance to β-lactam antibiotics. For 
progesterone, SigX an ECF sigma factor which promotes biofilm formation [1035], 
was increased. Hormone-specific findings also require more research ranging from in 
vitro to in vivo experimental models. Recent new methodologies such as Drug Affinity 
Responsive Target Stability (DARTS) may help in revealing specific interactions 
between hormones and bacterial target proteins to identify molecules of interest and 
previously unidentified binding targets [1074].  
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In conclusion, the mechanisms involved in P. aeruginosa causing UTIs are not well 
understood and require more research. This pathogen is highly adept due to its ability 
to form biofilms in nosocomial settings on catheters and its ability to acquire resistant 
genes leading to high rates of economic loss, morbidity and mortality [55], [635], 
[1075]. In this study, isolates from hospitals in Kuwait displayed worryingly high levels 
of resistance, thus, urgent epidemiological and surveillance studies are required.         
P. aeruginosa UTI isolates are genetically and phenotypically diverse. Like most other 
P. aeruginosa infections, my findings indicate that most isolates are of environmental 
origins, and no transmissible strains have been detected. In order to further 
understand uropathogensis of P. aeruginosa, I used an AUM model to compare the 
characteristics of the bacterium in comparison to the widely used LB media and urine. 
Our results suggest that AUM is an adequate model to study many P. aeruginosa 
mechanisms associated with pathogenesis. This is epitomised in the similar universal 
response to crucial virulence determinants such as iron acquisition mechanisms and 
T3SS in AUM and urine. However, the AUM formulation used in this study appears to 
have some limitations, specifically with the regards to the PQS QS system. Thus, this 
AUM formulation may benefit from adding other host factors such as THP protein, 
the most abundant protein in urine and antimicrobial peptides. Inclusion may lead to 
a more reflective response of P. aeruginosa in the urinary tract. In this study, I 
addressed some differences based on sex hormones and added oestradiol, 
testosterone and progesterone to the AUM media and conducted proteomic analysis 
to elucidate universal and hormone-specific responses. For instance, iron acquisition 
proteins were decreased globally in comparison to the control, suggesting a possible 
role for sex hormones in the urinary environment and this may lead to easier 
acquisition of iron by the bacteria. Overall, P. aeruginosa UTI requires more research 
and understanding. Further studies may lead to a personalised approach and more 
precision treatment based on individual attributes, rather than a single approach that 
is practiced to all patients. 
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